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1 Introduction 
 
1.1 Matrix metalloproteinases (MMPs)  
  The extracellular matrix (ECM) plays a critical physiological role for many cellular 
function of the organism [1-2]. Many of the extracellular signaling events that regulate cell 
behaviour occur at or near the cell membrane and are regulated by proteolytic processes [3].  
  MMPs are a family of Zn2+ and Ca2+-dependent endopeptidases that play a pivotal 
role in the degradation and remodeling of ECM. Collectively, they are able to digest all 
components of ECM and to regulate the cell-matrix interactions (Figure 1). The ability of the 
activated MMPs to degrade ECM and to cleave cell surface molecules influences diverse 
physiologic processes such as wound repair, apoptosis and tissue remodeling that take place 
during embryonic development and reproduction [4]. Under loss of their regular functions, 
MMPs are thought to promote tumor expansion and invasion so favoring the movement of 
cancer cells across the vascular membrane, the local growth and invasion of secondary 
tumors, and the formation of new blood vessels, which is an important requisite for tumor 
growth (Figure 2) [5-11]. MMPs also are implicated in many other diseases such as arthritis, 
atherosclerosis, tissue ulcers and fibrosis [12-14]. Due to their role in cancer progression, 
several MMPs are considered important drug targets for anticancer therapy. Over the past 
decade, significant advances have been made in the field of MMP research. These included a 
better understanding of the biochemistry of these enzymes in terms of their activation, 
regulation and substrate specificity, the determination of their structure by X-ray 
crystallography and NMR, and the design of orally-available inhibitors [15-19]. 
Unfortunately the clinical trials of the inhibitors designed so far have provided disappointing 
results. In fact in spite of the encouraging preclinical efficacy in pharmacological models, 
side-effects have been observed in the patients treated with these compounds. The lack of 
selectivity is considered at the origin of the observed side-effects and of the poor efficacy [8, 
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18]. Therefore, the major challenges in MMP research are a better understanding of the 
complex role of these enzymes in human diseases, and the design of selective inhibitors for 
the clinical use. 
  
 
 
Figure 1. Potential mechanisms of MMP-mediated cellular signaling (reprinted from ref. 17) 
 
1.2 Structural features of MMPs 
  To date, 24 different vertebrate MMPs have been identified. Of these, 23 have been 
found also in humans [20-22]. A typical full length MMP consists of a signal peptide, a 
prodomain, a catalytic domain, a linker peptide (called ‘hinge region’) and a C-terminal 
hemopexin domain (Figure 3 and 4). A catalytic domain and a C-terminal hemopexin 
domain are connected by a linker peptide. The hemopexin domain is absent in MMP-7, 
MMP-26 and MMP-23. MMP-23 has a unique cystein-rich domain and an immunoglobulin-
like domain. Gelatinase A (MMP-2) and gelatinase B (MMP-9) have three fibronectin 
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type II motifs inserted in the catalytic domain. MMPs are produced in their inactive 
zymogenic forms (pro-MMPs), which are subsequently proteolytically activated in an 
elaborate set of events. The latent MMPs (pro-MMPs) contain a conserved cysteine residue 
called “cysteine switch”, that interacts with the catalytic zinc ion, and maintains the enzymes 
in latent state. MMPs are activated in vivo in the extracellular space by the removal of the 
prodomain through the action by other MMPs, or in vitro by organomercurial compounds or 
different proteinases such as trypsin, furin and plasmin [23-25]. 
 
Figure 2. Matrix metalloproteinases (MMPs) in tumor progression. The cellular changes 
that occur as a normal cell becomes a benign, malignant, and metastatic tumor are depicted. 
MMPs have been classically thought to contribute to the tissue destruction required for cells 
to invade, intravasate, extravasate, and migrate. More recent evidence suggests these 
enzymes can also play a role in the growth of benign and malignant tumors, angiogenesis, 
and the sustained growth of metastatic lesions (reprinted from Nelson et al, J. Clin. Oncol., 
2000, 18, 1135-1149 
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Figure 3. Schematic representation of the structure of the 23 human matrix 
metalloproteinases (MMPs), which are classified into different groups on the basis of 
domain organization. Archetypal MMPs contain a signal peptide (necessary for secretion), 
propeptide, a catalytic domain that binds zinc (Zn2+) and a hemopexin carboxy (C)-terminal 
domain. Y, D, and G represent tyrosine, aspartic acid and glycine amino acids that are 
present in the catalytic domain of all collagenases. Matrilysins contain the minimal domain 
organization that is required for secretion, latency and catalytic activity. Gelatinases contain 
fibronectin type II modules that improve collagen and gelatin degradation efficiency. 
Convertase-activatable MMPs contain a basic insert in the propeptide that is targeted by 
furin-like proteases (convertase cleavage site). MMPs that belong to this group can be 
secreted enzymes, or membrane-anchored via GPI (glycosylphosphatidylinositol), type I or 
type II transmembrane (TM) segments. MMP-23A and MMP-23B contain unique cysteine 
array (CA) and immunoglobulin (Ig)-like domains in their C-terminal region (reprinted from 
Overall et al, Nat. Rev. Cancer, 2002, 2, 657-672). 
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Figure 4. The crystal structure of the full length of human MMP-1 (PDB code: 1SU3) 
 
  The catalytic domain contains an highly conserved zinc-binding sequence 
HEXXHXXGXXH, which is essential for the proteolytic activity of MMPs. Glutamate and 
aspartic acid rich sequences at the N- and C-terminal ends of the catalytic domain are 
thought to represent calcium-binding motifs. The catalytic domain also contains a conserved 
methionine, forming a “Met-turn” after the zinc- binding motif, which forms a base to 
support the structure around the catalytic zinc. With the exception of MMP-7, MMP-26 and 
MMP-23, all MMPs have an hemopexin domain that shows sequence similarity to the heme-
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binding protein hemopexin, and it is highly conserved among MMPs. Two cysteine residues 
in the hemopexin domain form a disulfide bridge folding the domain into a four bladed 
propeller structure [26-27]. The hemopexin domain plays a role in regulating both substrate 
specificity and proteolytic activities. It is also important for the binding of tissue inhibitors 
of metalloproteinases (TIMPs) [26].  
 
1.3 Members of the MMPs and their biological functions 
  On the basis of substrate specificity, domain arrangement and sequence similarity, 
MMPs are grouped into collagenases, gelatinases, stromelysins, matrilysin, membrane-type 
(MT)-MMPs and others (Table 1).  
  The human collagenases are MMP-1, MMP-8 and MMP-13. These MMPs are 
capable of degrading triple helical fibrillar collagens type I, II and III and of digesting other 
matix and non-matrix proteins [21, 28]. Also MMP-2 and MT1-MMP (MMP-14) can cleave 
fibrillar collagens [29-30]. Recent studies show that collagenases bind and partially unwind 
triple helical structure of native collagens before the hydrolysis of the peptide bonds, so 
suggesting that the hemopexin domain is essential for the catalytic mechanism [30-31]. 
Therefore, the catalytic domain and the hemopexin domain, have an important role in 
collagen degradation. Type I collagen is cleaved by several MMPs at specific sites and more 
exactly between Gly775-Ile776 of the α1(I) chain and Gly775-Leu776 of the α2(I) chain. 
These selective cleavages produce 3/4 N-terminal and 1/4 C-terminal collagen fragments, 
which can be denatured spontaneously into gelatin at body temperature, and can be further 
degraded by other MMPs [32]. MMP-1 can also activate the exodomain of protease 
activated receptor 1 (PAR-1) by cleaving the Arg-Ser bond [10, 33].  
  Gelatinases (MMP-2 and MMP-9) readily digest the denatured collagen and gelatin. 
They also digest a number of ECM components including type IV, V and XI collagens, 
laminin, aggrecan core proteins, etc. [34-35]. MMP-2, but not MMP-9, has collagenolytic 
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Table 1. Human matrix metalloproteinases and their substrates 
Enzyme Common name(s) Major substrates 
MMP-1 
 
MMP-2 
 
MMP-3 
 
MMP-7 
MMP-8 
 
MMP-9 
 
MMP-10 
MMP-11 
MMP-12 
MMP-13 
MMP-14 
MMP-15 
MMP-16 
MMP-17 
MMP-19 
MMP-20 
MMP-21 
MMP-23 
MMP-24 
MMP-25 
MMP-26 
MMP-27 
MMP-28 
Collagenase-1, interstitial  
collagenase 
Gelatinase A, 
 
Stromelysin-1 
 
Matrilysin-1 
Collagenase-2, neutrophil 
collagenase 
Gelatinase B 
 
Stromelysin-2 
Stromelysin-3 
Macrophage Metalloelastase 
Collagenase-3 
MT1-MMP 
MT2-MMP 
MT3-MMP 
MT4-MMP 
RASI-1 
Enamelysin 
XMMP 
CA-MMP 
MT5-MMP 
MT6-MMP 
Matrilysin-2, Endometase 
 
CMMP, Epilysin 
Collagen I, II, III, X, gelatin 
 
Gelatin, laminin, collagen I, 
IV, V, VII, fibronectin, elastin 
Proteoglycans, fibronectin, 
gelatin, collagen III, IV, V, IX 
Gelatin, fibronectin 
Collagen I, II, III, X, gelatin 
 
Gelatin, proteoglycans,  
collagen IV, V, VII, 
fibronectin, elastin 
Gelatin 
Gelatin, Elastin 
Collagen I, II, III 
Collagen, aggrecan 
Collagen, aggrecan 
 
 
Gelatin, fibronectin 
 
 
activity [30]. MMP-2 is activated on the cell surface through a unique multi-step pathway 
that involves MMP-14 (MT1-MMP) and the tissue inhibitor of metalloproteinase 2 (TIMP-
2) [36-37]. MMP-9 has been shown to mobilize vascular endothelial growth factor and to 
promote angiogenesis. In the K14-HPV16 carcinogenesis model, MMP-9 expression by 
inflammatory cells, leads to a keratinocyte hyperproliferation, angiogenesis and to an 
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increased incidence of squamous cell carcinomas [6]. 
  The stromelysins (MMP-3, MMP-10 and MMP-11) display a broad ability in 
degrading ECM proteins. Conversely they are unable to cleave the triple helical fibrillar 
collagens. MMP-3 and MMP-10 are similar in structure and in substrate specificity and they 
participate to proMMP activation [38]. 
  In matrilysins (MMP-7 and MMP-26) the hemopexin domain is absent. MMP-7 is 
synthesized by epithelial cells and is secreted apically. Besides ECM components MMP-7 
processes cell surface molecules such as pro-α-defensin, Fas-ligand, pro-tumor necrosis 
factor α and E-cadherin. MMP-26 is expressed in normal cells such as those of the 
endometrium and in some carcinomas. It digests several ECM molecules, and unlike most 
other MMPs, it is largely stored intracellularly [39]. 
  MT-MMPs, Type I transmembrane proteins (MMP-14, MMP-15, MMP-16 and 
MMP-24) and glycosylphophatidyinositol-anchored proteins (MMP-17 and MMP-25), have 
a furin recognition sequence at the C-terminal of the propeptide (Figure 3). The importance 
of these enzymes is related to their ability of activating pro-MMP-2 on the cell surface. With 
the exception of MT4-MMP (MMP-17), all MT-MMPs can activate proMMP-2. MT1-MMP 
serves as cell membrane receptor for the complex formed between the latent form of MMP-2 
(pro-MMP-2) and the tissue inhibitor of matrix metalloproteinases 2 (TIMP 2). In this way 
pro-MMP-2 is brought on the cell surface where another MT-MMP, free of TIMP, can cleave 
out the prodomain [17, 36].  MT1-MMP (MMP-14) has also collagenolytic activity on 
collagens type I, II and III [40]. 
  The other seven MMPs are not classified into the above categories. MMP-12, 
called macrophage metalloelastase, is mainly expressed by alveolar macrophages [41] and 
digests elastin, other ECM components [42] and non-matrix proteins such as myelin basic 
protein and α1-antitrypsin. It is also able to process tumour necrosis factor-a (TNF) to its 
mature form [43]. It is essential also for macrophage migration [44]. MMP-19 digests many 
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ECM molecules including the components of basement membranes [45] and it is also called 
RASI (rheumatoid arthritis synovial inflammation) as it is found in the activated 
lymphocytes and in the plasma of patients with rheumatoid arthritis. MMP-19 is also 
recognized as an autoantigen in patients with rheumatoid arthritis and systemic lupus 
erythematosis [46]. MMP-20, called also Enamelysin, is primarily located within newly 
formed tooth enamel and it is able to digest amelogenin [47] MMP-21 was originally found 
in Xenopus [48] and more recently in mice and human [49]. It is expressed in various fetal 
and adult tissues and in basal and squamous cell carcinomas [50]. It digests gelatin, but 
information about other activities towards the ECM components are not available. MMP-23 
is a unique member as it has unique C-terminal cysteine-rich immunoglobulin-like domains 
instead of the hemopexin domain and lacks the cysteine-switch motif of the prodomain [51]. 
MMP-27 was first found in chicken embryo fibroblasts [52]. Chicken MMP-27 digests 
gelatin and casein and causes autolysis of the enzyme, but little information are available on 
the activity of mammalian enzyme. The last MMP to be identified has been the Epilysin or 
MMP28, mainly expressed in keratinocytes. Expression patterns in intact and damaged skin 
suggest that this MMP might function in tissue homeostasis and wound repair [53].  
 
1.4 MMPs as drug targets 
  In general, MMPs are secreted as zymogens that are activated in vivo by 
proteinases including MMPs [21]. Low pH and heat treatment can also lead to activation of 
pro-MMPs. Since MMPs were activated, the proteolytic activity of mature enzymes is 
controlled by physiological inhibitors. As there is growing experimental evidence that 
malignant tumors utilize MMPs for tumor growth and spreading, inhibitors of MMPs may 
represent a new class of anticancer drugs [18, 54-55]. Native inhibitors of MMP activity are 
serum proteins such as α-2 macroglobulin and, more specifically, the family of tissue 
inhibitors of metalloproteinases (TIMPs). To date, four members of the family, TIMP-1, 
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TIMP-2, TIMP-3, and TIMP-4 have been characterized. These proteins are able to inhibit 
the activity of all known matrix metalloproteinases [36, 56-57]. However, the therapeutic 
use of these proteins is likely to be limited because of their low oral bioavailability and 
because of the limited tissue penetration. Synthetic inhibitors ideally have the desirable 
properties of high water solubility, oral bioavailability, and low toxicity. So far, the most 
extensively used inhibitor in clinical trials is marimastat, a hydroxamic acid derivative which 
exhibits broad-spectrum inhibitory activity against MMPs [54]. However, the use of broad-
spectrum MMP inhibitors in clinical trials has been disappointing, primarily because of lack 
of efficacy and survival benefits [8]. For these reasons, it is necessary to achieve a selective 
inhibition of each human MMP. Recently, to design selective inhibitors, the attention has 
been focused not only towards the S1' pocket of catalytic site but also towards the loop 
regions (Figure 5) [18, 58-60]. The S1' pocket plays an important role in determining P1' 
specificity but the mobility of loop regions is also important since it allows the protein to 
accommodate a variety of inhibitor moieties. Therefore, in the future, an accurate 
comparison of the S1' pockets and a deep investigation of the loop regions will provide 
valuable data for a rational design of specific inhibitors. In this context the availability of 
high resolution structures is of great help. 
  More recently, it is suggested that the investigation of the structural features of the 
hemopexin domain and of the linker peptide is important to understand the physiological 
role and for drug design [55,61]. Up to now, the functional roles of the hemopexin domain 
and that of the linker peptide of MMPs have not been completely clarified. In the case of 
collagenases (MMP-1, MMP-8, MMP-13), the hemopexin domain seems to mediate binding 
of the enzyme to the native collagen [62-64]. Therefore, the hemopexin domain and linker 
peptide of MMPs have an important role in regulating the degradation of their substrates 
(ECM components). Indeed, from the point of view of drug design, targeting sites 
contributing to the interaction with the substrates but far from the active site could be a good 
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strategy to enhance the selectivity of candidate drugs.  
 
 
 
 
 
Figure 5. Schematic representation of the active site cleft of MMPs complexed with 
hydroxamic acid inhibitor. Ra, α substituent; R1, P1’ substituent; R2, P2’ substituent; R3, 
P3’ substituent.  
 
 
1.5 Aim of the research 
  To accomplish the rational drug design, high resolution structures of the proteins 
are highly required. To analyze the structural details of each MMP, and the subtleties of the 
ligand-protein interactions, the availability of highly concentrated, soluble and stable protein 
samples is needed. Moreover, to investigate the interaction of the matrix metalloproteinases 
with physiological substrates (e.g. models of extracellular receptors or extracellular matrix 
components) the availability of full-length proteins is of fundamental importance. The 
present PhD project has been focused on the development of new methods for the expression, 
purification and refolding of recombinant human MMPs. Several catalytic domains of 
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human MMPs (MMP-1, MMP-7, MMP-8 and MMP-12), one full length active protein 
(MMP-12) and the hemopexin domain of MMP-12 have been obtained so far. Inactive 
mutants of the catalytic domain of MMP-1, MMP-12, and the full length active construct of 
MMP-12 (included an inactive Cd2+-substituted form of MMP-12 full length) have been also 
produced. For the full length and the hemopexin domain of MMP-12, indeed, it is hard to 
produce a large amount of the proteins because aggregation and precipitation occur during 
the refolding steps. Fortunately, large amounts of the proteins with well-folded and soluble 
state have been produced using the new methods developed during the present PhD research. 
Thanks to these methods, the solution structure of the hemopexin domain of MMP-12 has 
almost been solved and the solution structure of the full length of MMP-12 is in progress. 
Therefore, we expect that the solution structures of active full length MMP-12 will provide 
important clues for interaction studies of MMP with substrates such as collagen, elastin and 
for the design of selective inhibitors. 
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2 Methods 
 
2.1 Expression, purification and refolding of human MMPs  
  The development of new methods for MMP cloning, expression and purification 
that were the goals of this PhD project has been described in details in Chapter 3.  
All the proteins expressed during these research activities have been produced according the 
general strategy described below.  
  The cDNAs encoding the sequences for the different proteins were amplified from 
human cDNAs by polymerase chain reaction (PCR). The selected constructs were cloned 
into the pET21 expression vector (Novagen) using Nde I and Xho I or Nde I and Hind III as 
restriction enzymes (BioLabs). The recombinant vectors were transformed into Escherichia 
coli strains, BL21(DE3) Codon plus or in BL21(DE3). Single point mutations were 
performed using the QuickChange™ Site-Directed Mutagenesis Kit from Stratagene. The 
pET21 has been selected as plasmid vector since its efficiency in the expression of the 
catalytic domain of MMPs.  All the proteins were expressed at 37 0C using 0.5 mM of 
IPTG to induce the gene transcription. The expression was carried out in rich media (2 x 
YT) or in minimal media for 15N- and 13C-labeled proteins. The proteins, precipitated in the 
inclusion bodies, were solubilized after lysis of the cells in a solution containing 8 M urea or 
6 M guanidine hydrochloride. The protein was purified on the ion exchange columns, using 
a linear gradient of NaCl up to 0.35 M. The purified proteins were then refolded by using a 
multi-step dialysis against a buffer containing Tris, CaCl2, ZnCl2, NaCl, and 
acetohydroxamic acid (AHA). 
 
2.2 Crystallization  
  The crystals of the proteins (MMP-8, the active form of MMP-12, and the inactive 
form of MMP-12) were obtained by the hanging drop vapor diffusion method. Crystals of 
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MMP-12 were obtained as previously reported [66], while those of MMP-8 were grown at 
20 0C from a solution containing 0.1 M Tris-HCl, 20% PEG-3350, 0.2 M MgCl2 at pH 8. In 
both cases the crystallization buffer contained 200 mM of the weak inhibitor 
acetohydroxamic acid (AHA). To obtain the active uninhibited enzymes, MMP crystals were 
then extensively washed with the same crystallization buffers lacking AHA. The 
ProGlnGlyIleAlaGly peptide (INBIOS s.r.l., Naples) was soaked into the crystals for 1-3 
days in order to obtain the two- or the one-peptide adducts. 
 
2.3 Enzyme assays 
  Fluorimetric assay was performed in 50 mM HEPES buffer (pH 7.0), with 10 mM 
CaCl2, 0.05% Brij-35 and 0.1 mM ZnCl2 using 1 nM of enzyme and 1 µM of the 
fluorescent-quenched peptide substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Biomol 
Inc.) at 298 K. The inhibition constants for the investigated inhibitors were determined 
evaluating their ability to prevent the hydrolysis of the peptide. Activity tests were 
performed by following the UV absorption in a buffer containing 50 mM HEPES (pH 7.0), 5 
mM CaCl2, 0.1 mM ZnCl2, 0.05 % Brij-35, 1mM DTNB (5,5’-dithiobis-2-nitrobenzoic acid) 
at 25 0C, 100 uM of Ac-Pro-Leu-Gly-[2-mercapto-4-methyl-penntanoyl]-Leu-Gly-OC2H5 as 
substrate and 50 nM protein.  
 
2.4 Cadmium substitution 
  The sample of the full length of Cd2+-MMP12 was prepared by exhaustive dialysis 
of the Zn2+-MMP12 against a buffer containing 0.3 mM CdCl2. The Zn2+-MMP12 was 
firstly exchanged by dialysis against a buffer containing 10 mM HEPES (pH 6.7), 5 mM 
CaCl2, 0.3 mM CdCl2; 0.3 M NaCl and 0.2 M AHA. The final sample for structural studies 
was dialyzed against a buffer containing 20 mM Tris (pH 7.2), 10 mM CaCl2, 0.1 mM CdCl2, 
0.1 M NaCl and 0.2 M AHA.  
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2.5 NMR sample preparation  
  The NMR samples of the catalytic domains were obtained by dialyzing the protein 
against a buffer containing 10 mM Tris (pH 7.2), 10 mM CaCl2, 0.1 mM, ZnCl2, 0.3 M NaCl, 
0.2 M AHA, 10% D2O. In case of the hemopexin domain of MMP-12, the protein was 
dialyzed against a buffer containing 20 mM Tris (pH 7.2), 10 mM CaCl2, 0.15 M NaCl, 10% 
D2O. The NMR sample of the full length of MMP-12 was prepared by dialyzing the protein 
against a buffer containing 10 mM Tris (pH7.2), 10 mM CaCl2, 0.1 M NaCl, 0.2 M AHA, 
excess of N-isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid (NNGH), 10 % 
D2O. In case of the full length Cd2+-MMP12 sample, 0.1 mM CdCl2 was added instead of 
ZnCl2. 
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3 Results 
 
3.1 Catalytic domains of human MMPs  
MMP-1 
  Pro-cat MMP-1 (Pro21-Pro269) was cloned into pET21 expression vector using 
NdeI and XhoI as restriction enzymes and expressed in BL21(DE3) Codon Plus cells. For 
the 15N-labeled protein, the test expression was performed in minimal media at 37 0C (Figure 
6. A). Most of the proteins were expressed as inclusion bodies, even if some protein was 
soluble at 25 0C. After induction with 0.5mM IPTG, the cells were harvested for 4hrs. The 
bacterial pellets were collected by centrifugation and lysed by using the following protocol. 
 
 
 
                    A                       B 
Figure 6. SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) 
analysis of test expression of the pro-cat MMP-1 (Pro21-Pro269) in minimal media at 37 0C 
(A) and activation of the refolded protein (B; lane 1, after refolding; lane 2, after activation 
by 1 mM APMA at 40C overnight).  
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  The bacterial pellets were suspended in a lysis buffer containing 50mM Tris (pH 
8.0), 25% sucrose, 0.1 M NaCl, 0,2 mM EDTA, 1mM DTT, and then stirred with some 
lysozyme for 20 min at 4 0C. The same volume of a buffer containing 2% Triton, 50mM Tris 
(pH 8.0), 0.1 M NaCl, 0,2mM EDTA, 1mM DTT was added, and then the viscous solution 
was sonicated several times in cold room. After sonication, the solution was stirred with 1 
mg/ml DNase and 100 mM MgCl2 for 20 min at 4 0C. The pellets were collected by 
centrifugation, and then washed three times by suspension in 50mM Tris (pH 8.0), 5mM 
EDTA, 1mM DTT and followed by centrifugation. The pellets containing inclusion bodies 
were solubilized in 2 M urea, 20 mM Tris (pH 8.0).  
  The protein was purified on the Hitrap Q column (Pharmacia) with a buffer 
containing 2 M urea and 20 mM Tris (pH 8.0). The elution was performed using a linear 
gradient of NaCl up to 0.35 M. The purified protein was then refolded by using a multi-step 
dialysis. The refolded protein was activated by 1 mM APMA (4-aminophenylmercuric 
acetate) at 4 °C overnight (Figure 6. B). The catalytic domain of MMP-1 was purified using 
size-exclusion chromatography with a buffer containing 0.2 M AHA, and then dialyzed 
against a proper buffer for structural or biological studies. The detailed procedures and 
results are described in chapter 4.1. However, pro-cat MMPs require the activation of the 
protein and a gel filtration to remove prodomain, Unfortunately, we couldn’t obtain any 
crystal from the protein derived by removing the prodomain. Therefore, a different construct 
of the catalytic domain of MMP-1 (Asn106-Gly261) was cloned and expressed as described 
below. 
  The catalytic domain of MMP-1 (Asn106-Gly261) was cloned and expressed using 
the same method used for the pro-cat MMP-1. The test expression of the protein was 
performed in minimal media at 37 0C. SDS-PAGE analysis of the test expression of the 
proteins is shown in Figure 7.  
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Figure 7. SDS-PAGE analysis of test expression of the catalytic domain of MMP-1 in 
BL21(DE3) Codon Plus cells at 37 0C 
 
 
  In order to maximize the production of the protein, the incubation was continued at 
37 0C for 4 hrs after induction with 0.5 mM IPTG. The cell lysis was performed using the 
same protocol of the pro-cat MMP-1.   
  The protein was purified by the ion exchange column (Hitrap Q, Pharmacia), using 
a linear gradient of NaCl up to 0.35 M in 6 M urea, 20 mM Tris (pH8.0). The refolding of 
the protein was followed as described in below.  
  The purified and denatured protein was diluted in a 4 M urea solution containing 
50 mM Tris (pH 7.4), 10 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl, keeping the protein 
concentration below 0.15 mg/ml to minimize intermolecular interactions which could cause 
misfolding. During the dialysis steps, the concentration of urea was gradually decreased 
from 4 M to 2 M and then completely removed from the buffer. The presence of self-
hydrolysis has to be taking into account during the refolding process. For this reason, 
starting from the 2 M urea step, 0.2 M of acetohydroxamic acid (AHA), a mild MMPs 
inhibitor, was added to the refolding buffers. The choice of a mild inhibitor is of 
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foundamental importance since it can be easily removed or replaced by a stronger one. The 
folding of the protein has been investigated by NMR through 1H-15N HSQC (Heteronuclear 
single quantum coherence) spectra. A good spreading of the cross-peaks was found. The 
activity has been checked using a fluorescent substrate or a reactive thiolic peptide (see in 
Methods). The biophysical and biological properties of the refolded protein are summarized 
in Table 2 at the end of this chapter. 
  Thanks to the developed methods for expression, purification, and refolding of the 
catalytic domain of MMP-1, large amounts of protein were produced and employed to 
generate protein-ligand structural models by a combination of in silico tools and 
experimental NMR data (Chapter 4.1). The detailed results are described in Publications. 
 
MMP-7 
  The cDNAs encoding the sequence for the catalytic domain of MMP-7 (Tyr95-
Lys267) was cloned into pET21 expression vector using Nde I and Hind III (for MMP-7) as 
restriction enzymes and expressed in BL21(DE3) cells. Test expression of the protein was 
performed in minimal media at 37 0C and SDS-PAGE analysis of the test expression is 
shown in Figure 8.  
  The cell lysis was performed using the same protocol of the pro-cat MMP-1 with 
an additional step consisting in a dialysis against a 2 M urea solution containing 2% Triton, 
50mM Tris (pH 8.0), 5mM EDTA, 1mM DTT in order to remove the impurities. Then the 
protein was washed three times by 50mM Tris (pH 8.0), 5mM EDTA, 1mM DTT. After cell 
lysis the inclusion bodies were solubilized in 8 M urea solution containing 20 mM Tris pH 
(8.6). The protein was purified by the ion exchange column (Hitrap Q) using a linear 
gradient of NaCl up to 0.35 M with a buffer containing 20 mM Tris pH (8.6) and 6 M urea. 
  However the previous refolding methods used for MMP-1 were not suitable for 
this protein. Also by using the pro-cat MMP-7 construct (Leu20-Lys267), disappointing 
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results were obtained in terms of folding and solubility. These problems have been partially 
overcome using a new refolding strategy developed during this PhD project. 
 
 
 
 
Figure 8. SDS-PAGE analysis of test expression of the catalytic domain of MMP-7 in 
BL21(DE3) cells at 37 0C 
  
  The purified MMP-7 was diluted (<0.15mg/ml) in 4 M urea, 50 mM MES (pH 6.5), 
1mM ZnCl2, 10 mM CaCl2, 0.3 M NaCl at 4 0C. The diluted protein was dialyzed against 4 
M urea, 50 mM (Tris pH 7.0), 1mM ZnCl2, 10 mM CaCl2, 0.3 M NaCl. Then the 
concentration of urea was gradually decreased from 4M to 2M and finally completely 
removed from the buffer. The refolded protein was dialyzed against 10 mM Tris (pH 7.2), 
0.1 mM ZnCl2, 10 mM CaCl2, 0.3 M NaCl, 0.2 M AHA and then concentrated at 4 0C using 
an Amicon stirrer, fitted with a YM10 membrane in nitrogen atmosphere and with 
Centriprep concentrator, fitted with YM10 membranes. The final protein samples showed a 
good spreading of the 1H-15N HSQC spectra. The biophysical and biological properties of 
the protein are summarized in Table 2 at the end of this chapter. 
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MMP-8 
  The catalytic domain of MMP-8 (Asn85-Gly242, numbering from ref. 65) was 
cloned into the pET21 expression vector using Nde I and Xho I as restriction enzymes and 
expressed in BL21(DE3) Codon Plus cells. For the 15N- and 13C-labeled protein, the test 
expression was performed in minimal media at 37 0C (Figure 9). After induction with 0.5 
mM IPTG the best expression was obtained in 5hrs. 
 
 
 
Figure 9. SDS-PAGE analysis of test expression of the catalytic domain of MMP-8 in 
BL21(DE3) codon plus cells at 37 0C 
 
  The cell lysis was performed using the same protocol for the MMP-7. After cell 
lysis the inclusion bodies were solubilized in 8 M urea solution containing 20 mM Tris (pH 
8.0) and then purified by the Hitrap Q column using a linear gradient of NaCl up to 0.35M. 
The refolding of the protein was performed as described for the catalytic domain of MMP-1 
(Asn106-Gly261). By using this protocol the protein showed a good spreading of 1H-15N 
HSQC spectra. The biophysical and biological properties of the protein are summarized in 
Table 2 at the end of this chapter. These protocols allowed us to produce large amounts of 
stable and soluble samples which have been used in structural studies by NMR and x-ray 
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crystallography.  
   
MMP-12 
  MMP-12 (Gly106-Gly263) was cloned into pET21 expression vector and 
expressed in BL21(DE3) [66]. For inactive form (Glu219Ala), a single point mutation was 
performed using the QuickChange™ Site-Directed Mutagenesis Kit. The test expression of 
the protein was performed in minimal media at 37 0C (Figure 10).  
  
 
 
 
 
Figure 10. SDS-PAGE analysis of test expression of the catalytic domain of MMP-8 in  
BL21(DE3) cells at 37 0C. 
 
 
  The cell lysis was performed using the protocol already developed for the MMP-7. 
After cell lysis, the inclusion bodies were solubilized in a buffer containing 6 M urea and 20 
mM sodium acetate (pH 5.0). The protein was purified by the ion exchange column, Hitrap 
SP (Pharmacia), using a linear gradient of NaCl up to 0.35M. 
  For the refolding of MMP-12 (Glu219Ala), the methods previously described were 
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not suitable. Despite many attempts using different conditions such as a slow decreasing of 
urea concentration, direct refolding to 0 M urea, different concentration of NaCl or CaCl2, 
unfolded protein was obtained. Finally, we found that high concentration ZnCl2 (1 mM) like 
for MMP-7 was needed for the refolding. The concentration of ZnCl2 is then decreased up to 
0.1 mM in the last dialysis. Therefore, for proteins such as MMP-7 and MMP-12 (Glu219A) 
an high concentration of ZnCl2 is decisive for a good refolding. Although this phenomenon 
is unknown one hypothesis is that the high concentration of ZnCl2 may favor a correct fold 
of the denatured proteins by interacting with the histidine ligands. The biophysical and 
biological properties of the refolded proteins are summarized in Table 2. The good quality of 
the protocols developed is demonstrated by the several biophysical investigations carried out 
on MMP-12 in this laboratory during this PhD project. 
  The folding of all the proteins has been investigated by NMR through 1H-15N 
HSQC spectra. The activity, checked using a fluorescent substrate or a reactive thiolic 
peptide, was in agreement with the already published data. For all the proteins a good 
spreading of the resonances was found. With the exception of MMP-8, all proteins exhibited 
a good stability in presence of the weak inhibitor AHA. In the case of the MMP-8 catalytic 
domain, even in the presence of AHA, a modest self-hydrolysis was still present at 
concentrations above 0.5 mM. 
 
3.2 Crystallization procedures 
  Even if the protein exhibits limited stability, crystals of the catalytic domain of 
MMP-8 have been obtained by growing them at 20° C in a solution containing 0.1 M Tris-
HCl (pH 8.0), 20% PEG-3350, 0.2 M MgCl2. The final concentration was around 8 mg/ml 
of protein. The crystals of the catalytic domain of MMP-12 were obtained as previously 
reported [66].  
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Table 2. Biophysical and biological properties of the catalytic domain of MMP-1, MMP-7, 
MMP-8, MMP-12. *The result from our group [66]. aThe activity of the catalytic domain of human MMP-
12 (wild type) in the same assay condition at 37 0C (BIOMOL, Catalog No: SE-138) 
 
MMP-1 
(Asn106-Gly261) 
MMP-12 
(Gly106-Gly263) 
Properties 
Wild type 
E219A mutant 
(inactive) 
MMP-7 
(Tyr95-
Lys267) 
MMP-8 
(Asn85-
Gly242) 
F171D 
mutant* 
(active) 
F171D, E219A  
mutant 
(inactive) 
Yield (mg/L) from 
minimal media 
~8-10 ~8-10 ~15-18 ~12-15 ~30-40 ~30-40 
Purification 
Ion 
exchange 
Ion 
exchange 
Ion 
exchange 
Ion  
exchange 
Ion  
exchange 
Ion  
exchange 
Yield (%) after 
refolding 
>80 >50 <30 >75 >80 >70 
Folding state Good Good Good Good Good Good 
Solubility (mM) >2.0 mM >2.0 mM >0.5 mM >1.2 mM >2.0 mM >2.0 mM 
Stability of 0.5 
mM protein at 
R.T. for a week 
containing 
0.5 M AHA 
Stable Stable Stable 
Stable in  
<0.5 mM 
Stable Stable 
Activity (U/µg) 686 - 23 223 91 (86a) - 
 
In both cases the crystallization buffer contained 0.2 M of the weak inhibitor (AHA). 
Crystals of MMP12-AHA were obtained in the presence of LiCl2 as well. The complexes 
were obtained through soaking of MMP12-AHA crystals with a solution containing the 
inhibitor. To obtain the active uninhibited enzymes, MMP crystals were extensively dialyzed 
against the same crystallization buffers lacking AHA. 
  In order to deeply characterize the different steps of the catalytic mechanism of the 
 27 
MMPs, adducts of MMP-12 and MMP-8 with the collagen fragment ProGlnGlyIleAlaGly, 
which is known to be cleaved at the Gly-Ile bond, were prepared. As expected, the catalytic 
activity of the crystallized proteins results in a selective hydrolysis of the peptide. The 
peptide was soaked into the crystals for 1-3 days in order to obtain the two- or the one-
peptide adducts. Considering that the protein tends to digest itself, the crystallization was 
always carried out in the presence of AHA inhibitor. By playing with various crystals under 
crystal washing conditions we got the crystals of the uninhibited form of MMP-12 and of 
MMP-8. Also performing the experiments with the Glu219Ala mutant of MMP-12, no 
peptide-bound form could be identified, due to rapid hydrolysis. Therefore also the 
Glu219Ala mutant of MMP-12, whose MMP-1 analogue is known to retain only 0.1% of the 
enzyme activity, apparently hydrolyses the substrate [67]. On the other hand, well-resolved 
structures with a hydrolysis product inside the active site have been obtained for both MMP-
12. All the adducts mentioned above have been solved by x-ray crystallography. The detailed 
results are described in the attached publications. 
   
3.3 Expression of the catalytic and hemopexin domain (full length) of 
MMP-12 and the hemopexin domain of MMP-12 
  Our data shows that the full length active MMP-12 is highly sensitive to the self-
hydrolysis. In fact the protein is already completely degraded during the refolding steps. To 
avoid this phenomenon, the mutant Glu219Ala has been cloned and expressed. On the 
contrary the hemopexin domain of MMP-12 is stable during purification and refolding since 
the catalytic domain is absent.  
  The test expression for the isotope labeled proteins was performed in minimal media 
at 37 0C (Figure 11). The active full length MMP-12 (Glu219Ala) was expressed in BL21 
Codon Plus strains overnight after induction with 0.5 mM IPTG, and the hemopexin domain of 
MMP-12 was expressed in BL21(DE3) strains for 5 hrs after induction with 0.5 mM IPTG.  
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Figure 11. SDS-PAGE analysis of test expression of the full length (A) and the hemopexin 
domain (B) of MMP-12 in minimal media at 37 0C 
 
        
3.4 Development of purification and refolding methods for the full length 
of MMP-12 and the hemopexin domain of MMP-12 
  Considering that both the full length protein and the hemopexin domain construct 
contain two cysteines, a new refolding protocol has been developed. To avoid 
oligomerization phenomena, a solution of 6 M guanidinium chloride with reductants was 
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used to dissolve the inclusion bodies. Then the denatured protein was directly refolded 
without any purification by multi-step dialysis. However this approach was not efficient 
since an extensive precipitation occurred. 
  In the new approach the detergent Brj-35 is used to avoid the precipitation of the 
protein during the refolding. However, the detergent represents an obstacle for structural 
studies and it is not easy to remove. During the project we found that the detergent could be 
easily removed from the buffer, by using a weak cation exchange column (HiTrap CM FF, 
Pharmacia) and a gel filtration column (HiLoad™ 16/60: 120 ml, Pharmacia). The detailed 
protocol is described below.  
  The cell lysis was performed using the same protocol of the pro-cat MMP-1 with 
an additional washing by a 2M urea solution containing 2% Triton, 50mM Tris (pH 8.0), 
5mM EDTA, 1mM DTT. Then the sample was further washed twice with 6 M urea, 50 mM 
Tris (pH 8.0). Most of the impurities were removed during cell lysis by washing the sample 
with a 6 M urea solution. The inclusion bodies were completely denatured using a solution 
containing 6 M guanidinium chloride, 50 mM Tris (pH 8.0), 10 mM dithiothreitol (DTT), 20 
mM cystamine at 4 0C overnight. Then the supernatant was collected after centrifugation. 
The concentration of the denatured protein was roughly measured using the calculated 
extinction coefficient of the protein at 280 nm. The denatured protein was then diluted (< 
0.15 mg/ml) in 6 M guanidinium chloride, 20 mM Tris (pH 8.0), 1 mM DTT, 0.05% Brij-35 
and dialyzed against 20 mM Tris pH 7.2, 0.1 mM ZnCl2, 10 mM CaCl2, 150 mM NaCl, 
0.05% Brij-35, 5 mM β-mercaptoethanol, 1 mM 2-hydroyethyl disulfide. In the last dialysis 
the sample was dialyzed against the same buffer without β-mercaptoethanol. To remove the 
excess of oxidant and Brij-35, the protein was dialyzed against a solution containing 20 mM 
Tris (pH 7.2), 0.1 mM ZnCl2, 10 mM CaCl2, 150 mM NaCl and then several times against a 
buffer containing 20 mM Tris (pH 7.2), 10 mM CaCl2. Then the refolded protein was 
centrifuged to remove the precipitate, and purified on 5 ml (x 2) of HiTrap CM FF column 
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(Pharmacia) using 400 ml (20 CV) of 20 mM Tris (pH 7.2), 10 mM CaCl2. The protein was 
then eluted using the same buffer containing 0.3 M NaCl and 0.1 M AHA. To further purify 
the protein a gel filtration was performed using the same buffer. For NMR studies, the 
purified protein was washed with a buffer solution containing 20 mM Tris (pH 7.2), 10 mM 
CaCl2, 0.3 M NaCl, 0.2 M AHA, and 3 mM of the nanomolar inhibitor NNGH. The same 
protocol with minimal modification has been used for to refold the hemopexin domain of 
MMP-12. The formation of disulfide bridge between the two cysteins of the hemopexin 
domain has been checked by SDS-PAGE (Figure 12). Under reducing conditions, a 42 kDa 
band (for the construct Gly106-Cys470) corresponding to the reduced form of the full length 
of MMP-12 (Figure 12. A) and a 23 kDa band (for the construct Glu278-Cys470) 
corresponding to the reduced hemopexin domain of MMP-12 (Figure 12. B) were observed. 
On the contrary under non-reducing conditions a single dominant band appeared below the 
reduced form of each protein. 
  This refolding protocol has provided protein samples with a well spreading of the 
cross peaks in the 1H-15N TROSY (transverse relaxation-optimized spectroscopy) spectra 
(Figure 13). The solution structure the hemopexin domain of MMP-12 is in progress.  
However the “inactive” mutant of MMP-12 full length was still sensitive to self-digestion 
even in presence of inhibitors and it is rapidly degraded at concentration above 0.3 mM. The 
cleavage site has been identified performing the mass spectra of the resultant fragments. In 
particular the cleavage occurs in the linker (hinge region) between the amino acids Glu267 
and Asn268. The sensitivity of the active full length MMPs to the self-hydrolysis has been 
already reported [41, 43, 63, 68-71]. At this regard, several researchers believe that this 
process may have an important physiological role [68-69]. The tendency to the self-
hydrolysis can be strongly reduced by replacing the catalytic zinc ion with Cd2+ without 
relevant structural alteration [72]. The metal replacement was obtained by performing a 
multi-step dialysis against buffer solutions containing Cd2+ instead of Zn2+. The activity of 
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the full length Cd2+-MMP-12 was 400-fold lower with respect to that of the full length Zn2+-
MMP-12 protein. Although a very slow self-hydrolysis is still present, nevertheless the 
Cd2+-MMP-12 protein is much more stable with respect to the zinc analog allowing us to 
perform NMR experiments for the determination of the structure in solution. The solution 
structure of the protein is in progress. To further stabilize the protein we have already 
planned the expression of new mutants at the hinge region. 
 
 
 
     
     A         B 
 
Figure 12. SDS-PAGE analysis of the disulfide bridge of the full length of MMP-12 (A) and 
the hemopexin domain of MMP-12 (B) at reducing and non-reducing conditions. M, protein 
marker; lane 1, with 50 mM DTT; lane 2, without DTT. 
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               A. The hemopexin domain of MMP-12 
 
 
               B. The full length of MMP-12 
 
 Figure 13. 1H-15N TROSY spectra of the hemopexin domain (A) and the full length (B) of  
 MMP-12 
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A combination of in silico tools and experimental NMR data is proposed for relatively fast
determination of protein-ligand structural models and demonstrated from known inhibitors
of matrix metalloproteinases (MMP). The 15N 1H heteronuclear single quantum coherence
(HSQC) spectral assignment and the 3D structure, either X-ray or NMR, are needed. In this
method, the HSQC spectrum with or without the ligand is used to determine the interaction
region of the ligand. Docking calculations are then performed to obtain a set of structural models.
From the latter, the nuclear Overhauser effects (NOEs) between the ligand and the protein
can be predicted. Guided by these predictions, a number of NOEs can be detected and assigned
through a HSQC NOESY experiment. These data are used as structural restraints to reject/
refine the initial structural models through further in silico work. For a test protein (MMP-12,
human macrophage metalloelastase), a final structure of a protein-ligand adduct was obtained
that matches well with the full structural determination. A number of structural predictions
were then made for adducts of a similar protein (MMP-1, human fibroblast collagenase) with
the same and different ligands. The quality of the final results depended on the type and number
of experimental NOEs, but in all cases, a well-defined ligand conformation in the protein binding
site was obtained. This protocol is proposed as a viable alternative to the many approaches
described in the literature.
Introduction
Rational drug design strategies must rely on the
availability of high-throughput methods to experimen-
tally determine the structure of candidate drug-target
complexes.1 The obtained structural information is then
used to improve and optimize the candidate drug in a
cyclic procedure. Obtaining three-dimensional macro-
molecular structures is still a time-consuming task.
X-ray structure determination is becoming a high-
throughput method,2 but the method requires the easy
availability of protein crystals that are suitable for
soaking with the various candidate drugs. NMR is also
a high-throughput technique in drug discovery,3,4 but
its power lies mostly in the earlier phases of the process,
i.e., in the first screening of a relatively large number
of compounds. NMR quickly provides information on
binding affinity and on the region of interaction of the
candidate drug with the target molecule.5
NMR is of course also able to determine the three-
dimensional structure of the adduct, but the procedure
is time-consuming.6 Moreover, obtaining a 3D structure
depends on the full assignment of thousands of intra-
protein nuclear Overhauser effect spectroscopy (NOE-
SY) cross-peaks, while the only relevant ones are the
few intermolecular cross-peaks between protein and
ligand signals. In silico prediction of the structure of
the adduct through docking programs, while valuable
in the early ligand design phases, is not reliable at this
stage.7-9 Independently of the docking program used,
in many cases more than one binding poses are found
that do not significantly differ in predicted binding
energies.
The availability of a fast and reliable method able to
provide a molecular model based on few experimental
restraints is an ambitious goal for overcoming these
problems. Recently, several efforts have been performed
in this direction.10-13 For instance, a suite of NMR
experiments has been recently proposed as a tool to
provide structural information on protein-ligand ad-
ducts,12 through intermolecular NOEs detected in se-
lectively labeled proteins. The method is applicable to
very large proteins once their three-dimensional struc-
ture is known.
For smaller proteins, it is worth to investigate whether
a few NOEs may be obtained even without selective
labeling of the proteins. We propose here a combined
use of computational tools and a small number of
experimental NMR restraints as an efficient way of
selecting the correct binding pose among those proposed
by docking programs. The experimental restraints are
(i) the heteronuclear single quantum coherence (HSQC)
chemical shifts to select the region of interest on the
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target, and (ii) the few ligand-target NOEs that can be
unambiguously identified from 15N NOESY-HSQC
experiments. Besides the protein three-dimensional
structure, only a singly 15N-labeled protein sample and
a preexisting assignment of its 15N 1H HSQC spectrum
are required.
The method has been validated by reproducing the
known docked conformation of N-isobutyl-N-[4-meth-
oxyphenylsulfonyl]glycyl hydroxamic acid (NNGH, see
Chart 1) bound to matrix metalloproteinase 12 (MMP-
12, human fibroblast metalloelastase). The method has
been then applied to obtain the docked conformations
of NNGH and other three ligands, (3-[[1-[[2-(hydroxy-
methyl)-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbam-
oyl]-octanohydroxamic acid (actinonin), N-[(2R)-2-(hy-
droxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryp-
tophan methylamide (galardin), and (2R)-2-mercap-
tomethyl-4-methylpentanoyl-L-phenylalanyl-L-alanine
amide (SIMP-1) (see Chart 1) to MMP-1 (human fibro-
blast collagenase). MMPs belong to a family of zinc-
dependent endopeptidases responsible for the metabo-
lism of extracellular matrix proteins,14-16 and alterations
in their levels are implicated in a wide range of
pathological states,17,18 so that these proteins represent
attractive drug targets.
Methods
The protocol consists of the following steps, reported
in Scheme 1: (a) identification of the protein binding
site, (b) calculation of possible protein-ligand adducts,
(c) prediction of the map of NOEs corresponding to each
computed conformation, (d) determination of few ex-
perimental restraints, able to select the real adduct
among those calculated, and (e) validation and cyclic in
silico refinement of the ligand position in the protein
scaffold. The identification of the protein binding site
can be conveniently performed from the analysis of the
chemical shifts acquired in the presence and in the
absence of the ligand. NOEs between ligand protons and
protein protons are obtained from 15N NOESY-HSQC
Chart 1
Scheme 1
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spectra. The protocol requires that the protein structure
and the assignment of its 15N 1H HSQC spectrum is
known.
HSQC spectra of the protein in the presence and in
the absence of the ligand must be acquired. Most of the
protein peaks will coincide in the two spectra. Only
peaks corresponding to amide protein protons close to
the ligand will be in different positions, but their shift
is usually small enough to be easily assigned. This
information is used to identify the protein binding site,
according to the value of the combined 1H/15N shift
perturbation upon complexation, given by ¢ ) (¢ä(1H)2
+ (¢ä(15N)/6)2)1/2.19 The residues with a significantly
large value of ¢, except those at sizably larger distance
from all others, are used to identify the grid for docking
calculations. The latter is centered on the protein
surface atom closest to the center of the smallest sphere
that comprises all the selected nitrogen atoms.
Due to the complexity of the energy landscape on the
path to the global minimum region,20 a specific ligand-
protein docking program is invoked in order to ac-
curately probe and select the conformations of the ligand
according to appropriate scoring functions. We use the
program Autodock because it has been amply validated
and tested on the target proteins selected for this study.
The docking program can be run to obtain clusters of
the possible adducts. Such clusters are then used to
predict NOEs between protein and ligand nuclei. In fact,
a map of distances between ligand and protein nuclei
can be obtained for each of the different clusters. The
presence of cross-peaks can thus be predicted for the
different possible adducts and compared with the cross-
peaks actually present in the experimental spectra.
The following experiments must be performed: 15N
NOESY-HSQC spectra of the protein-ligand adduct
and of the free protein, and the 1D 1H spectrum of the
free ligand in water. The latter experiment provides an
estimate of where the chemical shifts of ligand signals
in the adduct have to be looked for. The presence of
intermolecular cross-peaks, i.e., peaks between frequen-
cies close to those of the free ligand in one dimension,
and those of the protein amide protons predicted to be
in the vicinity of the ligand in the other dimension, is
checked. Such cross-peaks, if absent in the free protein
spectrum and not attributable to nuclei of other neigh-
boring protein residues, are unambiguously assigned.
A good correspondence between expected and observed
cross-peaks is a clear indication of the goodness of the
corresponding cluster. On the other hand, direct evi-
dence of the unacceptability of some of the clusters
generated by Autodock can be obtained. The experi-
mental NOEs, translated into upper distance limits, can
then be used to refine the remaining acceptable struc-
tures and possibly to further discriminate among them.
The refinement procedure has been developed using
Xplor-NIH. In such procedure, the protein side chains
are left free to move, thus allowing a better docking to
be obtained with respect to docking programs where the
protein is completely rigid.
The refinement procedure consists of loading the
calculated adduct and performing an in vacuo molecular
dynamics simulation in internal coordinates, with back-
bone atoms grouped together to constitute a rigid
structure. A simulated annealing is performed by heat-
ing the system to 1500 K and then cooling it to 50 K in
steps of 50 K. At each temperature, 750 steps of
molecular dynamics simulations are performed with
time steps of 2 fs. The force constant of NOE restraints
is fixed to 30 kcal mol-1 Å-2, and van der Waals,
electrostatic terms and the protein and ligand force field
(angles, bonds, dihedrals and impropers) are also in-
cluded. The resulting structures are then refined with
a Powell minimization, and ordered according to the
value of the target function. The latter is calculated
considering the ligand-residue and residue-residue
interactions only for residues up to 8 Å from the ligand.
This helps reducing the energy “noise” originating from
slight changes in residue-residue interactions far away
from the ligand site. In all cases, the best 10 structures
over 200 calculated through Xplor-NIH starting from
each tentative docking structure are very similar to one
another.
The structure of the adduct is thus calculated through
the consecutive use of the program Autodock and the
refinement procedure working in Xplor-NIH. Xplor-NIH
calculations can significantly change the protein side
chain positions after complexation. Therefore, cycling
between Autodock and Xplor-NIH refinement is neces-
sary until convergence to a fixed protein structure is
achieved. We have tested that such approach can
actually select the correct ligand-protein docking,
among those proposed by Autodock. Furthermore, the
introduction of experimental data and the allowed
mobility of the protein side chains provide more confi-
dence in the obtained adduct.
MMP systems, the receptors that we used in this
work, have a catalytic zinc ion as active center, coordi-
nated to three histidines. The three zinc-coordinated
histidines were treated as the neutral form with the
hydrogen on ND1, whereas other histidines used the
default option with hydrogen on NE2. Glutamates were
treated as charged form as default, except the catalyti-
cally essential glutamate 219,21 at the second shell of
the zinc binding site. The latter residue was protonated,
with the hydrogen on the oxygen nearest to the catalytic
zinc, or deprotonated depending on whether the zinc
donor atom closest to it was deprotonated (hydroxamate
ligands)21 or protonated (thiol ligands). To take into
account the electron density delocalization due to coor-
dination of ligands, the charge of the zinc ion was
distributed among the protein ligands.21
Results
Test with a Known Structure: MMP-12-NNGH.
NNGH is a broad spectrum MMP inhibitor able to
interact with both the catalytic zinc and the S1′ cav-
ity.6,22 In particular, it is able to bind MMP-12 with
nanomolar affinity (Kd ) 10 nM),6 and for this reason
it has been chosen as a model system to study protein-
inhibitor interactions. Its molecular structure is re-
ported in Chart 1.
The structure of MMP-12 complexed to NNGH is
already known,6 as both the X-ray (Figure 1A) and the
NMR structures of the adduct have been solved. There-
fore, we used such system as a test for our protocol. The
HSQC spectra of the protein without and with the
NNGH in solution were acquired. Inspection of residues
showing significant chemical shift perturbation (see
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Table 1) permitted to define the ligand binding region
as the protein catalytic site (defined here as constituted
by the zinc binding region, the S1′ pocket and the
substrate binding groove) with reasonable accuracy. As
expected from the crystal structure of the MMP-12-
NNGH adduct, among the affected resonances are
residues 210, 211, 215, and 216 on the R helix at the
bottom of zinc binding site, residues 237, 239-240 and
242 forming the hydrophobic S1′ cavity, and residues
179-182 and 184 on the strand facing both the catalytic
metal and the S1′ pocket (Figure 1B).
Calculations were performed using the X-ray struc-
ture of the protein (PDB 1Y93) at 1.03 Å resolution.6
Autodock was used to select the lower docking energy
conformations. Docked conformations were clustered
according to a maximal RMSD of 1 Å (Figure 2). The
docking energies for the first, second, third and fourth
clusters were -15.89, -15.84, -15.01, and -14.44 kcal
mol-1, respectively. The second cluster is in accordance
with the X-ray structure of the adduct (PDB 1RMZ).6
The plane containing the hydroxamic group in the first
and third cluster is oriented perpendicularly to the
plane containing the hydroxamic group in the second
cluster. The p-methoxy-phenyl group enters more deeply
in the S1′ pocket in the first than in the third cluster.
In the fourth cluster the p-methoxy-phenyl group does
not sit in the S1′ pocket.
These structures were separately refined with Xplor-
NIH using the already available NOEs with protein
backbone NH atoms (see Figure 3B).6 The second cluster
remains essentially unchanged, with total energy -1184
kcal mol-1 (see Figure 2). The structure calculated using
the third cluster as starting conformation is similar to
the previous one, with total energy -1179 kcal mol-1.
The structure calculated from the first cluster has total
energy -1062 kcal mol-1, and no coordination of the
hydroxamic group to the metal ion; the one calculated
from the fourth cluster has total energy -734 kcal
mol-1, and the p-methoxy-phenyl group outside the S1′
pocket.
Slight changes in the side-chain protein structure
were obtained, and new Autodock calculations were thus
performed using the three lowest energy Xplor-NIH
protein structures. Remarkably, the lowest docking
energy clusters calculated by Autodock now converge
to similar conformations using the second and third
Xplor-NIH protein structure (see Figure 2). These
conformations are in agreement with the X-ray struc-
ture, with docking energy from -15.85 kcal mol-1 to
-15.63 kcal mol-1. Xplor-NIH refinements provided
structures (see Figures 2 and 3B) with lowest total
energy from -1197 to -1180 kcal mol-1, in agreement
with the X-ray structure (see Figure 3A).
Analogous calculations were performed also using the
X-ray structure PDB 1OS9, with 1.85 Å resolution.23 In
this structure the active site of one molecule is not
hosting an external ligand but the N-terminal part of
the neighboring protein molecule. The calculations
converged to the same adduct obtained starting from
the 1Y93 structure.
Determination of Structural Models for Ligand
Adducts of MMP-1. NNGH itself and three other
known strong inhibitors of MMPs were selected as
representatives of different classes of ligands and tested
against MMP-1. The test consists in following the
protocol described above and checking whether (i)
unambiguous NOEs could be obtained and (ii) the
cycling between Autodock and Xplor-NIH calculations
permits the selection of one ligand conformation. Cal-
culations were performed using the X-ray structure of
the inhibitor-free protein (PDB 1CGE) with 1.90 Å
resolution.24
MMP-1-NNGH. The first ligand examined is the
same ligand used to validate the protocol with MMP-
12. The structure of the NNGH adduct with MMP-1 is
not known, although it is reasonable to believe that it
will adopt a similar conformation. We measured an IC50
value for the adduct of 174 nM.
Chemical shift perturbation affects the zinc binding
histidine 228 and the neighboring residues 226, 227, and
229, residues 239, 240, and 243 forming the S1′ hydro-
phobic pocket, residues 215, 217, and 219 on the R-helix
where the metal binding site is inserted, and residues
180 and 184 on the parallel strand (see Figure 1C). This
is an expected feature, but it is a new independent
experimental information based on which an Autodock
grid was generated. The grid resulted nicely centered
around the known catalytic site. Autodock calculations
using this grid were thus performed.
The four lower docking energy clusters were analyzed.
The docking energies were -14.68, -13.99, -13.94, and
-13.81 kcal mol-1, respectively. The structures in the
first and third clusters show similar hydroxamate
Figure 1. X-ray structure of the MMP-12-NNGH adduct
(PDB 1RMZ) (A), residues of MMP-12 affected by chemical
shift perturbation upon complexation with NNGH (B), and
residues of MMP-1 affected by chemical shift perturbation
upon complexation with NNGH (C), actinonin (D), galardin
(E), and SIMP-1 (F) (see Table 2).
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coordination to the catalytic zinc. The ligands in the
second cluster are oriented similarly to those in the first
cluster, but the hydroxamic acid is coordinated to zinc
only though the carboxylic oxygen. The structures in the
fourth cluster show coordination of the sulfonate oxygen
(SO) atoms to zinc. In all cases the p-methoxy-phenyl
group sits in the S1′ hydrophobic pocket. The position
of the i-butyl group changes in the four adducts. In the
first and second clusters it prevents the formation of
hydrogen bonding between the hydroxamic HN and
alanine 182 oxygen, whereas the latter hydrogen bond
is present in the third cluster.
NOE restraints were obtained in the following way.
In the 15N NOESY-HSQC spectrum, a cross-peak at
chemical shift of 11.7 ppm is present in the N leucine181
plane (Figure 4). Such a shift is too high to be assigned
to a protein signal, as no tryptophan residue is close to
the active site. Therefore, it was assigned to the unique
amide proton of NNGH. Aromatic protons of NNGH are
close to N of residues glycine 221, histidine 222, alanine
216, and arginine 214 according to the structures calcu-
lated by Autodock. We have searched in the spectrum
all the long range NOEs between aromatic protons and
amide groups of these residues. New peaks in the
spectrum of the adduct that cannot be due to intrapro-
tein interactions actually appear in the aromatic region
(Figure 4) and were assigned as reported in Table 2.
The structural families obtained with Xplor-NIH
starting from the first three lowest Autodock docking
energy structures converged to the same conformation
(see Figure 5). This conformation was similar to the
conformation of the third Autodock cluster, with the
exception that the sulfur oxygen H-bonded to alanine
182 was the most external oxygen atom rather than the
internal one. The lowest total energies were -622, -617,
and -615 kcal mol-1, respectively. The lowest total
energy of the structural family obtained with Xplor-NIH
starting from the fourth Autodock structure was -592
kcal mol-1. This adduct, slightly different from the other
three for the fact that zinc coordination by hydroxamate
was loose, can be excluded due to its larger energy.
No appreciable changes in the protein side chain
positions are observed and thus further Autodock/Xplor-
NIH cycles were not needed. Therefore, the structural
family shown in Figure 3C represents an experimentally
validated and unique structural model for the MMP-
1-NNGH adduct.
MMP-1-Actinonin. Actinonin, whose molecular
structure is reported in Chart 1, is a well-known
inhibitor of aminopeptidases and peptide deformylase.25
It is also a strong inhibitor for some MMPs, with a Ki
of 300 nM for its adduct with MMP-1.26
Chemical shift perturbations again allow us to map
the region of interest on the protein surface. Residues
215, 217, 218, 220, 223, and 227 forming the metal
binding site, residues 235, 236, and 249 on the loop that
covers the S1′ pocket, and residues 180 and 182 on the
spatially close strand (see Figure 1D) define the ligand
binding region and were used for the definition of the
Autodock grid. Despite the incomplete correspondence
of the affected residues with those found for the NNGH
adduct, the resulting grid was quite similar. Four
clusters were then calculated (docked conformations
were again clustered according to a maximal RMSD of
1.0 Å, see Figure 6). In all structures the hydroxamate
is bound to the catalytic zinc. However, whereas in the
first two structures the pentyl group is located inside
the S1′ hydrophobic pocket and the external propyl
group is differently oriented, in the third and fourth
structures the two groups are interchanged. The lowest
docking energy for the structures in the four clusters
were -19.91, -19.11, -18.82, and -18.62 kcal mol-1,
respectively.
Cross-peaks of all protons belonging to the ligand with
the HN protein protons expected at distances shorter
than 5 Å for one or another cluster were looked for in
the 15N NOESY-HSQC spectrum. Since the NH of
tyrosine 240 has two unassigned cross-peaks at fre-
quencies typical of methyls, they must be related to two
methyl groups that are close in the structure of the
adduct. From the clusters generated by Autodock, they
can only be H′ and H′′′. The following peaks were thus
assigned: (a) methyl protons H′′′ with tyrosine 240 and
with the aligned threonine 241 and (b) H′ with tyrosine
240. Among the clusters generated by Autodock, the
third and fourth clusters can be readily excluded,
because in such structures the above cross-peaks could
not be observed. Therefore, by looking at the other two
clusters, we also assigned the following cross-peaks,
which cannot be assigned to other intraresidue protons
or to side chain protons of close residues: (c) alanine
184 with H1 and tyrosine 240 with H6, as such protons
are the closest to the coupled HN protons; (d) leucine
181 and tyrosine 240 with H′, as they are aligned and
close to one another.
Xplor-NIH calculations were thus performed to refine
the selected Autodock structures. Actually, we per-
Table 1. MMP Residues Subjected to Significant Chemical Shift Perturbations (in bold)a
seq 163 171 174 186 204 209
MMP12+NNGH F A R G A H G D D .. F D G K G G I L A H A F G .. T T H S G G
MMP1+NNGH F V R G D H R D N .. F D G P G G N L A H A F Q .. T N N F R E
MMP1+act F V R G D H R D N .. F D G P G G N L A H A F Q .. T N N F R E
MMP1+SIMP1 F V R G D H R D N .. F D G P G G N L A H A F Q .. T N N F R E
MMP1+gal F V R G D H R D N .. F D G P G G N L A H A F Q .. T N N F R E
seq 210 230 235 243 249
MMP12+NNGH T N L F L T A V H E I G H S L G L G H S S .. V M F P T Y K Y V S
MMP1+NNGH Y N L H R V A A H E L G H S L G L S H S T .. L M Y P S Y T F S A
MMP1+act Y N L H R V A A H E L G H S L G L S H S T .. L M Y P S Y T F S A
MMP1+SIMP1 Y N L H R V A A H E L G H S L G L S H S T .. L M Y P S Y T F S A
MMP1+gal Y N L H R V A A H E L G H S L G L S H S T .. L M Y P S Y T F S A
a Residue numbers refer to the MMP-1 sequence. Chemical shifts for residues in italics are not available.
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formed the calculations not only starting from the first
two structures, but also starting from the structures
excluded according to the observation of the 15N NOE-
SY-HSQC spectrum. The first and second family of
structures calculated with Xplor-NIH are very similar
to the corresponding Autodock structures; the third
Xplor-NIH structural family shows significant rear-
rangements in the position of the ligand branches, but
the pentyl group remains located outside the hydropho-
bic pocket; in the fourth Xplor-NIH structural family
the pentyl group lies in the hydrophobic pocket, thus
resulting similar to the first and second families. Xplor-
NIH energies for the four families are -870, -862,
-811, and -840 kcal mol-1, respectively. This indicates
that the third structure, quite different from the other
three, is not acceptable. The calculations show that the
method is indeed robust. In fact, the first two Autodock
structures that were selected from the observation of
the NMR spectra actually have the lowest energy,
whereas the third has a sizably larger energy even after
Figure 2. Representative structures of the MMP-12-NNGH adduct for the four lowest energy clusters obtained from Autodock
(first row), Xplor-NIH (second row), a second Autodock run (third row), and further Xplor-NIH calculations (fourth row). The
final validated structures are highlighted.
Combining in Silico Tools and NMR Data Journal of Medicinal Chemistry, 2005, Vol. 48, No. 24 7549
Xplor-NIH refinement. Interestingly, the fourth Au-
todock structure, initially completely different from the
first two, was brought by Xplor-NIH calculations to
converge with the first two.
A second Autodock and Xplor-NIH cycle was per-
formed starting from the lowest energy protein struc-
ture. The calculated Xplor-NIH structures, in fact,
showed slightly different positions of protein side chains,
in particular of residues leucine 181, proline 238, and
tyrosine 240. Such new protein conformation was pro-
vided to Autodock for a new docking calculation. The
best four Autodock clusters (docking energy -20.61,
-19.07, -18.99, and -18.88 kcal mol-1) were then
provided to Xplor-NIH. The first, third and fourth
clusters display both the hydroxamate and the pentyl
group in similar positions; the second one is completely
different (the hydroxamate does not bind the zinc ion).
All lowest energy Xplor-NIH structures (see Figure 3D),
with the exception of those calculated starting from the
second Autodock structures, converged to the third
Autodock conformation, and are equivalent to the lowest
energy Xplor-NIH family calculated in the first cycle.
The total energies for these structures are -881, -880,
and -870 kcal mol-1. The Xplor-NIH structure calcu-
lated starting from the second Autodock structure has
a total energy of -810 kcal mol-1 and can thus be
excluded. Therefore, the structure family of Figure 3D
is a unique structural model for the MMP-1-actinonin
adduct.
MMP-1-Galardin. Galardin (see Chart 1) is a broad
spectrum peptidomimetic inhibitor of MMPs16 with an
IC50 of 1.5 nM for MMP-1.27 Chemical shift perturbation
involved residues 215, 216, 218, 220, 223, 227, and 228
at the metal binding site, 236, 237, 240, and 243 at the
large loop covering the S1′ cavity, and 179 and 183 at
the strand facing the S1′ cavity and the metal binding
site (Figure 1E). These residues were used to define the
Autodock grid, which again was found very similar to
the previous ones. The four lowest docking energy
clusters calculated by Autodock (-19.79, -19.51, -18.59,
and -17.48 kcal mol-1, respectively) showed the follow-
ing features (see Figure 7). In the first, second and third
cluster the i-butyl group enters the S1′ pocket, whereas
in the fourth cluster it is outside. The structures in the
first and second clusters are very similar, as they differ
only for the orientation of the indole group, positioned
outside the S1′ pocket. The structures in the third and
fourth cluster are quite different from those in the first
and second cluster, including the position of the indole
group, which in any case remains outside the S1′ pocket.
In the 15N NOESY-HSQC spectrum, two cross-peaks
are present in the N phenylalanine 242 and tyrosine
240 planes. Such peaks are at chemical shifts typical of
methyl groups and cannot be assigned to any intraresi-
due proton or proton of close residues. Since in galardin
there are three methyl groups, two of them being close
in the structure, the latter (H′ and H′′) were assigned
to these peaks. Another cross-peak is present that
cannot be assigned to protein protons in the plane of
tyrosine 240. This cross-peak falls into the aliphatic
region, and therefore it could be provided by CH or CH2
protons. Since such proton must be close to H′ and H′′,
which have also a cross-peak with tyrosine 240, it was
assigned to H6 or H7.
Figure 3. X-ray structure of the MMP-12-NNGH adduct (A),
structures calculated with the proposed protocol of the MMP-
12-NNGH adduct (B), and structures calculated with the
proposed protocol for the adduct of MMP-1 with NNGH (C),
actinonin (D), galardin (E), SIMP-1 (F). Labels in panels B-F
indicate the residue numbers of amino acids exhibiting NOE
contacts to the ligands.
Figure 4. Protein-ligand cross-peaks observed in the 15N
NOESY-HSQC spectrum of the MMP-1-NNGH sample.
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Xplor-NIH calculations change only slightly the con-
formations obtained with Autodock relative to the first
three clusters. The structure obtained starting from the
fourth Autodock cluster is instead modified by the NOE
restraints to have the i-butyl group inside the S1′ pocket
as in the other three clusters. The total energy of the
Xplor-NIH structures are -575, -578, -565, and -527
kcal mol-1, respectively. Only small changes in the side
chain positions have been observed, regarding in par-
ticular residues from 238 to 241.
The three protein structures with the smallest Xplor-
NIH energy were used to repeat Autodock calculations.
In the first case Autodock produced the two lowest
docking energy clusters very similar to those obtained
in the first run (-18.87 and -18.57 kcal mol-1), whereas
the third and fourth clusters (with docking energy
-18.08 kcal mol-1) have now the indole group inside
the S1′ pocket. These conformations can be excluded by
the observed NOEs. It is remarkable that such faulty
Autodock behavior occurs in the second round, i.e., after
adjustment of the structure by Xplor-NIH minimization.
This observation underlines the need for experimental
restraints to gain confidence in in silico models. In the
second case, the three lowest docking energy clusters
are again very similar to those obtained in the first run
(-19.59, -19.56, and -18.14 kcal mol-1), whereas in
the fourth cluster (with docking energy -17.83 kcal
mol-1) the i-butyl group is outside the S1′ pocket. In
the third case, the lowest docking energy cluster is again
similar, with energy -18.42 kcal mol-1. The Xplor-NIH
calculations performed with the four lowest docking
energy structures as starting conformations converged
to a unique conformation (-586, -584, -576, and -576
kcal mol-1), except for the indole group, which, being
outside the S1′ pocket, is free to move (Figure 3E).
Again, the family of Figure 3E can be confidently taken
as a validated structural model for the galardin adduct
of MMP-1.
MMP-1-SIMP-1. SIMP-1 is a polypeptide derivative
able to inhibit collagenases.16 Its molecular structure
is reported in Chart 1. We measured an IC50 value for
the adduct of 46 nM. In the MMP-1-SIMP-1 adduct,
affected resonances include residues 215, 217-218, 220,
222, 223, 227, and 228 on the R helix of the zinc binding
site, residues 235-237, 239, 240, and 242 forming the
S1′ cavity, and residues 179, 180, and 184 on the strand
facing both the catalytic metal and the S1′ pocket
(Figure 1F). The four clusters with smallest docking
energy calculated by Autodock (see Figure 8) have
docking energy of -16.15, -15.92, -15.76, and -15.72
Table 2. Observed NOEs between MMP-1 Amide Protons and Ligand Protons
181 182 184 214 216 221 240 241 242
NNGH H1 (H10,H11) (H10,H11) H12
H13
actinonin H′ (H3,H4) H1 H′′′ H′′′
H6 H′ (H23,H24)
H6
galardin H′ H′
H′′ H′′
(H6,H7)
SIMP-1 (H17,H18,H19,H20,H21) H′ H′′
H′′
Figure 5. Representative structures of the MMP-1-NNGH adduct for the four lowest energy clusters obtained from Autodock
(first row) and from Xplor-NIH (second row). At this point convergence was obtained. The final validated structures are high-
lighted.
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kcal mol-1. In the first and second clusters the sulfur
atom coordinates the catalytic zinc; in the first cluster
the S1′ pocket interacts with the ligand benzyl group,
in the second with the i-butyl group. In the third cluster
the sulfur atom is hydrogen bonded to the oxygen of
glycine 179, on the other site of the catalytic pocket with
respect to the zinc ion, and the ligand benzyl group sits
in the S1′ pocket. In the fourth cluster, the ligand is
oriented similarly as in the first cluster, but the ligand
sulfur atom is loosely coordinated to the zinc ion, and
hydrogen bonded to glutamate 219.
In the 15N NOESY-HSQC spectrum, in the N plane
of residue leucine 181, there are two signals in the
aromatic region that cannot be assigned to protein side
chains. Therefore, they must be assigned to protons of
the aromatic ring of the SIMP-1. Two cross-peaks, one
of low and one of high intensity, are present in the N
plane of tyrosine 240 at frequencies typical of methyl
Figure 6. Representative structures of the MMP-1-actinonin adduct for the four lowest energy clusters obtained from Autodock
(first row), Xplor-NIH calculations (second row), a second Autodock run (third row), and further Xplor-NIH calculations (fourth
row). The final validated structures are highlighted.
7552 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 24 Bertini et al.
groups that cannot be assigned to intraresidue or
sequential contacts. In one of the clusters calculated by
Autodock, N of tyrosine 240 is close to two of the three
methyls of SIMP-1, H′ being closest than H′′, and thus
the cross-peaks were correspondingly assigned (see
Table 2). A further distance restraint is determined from
another cross-peak in the N plane of threonine 241,
aligned with the signal assigned to H′′.
Xplor-NIH calculations select the second Autodock
cluster as the correct one. In fact it remains almost
unchanged after refinement, with total energy -709
kcal mol-1. Calculations performed starting from the
other clusters provide structures very different from the
starting ligand conformation, and with the ligand not
coordinated to the zinc ion. Their total energies are
larger than -634 kcal mol-1 and such structures are
thus excluded.
Slight changes in the protein side chain positions are
observed, in particular on residues 180, 214 and 219. A
second Autodock calculation was thus performed. The
first three clusters (with docking energy of -16.15,
-16.12 and -15.88 kcal mol-1, respectively) show a
Figure 7. Representative structures of the MMP-1-galardin adduct for the four lowest energy clusters obtained from Autodock
(first row), Xplor-NIH calculations (second row), a second Autodock run (third row), and further Xplor-NIH calculations (fourth
row). The final validated structures are highlighted. The configuration of the indole ring is not defined because of lack of
experimental restraints and strong energetic preference in Xplor-NIH calculations.
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ligand pose similar to that calculated in the first and
fourth clusters of the first Autodock run. The fourth
cluster, with docking energy -15.77 kcal mol-1, is
instead similar to the pose already identified as correct.
Xplor-NIH calculations again confirmed such structure
as the correct one, with total energy -708 kcal mol-1.
The corresponding family is shown in Figure 3F. This
family represents the validated structural model of the
MMP-1-SIMP-1 adduct.
Backbone Mobility. To test the protocol for possible
protein backbone rearrangements upon complexation,
Xplor-NIH calculations were also performed with al-
lowing the protein backbone to move in the protein
region affected by chemical shift perturbation. In all
Figure 8. Representative structures of the MMP-1-SIMP-1 adduct for the four lowest energy clusters obtained from Autodock
(first row), Xplor-NIH calculations (second row), a second Autodock run (third row), and further Xplor-NIH calculations (fourth
row). The final validated structures are highlighted.
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cases we found no appreciable differences in the results.
In fact, for all adducts the lowest energy structures
corresponded to those identified as correct in the
calculations performed with rigid backbones.
Discussion
A protocol has been developed to merge the “pure”
docking capability of Autodock (or other docking pro-
grams) with the exploitation of available experimental
restraints. For the relatively strong ligands (Kdiss ap-
proximately micromolar or less) elected here, the pro-
tocol has been shown to be efficient, robust and reliable.
As shown in Scheme 1, the protein binding site is
identified from chemical shift perturbation in the HSQC
spectrum of the protein upon complexation. The obser-
vation of shift perturbations on passing from the as-
signed spectrum of the free protein to the spectrum of
the adduct permits the definition of the protein grid to
be used in Autodock calculations. Autodock usually
provides several clusters of structures for the adduct,
which often have similar docking energy. These struc-
tures are used to calculate maps of NOEs, to be
compared with NOEs actually observed in the 15N
NOESY-HSQC spectrum of the adduct. A few ligand-
protein NOEs can always be assigned, and the latter
can be used as restraints in Xplor-NIH calculations for
selection, validation and refinement of the Autodock
structures. One-two cycles at most may be needed in
case Xplor-NIH calculations modify some protein side
chain positions with respect to the structure provided
to Autodock. All these steps could be performed semi-
automatically, if required.
The protocol relies on the following information to be
available: the protein structure; the assigned HSQC
spectrum of the free protein; the 15N NOESY-HSQC
spectrum of the free protein; the HSQC and 15N NOE-
SY-HSQC spectra of the protein-ligand adduct; and
the 1D 1H spectrum of the ligand. The protocol has been
developed in order to avoid preparation of doubly
labelled samples and assignment of protein side chains,
thus resulting in a much faster throughput.
We have shown that such approach is actually ef-
ficient in finding the protein-ligand structure for four
adducts of MMP-1 with different ligands. The peculiar-
ity that makes this approach successful in the cases here
examined is the combination of a docking program, able
to quickly and efficiently sample the possible binding
poses, with a molecular dynamics program, which
selects the proposed poses using few unambiguous
experimental data. In this way the efficiency of the
former program is coupled to the complexity of the
latter, which also allows for protein side chain move-
ments. The program has been deliberately tested using
only unambiguous NOEs obtainable from the assign-
ment of HN, but it is obviously open to the use of
additional or different restraints. We decided to use the
chemical shift perturbations only for the determination
of the grid to be used for the docking program calcula-
tions, without including them as restraints in the
molecular dynamics program due to their ambiguous
nature, although ambiguous restrains could be in
principle used, either as such, as recently proposed,13
or through calculation of j-surfaces.10 The use of chemi-
cal shift perturbations for the determination of the grid
is much less stringent than their use as constraints, as
a few “second sphere” shifts erroneously mistaken for
first sphere shifts may drive the ligand in wrong
positions, while the resulting grids are expected to be
only somewhat broadened. As a matter of fact, differ-
ences in perturbed residues from one ligand to another
do not result in grossly different grids, and the latter,
in all cases, encompassed the whole catalytic site.
Several predicting programs for protein-ligand ad-
ducts have been proposed in the literature. Inclusion of
biochemical and biophysical data in docking protocols,
called guided docking,28,29 is a common approach to
reduce the conformational variety of the proposed
solutions. Some other programs7-9,30-35 work totally in
silico, without experimental information on the inves-
tigated adduct, and perform docking calculations with
an improved level of sophistication. They can be suc-
cessful, but the level of confidence for the proposed
adduct is difficult to establish. Furthermore, a strong
bias toward known solutions or preconceived require-
ments is introduced if the docking is restrained accord-
ing to chemical information derived from databases of
protein-ligand complexes. Other programs36-39 use the
experimental NMR information more systematically,
thus being similar to structural determination programs
and therefore more time-consuming. NMR-derived re-
straints were also used in docking programs to identify
the location of the ligand binding10 and to restrict the
conformational space for molecular modeling routines.11
NMR experiments on selectively labeled proteins were
also used to obtain structural information on protein-
ligand complexes.12 This approach, although more ex-
pensive than the one here proposed, is probably the only
viable in case of large proteins. To our knowledge this
is the first time that an approach is proposed where few
experimental data are used to select and refine poses
proposed by fast docking programs.
Autodock has been selected among the docking pro-
grams because in the case of MMPs it was demonstrated
to be a robust program with good docking accuracy and
reliability, including the correct geometry of the zinc
binding groups.21,40 It employs a genetic algorithm
searching function, able to efficiently sample large
search spaces. Different docking programs could how-
ever be used if considered more reliable in other cases.
In the same way, other molecular dynamic programs
could be used instead of Xplor-NIH. We used Xplor-NIH
as an NMR-oriented widespread general program for
structural calculations using simulated annealing. Ligand
growing procedures30 may also be implemented in Xplor-
NIH, resulting probably useful especially in case of large
ligands.
Although the presence of the metal ion in MMPs tends
to restrict the number of Autodock clusters by favoring
poses where the hydroxamic moiety is coordinated to
the metal, the protocol is expected to be useful also in
case of proteins not containing catalytic ions. Actually,
docking programs are developed to work mainly in their
absence, and, in case they propose several different
conformations, the detection of NOEs may result deci-
sive for the selection of the correct one. Indeed, as we
have seen, Autodock does not always succeed in cor-
rectly binding the metal to the hydroxamic moiety.
Furthermore, in the absence of the metal, further
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H-bonds or van der Waals contacts should occur for
strong ligands, which would likely provide additional
intermolecular NOEs.
We have shown that it is possible to obtain few
intermolecular experimental NOEs through fast NMR
experiments without the necessity to assign all protein
NOESY cross-peaks. Only unambiguous NOEs between
protein and ligand protons have been considered; there-
fore, cross-peaks were assigned to ligand protons only
if they could not be reasonably assigned to any protein
side chain proton, taking into account the structural
adducts proposed by Autodock. In all cases here ad-
dressed, experimental restraints have been shown to be
necessary and sufficient to extract the adduct conforma-
tion among the several proposed by Autodock with
similar docking energy, and thus are used to validate
them. Furthermore, the approach proposed can also be
useful to refine the structure of the ligand-protein
adduct, especially because local small modifications in
the protein structure (of side chains, if sufficient as in
the present case, but also in the protein backbone, if
needed - see below) can be accommodated by cycling
between Autodock/Xplor-NIH runs. This makes the
present approach preferable to the direct introduction
of distance restraints in docking programs with a fixed
protein matrix.
The solution structure of the inhibitor-free MMP-1,
obtained from a series of 3D triple-resonance NMR
experiments, shows nearly identical both backbone and
secondary structures than the crystallographic struc-
tures.41 Furthermore, the backbones of the solution
structures of the inhibitor-free MMP-1 and of the
MMP-1 complexed with a sulfonamide derivative of the
hydroxamic acid compound have been shown to be
essentially identical,42 although mobility measurements
indicate that the region near the active site is highly
mobile.41,42 It is thus reasonable, at least in our case, to
assume that the protein backbone remains rigid during
complexation in solution, and with structure identical
to the crystallographic structure.
Although not necessary for the present calculations,
also the protein backbone could be allowed to (partially)
move in Xplor-NIH calculations (see results). This could
be important if modest backbone rearrangements are
expected upon ligand binding, as could be indicated by
chemical shift perturbations spread out over a wider
region.
It is known that effective MMP inhibitors achieve
tight binding via extensive van der Waals contacts with
the hydrophobic interior of S1′ and by strong electro-
static interactions with zinc and nearby charged or polar
side chains.43 All calculated adducts indeed show ligand
coordination to the catalytic zinc and the formation of
a net of hydrogen bonds between ligand and protein
residues. This result is not trivial as it may seem, as
several of the initially obtained Autodock structures had
severely distorted - or were even lacking - hydroxam-
ate coordination to the zinc ion.
The distance between zinc and hydroxamate oxygens
is in all calculated structures between 1.95 and 2.25 Å.
The O-Zn-O angle is always between 86 and 93°. The
coordination geometry is distorted square-pyramidal in
MMP-12-NNGH and MMP-1-actinonin, and distorted
trigonal bipyramidal, with hydroxamic O2 and N his-
tidine 222 in axial positions, in MMP-1-NNGH and
galardin. All hydrogen bonding interactions between
MMPs and ligands are reported in Table 3. In particu-
lar, H-bonds are present in all adducts with NNGH,
actinonin, and galardin between oxygen of alanine 182
and the amide proton of the hydroxamic group, as well
as between the protonated glutamate 219 and the
oxygen of the hydroxamic group. H bonds are also
present between ligands and HN of Leu 181, as previ-
ously seen in the MMP-1-CGS42 and in the MMP-12-
NNGH adducts. In the MMP-1-SIMP-1 adduct, with a
distorted tetrahedral coordination geometry around the
zinc ion, constituted by the three histidine nitrogen
atoms and the sulfur SIMP-1 atom, a net of hydrogen
bonds is formed, connecting the ligand to the protein
atoms (see Table 3). Both the coordination geometry and
the H-bonding network can be used to assess the
reliability of the obtained adducts. In all the adducts,
the inhibitors establish enough interactions to reach
nanomolar affinity. In particular, all the ligands bind
the metal, place a lipophilic moiety into the S1′ cavity
and establish two or more hydrogen bonds with atoms
of the protein groove. This binding mode is reasonable
and is indeed adopted by many strong ligands of MMPs.
Cycling between fast docking programs and Xplor-
NIH calculations can be used to assess ligand-protein
structures also in the presence of restraints different
from NOEs. Diamagnetic residual dipolar couplings
have already been demonstrated to be extremely useful
to predict the structure of protein-protein adducts.20,44-46
Also pseudocontact shifts have been used for the study
of protein-protein docking.47 Paramagnetism-based
restraints, and in particular paramagnetic relaxation
rates, pseudocontact shifts and residual dipolar cou-
plings, arising when a paramagnetic metal ion is
coordinated to the protein, could be employed as re-
straints in the proposed protocol for protein-ligand
docking. Xplor-NIH has the advantage that it already
contains the tools needed to deal with such restraints.48
Table 3. Predicted H-bonds between Protein and Ligand
Nuclei
MMP-12-NNGH 181 Leu HN NNGH O4/O3
182 Ala HN NNGH O3
219 Glu HO1 NNGH O1
NNGH H1 182 ALA O
MMP-1-NNGH 182 Ala HN NNGH O4
219 Glu HO1 NNGH O1
NNGH H1 182 Ala O
MMP-1-actinonin 181 Leu HN act O3
219 Glu HO1 act O1
240 Tyr HN act O4
act H1 182 Ala O
act N2 238 Pro O
MMP-1-galardin 181 Leu HN gal O3
182 Ala HN gal O3
219 Glu HO1 gal O1
240 Tyr HN gal O4
gal H5 238 Pro O
gal H1 182 Ala O
MMP-1-SIMP-1 181 Leu HN SIMP1 O1
182 Ala HN SIMP1 O1
240 Tyr HN SIMP1 O2
SIMP1 H8 238 Pro O
SIMP1 H1 219 Glu OE1
SIMP1 H23 179 Gly O
SIMP1 H26 210 Tyr OH
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Conclusions
A novel protocol to obtain validated structural models
of protein-ligand complexes has been developed and
applied for the determination of the structure of the
adducts of the protein MMP-1 with four different
ligands. The method was shown to be reliable, as tested
for the known structure of the adduct of one of these
ligands with MMP-12. It uses NMR derived restraints
obtained using singly (15N) labeled proteins. The strat-
egy that we propose promises to be generally useful also
for the structural determination of different protein-
ligand adducts, whenever the structure of the free
protein is known and the structural changes upon
complexation are not expected to be dramatic.
Experimental Section
Sample Preparation. The fragment of human fibroblast
collagenase corresponding to proMMP-1 (Pro21-Pro269) and
bearing an additional methionine at the N-terminal, was
expressed in Escherichia coli. The cDNA was cloned into the
pET21 vector (Novagen) using NdeI and XhoI as restriction
enzymes. The E. coli strain BL21 Codon Plus cells, transfected
with the above vector, were grown in 2  YT media at 37 °C.
The protein expression was induced during the exponential
growth phase with 0.5 mM of IPTG. Cells were harvested for
4 h after induction. Uniform15N-labeled protein was obtained
by growing the transfected BL21 Codon Plus cells in minimal
media at 37 °C. The cells were lysed by sonication and the
inclusion bodies, containing the proMMP-1, were solubilized
in 2 M urea, 20 mM Tris (pH 8.0). The protein was purified
on the Hitrap Q column (Pharmacia) with a buffer containing
2 M urea and 20 mM Tris (pH 8.0). The elution was performed
using a linear gradient of NaCl up to 0.35 M. The purified
protein was then refolded by using a multistep dialysis against
solutions containing 50 mM Tris (pH 7.2), 10 mM CaCl2, 0.1
mM ZnCl2, 0.3 M NaCl. The refolded protein was exchanged,
by dialysis, against a buffer with 10 mM Tris (pH 7.2), 5 mM
CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl. The protein was activated
by 1 mM APMA (4-aminophenylmercuric acetate) at 4 °C
overnight and dialyzed with a buffer containing 10 mM Tris
(pH 7.2), 5 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl, 0.2 M
acetohydroxamic acid (AHA). The activated protein (Val 101-
Pro 269) was concentrated using an Amicon stirrer and
Centriprep concentrators, fitted with a YM10 membrane in
nitrogen atmosphere at 4 °C. Catalytic domain of MMP-1 was
purified using size-exclusion chromatography with the final
dialysis buffer and concentrated up to 0.5 mM using an
Centriprep concentrators in nitrogen atmosphere at 4 °C. The
final protein sample was dialyzed against a solution containing
50 mM sodium acetate, 100 mM NaCl, 5 mM CaCl2, 0.1 mM
ZnCl2, with 10% of D2O (pH 6.5).
Inhibited proteins were prepared by titration of the free-
MMP-1 with equimolar amounts of NNGH, SIMP-1, galardin,
and actinonin.
NNGH, galardin, and actinonin were purchased by BIO-
MOL International; SIMP-1 was purchased by Peptide Inter-
national, Inc.
In Vitro Assay. The compounds were evaluated for their
ability to inhibit the hydrolysis of fluorescence-quenched
peptide substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Bio-
mol, Inc.). The assays were performed in 50 mM HEPES
buffer, containing 10 mM CaCl2, 0.05% Brij-35, at pH 7, using
1 nM of MMP-1 catalytic domain and 1 íM of peptide. The
enzyme was incubated at 25 °C with increasing concentration
of inhibitor and the florescence (excitationmax 328 nm; emis-
sionmax 393 nm) was measured for 3 min after the addition of
the substrate using a Varian Eclipse fluorimeter. Fitting of
rates as a function of inhibitor concentration provided the IC50
values. In our experimental conditions with low enzyme
concentration and peptide concentration much lower than KM
(the concentration of the substrate that leads to half-maximal
velocity of the enzymatic hydrolysis reaction); the IC50 values
provide a good estimate of the dissociation constant of the
adduct. The inhibitor N-isobutyl-N-[4-methoxyphenylsulfonyl]-
glycyl hydroxamic acid (Biomol, Inc.) was used as control.
NMR Measurements. 1H 15N HSQC experiments imple-
mented with the sensitivity enhancement scheme49 and 15N
NOESY-HSQC spectra50 were performed on the free MMP-1
catalytic domain and on each protein-ligand adduct. 15N
NOESY-HSQC experiments were acquired with a mixing
time of 110 ms and with data sets comprising 256(1H)  64-
(15N)  2048(1H) data points. The NMR spectra were recorded
on Avance 900 Bruker spectrometer, operating at proton
nominal frequencies of 900.13 MHz and equipped with a triple
resonance cryoprobe. All NMR experiments, recorded at 298
K, were processed using the standard Bruker software (XWIN-
NMR), and analyzed through the XEASY program.51
Computer Programs. Autodock 3.0.5 was used to predict
protein-ligand docking. It uses a Lamarckian genetic algo-
rithm as global optimizer combined with energy minimization
as a local search method.52 Its scoring function is provided by
the sum, with empirically determined scaling factors, of a
Lennard-Jones 12-6 dispersion/repulsion term, a directional
12-10 hydrogen bond term, a Coulombic electrostatic poten-
tial, a term related to unfavorable entropy due to restrictions
in conformational degree of freedom of the ligand, and a
desolvation term. The PDB file was processed by Autodock Tool
Kit. Reliable zinc parameters were provided as in ref 21. A
box of 70  70  70 points with a grid spacing of 0.375 Å was
defined as docking space. The ligands were generated and
minimized using semiempirical calculations (AM1 type Gauss-
ian 98),53 and the pdbq files, comprising all protons, were
provided to Autodock after all the Gasteiger-Marseli charges54
were assigned by BABEL. For each run, a maximum number
of 28 000 genetic algorithm operations were generated on a
single population of 50 individuals. For each ligand, a total of
100 docking runs were performed, and the results were ranked
according to the docking energy. Crossover, mutation, and
elitism weights were set to 0.80, 0.02, and 1, respectively.
All minimization and dynamics calculations were carried
out using the program Xplor-NIH.55,56 The parameter and
topology files for the ligands were generated using Xplo2D,57
the improper angles being manually edited and the dihedral
angles being set with force constant equal to zero. Protein
electrostatic and van der Waal energy parameters have been
evaluated using CHARMM nonbonded parameters.58
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Matrix metalloproteinases (MMPs) are a family of Zn-dependent endo-peptidases known for their ability
to cleave several components of the extracellular matrix, but which can also cleave many non-matrix
proteins. There are many evidences that MMPs are involved in physiological and pathological processes,
and a huge effort has been put in the development of possible inhibitors that could reduce the activity of
MMPs, as it is clear that the ability to monitor and control such activity plays a pivotal role in the search for
potential drugs aimed at finding a cure for several diseases such as pulmonary emphysema, rheumatoid
arthritis, fibrotic disorders and cancer.
A powerful method currently available to study enzyme–inhibitor interactions is based on the use
of the surface plasmon resonance (SPR) technique. When MMP interactions are studied, a procedure by
which inhibitors are normally anchored on sensor chips and SPR technique is used in order to study their
interaction with MMPs molecules is usually followed. This is because it is currently believed that MMPs
cannot be anchored on the sensor-chip surface without losing their activity. However, this approach gives
rise to problems, as the anchoring of low-molecular-weight inhibitors on gold surfaces easily affects their
ability to interact with MMPs. For this reason, the anchoring of MMPs is highly desirable.
A new experimental protocol that couples the Fourier transform-SPR (FT-SPR) technique with
electrospray ionization-mass spectroscopy (ESI-MS) is described here for the evaluation of the activity
of MMP-1 catalytic domain (cdMMP-1) anchored on gold surfaces. The cdMMP-1 surface coverage is
calculated by using FT-SPR and the enzyme activity is estimated by ESI-MS. The proposed method is
label-free. Copyright  2005 John Wiley & Sons, Ltd.
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INTRODUCTION
Matrix metalloproteinases1 (MMPs) are a family of zinc-
dependent endo-peptidases known for their ability to cleave
several components of the extracellular matrix,2 but they can
also cleave many non-matrix proteins.3 Human fibroblast
collagenase (matrix metalloproteinase-1, MMP-1) was the
first vertebrate collagenase both purified to homogeneity as
a protein and cloned as a cDNA.4,5,6,7 It participates in the
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Chimiche, Universita` di Catania, Viale Andrea Doria 6, 95125,
Catania, Italy. E-mail: gspoto@dipchi.unict.it
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Contract/grant sponsor: MIUR; Contract/grant number: (FIRB
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turnover of collagen fibrils in the extracellular space, but
also plays a role in the regulation of cellular behaviour.
Furthermore, MMP-1 plays an important role in diverse
physiological processes such as tissue morphogenesis and
wound repair. Likewise, it seems to be implicated in a variety
of human diseases including cancer,8 rheumatoid arthritis,
pulmonary emphysema and fibrotic disorders.9
As the role of MMPs in diseases has become better
understood, interest in the control of their activity has
increased. While in vivo the degrading actions of the MMPs
are limited by the tissue inhibitors of metalloproteinase
(TIMP) family of natural macromolecular inhibitors, it is
now clear that MMPs are often overexpressed in diseases
such as cancer. A huge effort has been put towards the
development of inhibitors able to selectively target MMPs10,11
Copyright  2005 John Wiley & Sons, Ltd.
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Figure 1. Schematic presentation of the proposed experimental protocol. (a) A gold chip functionalized with dithiobis
succinimidylpropionate was used to immobilize the cdMMP-1 molecules. A solution of the cdMMP-1 substrate AMFLEA was then
put in contact with the modified chip surface. (b) After appropriate time intervals (as described in the text), portions of the solution in
contact with the surface, negligible in volume with respect to the total volume used for the experiment (ratio in the range of 1 : 50),
were sampled and analysed by ESI-MS to quantify the amount of fragmented substrate.
for therapeutic intervention in a variety of pathological
events. It is clear then that the ability to monitor MMP
activity plays a pivotal role in the search for possible drugs.12
The current methods to monitor the activity of MMPs
are mostly based on spectrophotometric assays13,14,15 and
they have to be carried out in solution. Such methods suffer
from inconveniences such as the inner filter correction16 and
the impossibility to recycle the MMPs for different analyses.
Moreover, they require a fluorescent tag to be present in the
substrate.
To our knowledge, only very few attempts have been
made towards the development of high-throughput, low-
volume enzyme assays on solid support17,18,19,20 and none of
them has been used to evaluate MMPs’ activity. Recently,
a solid-phase assay for analysis of MMPs’ activity has been
proposed but fluorescence tag in the substrate was still
necessary to detect the activity.21 Although it is clear now
that coupling different techniques, such as surface plasmon
resonance (SPR) and mass spectrometry (MS), is a very
powerful way of studying biological molecules,22,23 only
very recently a new strategy for identifying general enzyme
inhibitors and monitoring enzyme activity by SPR combined
with MS has been demonstrated.24
Furthermore, every attempt to study MMPs by SPR
has been carried out by anchoring the possible inhibitor
and keeping the MMP molecules in the liquid phase,25 as
it is commonly believed that ‘immobilization of MMPs is
unfavorable because of incorrect orientation of most of the
enzyme’.26 We proved that this last assertion is incorrect as
anchoring the MMP-1 molecules on gold surface is not only
possible but also very convenient, as some MMPs inhibitors
bind to the gold surface with the same chemical groups that
should interact with the enzyme.
We developed a new experimental protocol to anchor
the catalytic domain of human MMP-1 (hereafter cdMMP-1)
on gold surface, preserving its activity. We used the Fourier
transform- surface plasmon resonance (FT-SPR) technique to
calculate cdMMP-1 gold surface coverage and electrospray
ionization-mass spectrometry (ESI-MS) to monitor cdMMP-1
activity (Fig. 1). To our knowledge, this is the first time that
cdMMP-1 activity is monitored in a quantitative fashion by
ESI-MS.
We believe that this experimental protocol can be widely
applied to a vast range of biological systems so that the
enzyme is anchored on a gold surface, its interaction with
possible inhibitors/substrates can be studied by SPR and
its activity can be monitored by ESI-MS. We reasoned that
an assay format providing a large contact area between
the enzyme and the substrate might give the possibility
of monitoring the interaction of some systems that cannot
be studied otherwise, as it is in the case of interfacial and
low-solubility enzymes.17
EXPERIMENTAL
Expression and purification of human cdMMP-1
The cDNA of proMMP-1 (Pro21-Pro269) was cloned into the
pET21 vector (Novagen) using Nde I and Xho I as restric-
tion enzymes. One additional methionine at position 20 was
present in the final expression product. The Escherichia coli
strain BL21 Codon Plus cells transfected with the above vec-
tor were grown in 2 ð YT media at 37 °C. The protein expres-
sion was induced during the exponential growth phase with
0.5 mM of Isopropyl ˇ-D-1-Thiogalactopyranoside (IPTG).
Cells were harvested for 4 h after induction.15N-labeled pro-
tein was expressed in minimal media at 37 °C. After lysis of
the cells, the inclusion bodies containing the proMMP-1 were
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solubilized in 2 M urea; 20 mM Tris (pH 8.0). The protein was
purified on the Hitrap Q column (Pharmacia) with a buffer
containing 2 M urea; 20 mM Tris (pH 8.0). The elution was
performed using a linear gradient of NaCl up to 0.35 M. The
purified protein was then refolded by using a multi-step dial-
ysis against solutions containing 50 mM Tris (pH 7.2), 10 mM
CaCl2, 0.1 mM ZnCl2 and 0.3 M NaCl. The refolded protein
was exchanged, by dialysis, against a buffer with 10 mM Tris
(pH 7.2), 5 mM CaCl2, 0.1 mM ZnCl2 and 0.3 M NaCl. The pro-
tein was activated by 1 mM APMA (4-aminophenylmercuric
acetate) at 4 °C overnight and dialysed with a buffer contain-
ing 10 mM Tris (pH 7.2), 5 mM CaCl2, 0.1 mM ZnCl2, 0.3 M
NaCl, and 0.2 M acetohydroxamic acid (AHA). The activated
protein (Val101-Pro269) was concentrated using an Ami-
con stirrer and Centriprep concentrator fitted with a YM10
membrane in nitrogen atmosphere at 4 °C. Catalytic domain
of MMP-1 was purified using size-exclusion chromatogra-
phy with the final dialysis buffer and concentrated using a
Centriprep concentrator at 4 °C.
Anchoring of cdMMP-1 on gold surface
The anchoring of enzyme molecules on gold surface is
usually done in several steps by using a carboxymethyl
dextran matrix.26,27 In our experimental protocol, cdMMP-
1 was anchored on the gold surface in just two steps.
Firstly, bare gold chips were incubated with dithiobis
succinimidylpropionate (Lomant’s Reagent) (0.0097 g in 2 ml
of dimethyl sulfoxide (DMSO), Sigma-Aldrich) for 48 h. This
step was necessary in order to have several succinimidyl
ester groups on the surface that could react with the
terminal amino groups of the protein that we wanted to
be bonded to the surface.28 The surface so treated was
washed with pure DMSO and high-purity water (Milli-Q
Element Ultrapure Water) and could react directly with
cdMMP-1. We found that the choice of the running buffer
(also used for sample dilution) is crucial for the positive
result of the whole experiment. The best buffer to be used in
order to anchor the cdMMP-1 molecules to the gold surface,
preserving their activity, is N-(2-hydroxyethyl)piperazine-
N0-(2-ethanesulfonic acid) sodium salt (0.01 M HEPES, 0.15 M
NaCl, pH 7.4; HBS-N, Biacore International AB), indicated
as HBS-N buffer hereafter.
cdMMP-1 was anchored on the sensor-chip surface
previously modified with the Lomant’s reagent by leaving
the surface in contact with a 4.5 µM solution of cdMMP-1 in
HBS-N buffer for 10 min.
Two different peptides were used as cdMMP-1 substrate.
The first one does not have a fluorescent group and it has the
sequence AMFLEA (Ac-Ala-Met-Phe-Leu-Glu-Ala-CONH2).
It was synthesized on solid phase using Rink Amide MBHA
resin (Novabiochem, Switzerland) with standard Fmoc (N-
(9-fluorenyl)methoxycarbonyl) chemistry. Cleavage from
the resin was achieved by treatment with trifluoracetic
acid, triisopropyl silane and water (95; 2.5; 2.5) at room
temperature for 3 h. Purity and identity of the peptides
were assessed by HPLC and MALDI-ToF MS. The second
peptide was bought from Biomol International L.P. (PA,
USA) and is a known fluorogenic substrate for MMPs
having the sequence Ac-Pro-Leu-Gly-[2-mercapto-4-methyl-
pentanoyl]-Leu-Gly-OC2H5 (P125).29
N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydrox-
amic acid (NNGH) purchased from Biomol International L.P.
(PA, USA) was used as cdMMP-1 inhibitor.30
Fourier transform- surface plasmon resonance
FT-SPR experiments were carried out by using an FT-SPR
100 (GWC Instruments, USA) apparatus. The light beam
from an external port of a Nexus 870 FT-IR spectrometer
(Nicolet, USA), equipped with a quartz-halogen source and
an XT-KBr beam splitter, was used as the near-IR source
of the FT-SPR. Gold substrates (GWC Instruments, USA)
were obtained by thermally evaporating a gold layer (450 A˚)
on to SF-10 glass slides (Schott, USA). Chromium (50 A˚) was
used as the adhesion layer. Gold substrates were brought into
optical contact with the SF-10 equilateral prism present in the
FT-SPR by using a refractive index matching fluid (Cargille
Laboratories, USA). FT-SPR experiments were carried out
by using a 60-µl flow cell (GWC Technologies, USA) and a
Masterflex L/S (Cole-Parmer, USA) peristaltic pump.
The FT-SPR sensor response was converted into refractive
index changes by using independent sucrose aqueous
calibrating solutions (r2 D 0.999). The refractive indices of
the sucrose solutions were obtained from the literature.31
cdMMP-1 surface coverage
In order to estimate the number of cdMMP-1 molecules
anchored on 1 cm2 of gold surface, we followed the method
described in the literature32 where the adlayer thickness (d)
is obtained from the measured SPR response (R), that is the
shift in wavenumber of the FT-SPR minimum in reflected
light intensity associated with changes in the index of refrac-
tion of the medium in contact with the metal surface of the
FT-SPR device.
The calculation requires that both the refractive index of
the buffer and that of the adsorbate to be known. For this
purpose, the refractive index of the buffer was measured
with an ABBE-3L refractometer, which provided the value
of 1.3349 for the HBS-N buffer, while the refractive index of
the adsorbate (the pure cdMMP-1 protein in our case) was
taken to be 1.57.32,33
About 2 ml of a 4.5 µM solution of cdMMP-1 in HBS-
N buffer (this concentration was chosen in order to
have the right cdMMP-1 surface coverage for the activity
measurements) was eluted in the FT-SPR flow cell at a flow
rate of 0.1 ml/min in order to immobilize the enzyme on the
sensor-chip surface previously modified with the Lomant’s
reagent. The flowing HBS-N buffer was then introduced
into the flow cell. The FT-SPR shift due to the anchoring
of the cdMMP-1 was determined (Fig. 2) and a value for
the adlayer thickness d D 0.84 nm was obtained. It is then
straightforward34,35 to convert the adlayer thickness into the
surface concentration, , in molecules per square centimeter:
molecules/cm2 D dcm ð Nmolecules/cm3 1
where N is the bulk number density of the adsorbate and
can be estimated from the bulk density of the adsorbate, ,
in units of g/cm3, just by dividing by the molecular weight
and multiplying by Avogadro’s number. In our case,  D
1.30 g/cm3 was obtained from literature32 and  D 3.6 ð 1012
(molecules/cm2) was calculated by using Eqn (1).
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Figure 2. FT-SPR sensorgram for cdMMP-1 immobilization on
the sensor-chip surface according to the following steps:
0–80 s: HBS-N buffer solution; 80–700 s: 2 ml of cdMMP-1 in
HBS-N buffer (4.5 µM); 700–900 s: HBS-N buffer solution.
Flow-rate 0.1 ml/min. The double head arrow indicates the
FT-SPR response that is proportional to the amount of
anchored cdMMP-1.
Electrospray ionization-mass spectrometry
(ESI-MS)
All the ESI-MS measurements were carried out by using
a Finnigan LCQ DECA XP PLUS ion trap spectrometer
operating in the positive ion mode and equipped with an
orthogonal ESI source (Thermo Electron Corporation, USA).
Sample solutions were injected into the ion source at a flow-
rate of 10 µl/min, using nitrogen as the drying gas. The mass
spectrometer operated with a capillary voltage of 46 V and a
capillary temperature of 200 °C, while the spray voltage was
4.3 kV.
Xcalibur software was used for the elaboration of mass
spectra and for the quantitative evaluation of the MS data.
According to several other quantitative studies,36,37 the
unavailability of an internal standard for the analysis can be
overcome by the use of a calibration curve. To prepare stock
standard solutions, 0.0006 g of AMFLEA was accurately
weighed and dissolved in 1 ml of HBS-N buffer to generate
a solution of 914 µM that was further diluted in order to
generate calibration standards, covering the concentration
range 10–600 µM. Ten calibration standards were used to
define the calibration curve (10, 100, 130, 151, 230, 270,
350, 402, 450 and 503 µM) (Fig. 3). Four quality control (QC)
standards (100, 151, 270 and 402 µM) were also used for intra-
and inter-day validation.
It was noted that subtle changes in the amount of NaCl
dissolved in the buffer cause appreciable changes in the
amount of AMFLEA detected by ESI-MS.38 In order to obtain
high-sensitivity spectra, peptide solutions were injected as
25 µl aliquots into the ESI-MS apparatus and data were
recorded in SIM mode (centre m/z 766 and width 50 Da for
AMFLEA). The peptide was represented in the ESI-MS pos-
itive ion spectra by two peaks at m/z 744.5 and 766.4 (mono-
and bi-sodiate respectively). Quantitation of the peptide con-
centration was carried out by monitoring the most intense
peak at m/z 766.4, and all calibration curves showed good
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Figure 3. ESI-MS calibration curve for AMFLEA. The ion at m/z
766.4 was selected for SIM mode (centre 766, width 50). The
solid line results from the linear regression of the MS data
(r2 D 0.998), while the dashed lines represent the upper and
lower 95% prediction limits.
linearity (r2 > 0.99) over the concentration range. By setting
the base peak atm/z 766 it was possible to obtain an ion chro-
matogram that presented a shape approaching a rectangle,
the integral of which was proportional to the concentration
of the peptide solution injected.
The results were reproducible only if the buffer solution
had always the same amount of NaCl dissolved. For this
reason, we always used the same buffer and gave particular
attention in order to avoid solvent evaporation.
RESULTS AND DISCUSSION
A critical aspect of the cdMMP-1 activity assay described
here was represented by the proper preparation and mainte-
nance of the modified gold chip surface. In particular, it was
found that a too dense packing of the anchored cdMMP-1
affected the enzyme activity while lower surface concentra-
tion of cdMMP-1 was not suitable for the reliable ESI-MS
detection of the substrate used in the enzyme kinetics assay.
The negative influence of higher surface packing of uninhib-
ited cdMMP-1 has been attributed to the autolytic cleavage
of the enzyme molecules.39 Another critical point arises from
the necessity to keep the cdMMP-1 anchored on the surface
constantly wet in order to preserve the enzyme activity (data
not shown).
In our approach, the quantitative responses of the FT-SPR
shift with solutions of known concentration of cdMMP-1
were used to estimate the enzyme coverage of the gold
surface (Experimental Section). We found that a surface
coverage of 3.6 ð 1012 molecules/cm2 is adequate for an
ESI-MS kinetics assay of cdMMP-1 anchored on gold chips.
The positive ion ESI-MS spectrum of the AMFLEA
substrate peptide (MW D 722 Da) showed a peak at m/z
766.4 attributed to the bi-sodiated [AMFLEA-H C Na2]C ion
species and a peak at m/z 744.5 attributed to the mono-
sodiated [AMFLEA C Na]C peptide ions. (Fig. 4(a)) When
AMFLEA solutions were left in contact with the cdMMP-
1 anchored onto the gold chip surfaces, new species were
generated. The cdMMP-1 cleavage of the substrate generates
two peptide fragments40 detectable by ESI-MS at m/z
Copyright  2005 John Wiley & Sons, Ltd. J. Mass Spectrom. 2005; 40: 1565–1571
MMP-1 on gold activity assay 1569
100
80
60
40
20
0
R
el
at
iv
e 
ab
un
da
nc
e
200 400 800 1000600
m/z
744.5
766.4
(a)
100
80
60
40
20
0
R
el
at
iv
e 
ab
un
da
nc
e
200 400 800 1000600
m/z(b)
288.4
454.3
Figure 4. (a) Representative positive ion ESI-MS spectrum of
the AMFLEA peptide in HBS-N buffer (flow rate 10 µl/min). The
peaks of the peptide at m/z 766.4 and 744.5 are visible
together with many other peaks of the HBS-N buffer.
(b) Representative positive ion ESI-MS spectrum of the
AMFLEA peptide in HBS-N buffer after incubation for 1 h with
cdMMP-1. The peaks at m/z 766.4 and 744.5 disappear and
two new peaks at m/z 454.3 and 288.4 are now present.
Explanation is in the text.
454.3 [AcAMF  Na2]C and at m/z 288.4 [LE-NHCHCH3]C
(Fig. 4(b)). Unfortunately, many peaks coming from the HBS-
N buffer are found to be around the 200–500-Da range,
so that working quantitatively in this range suffers from
interference from the buffer. For this reason, ESI-MS data
for the quantitative evaluation of the progressing of the
cdMMP-1/substrate reaction were based on the decrease in
the m/z 766.4 peak intensity (SIM mode, centre m/z 766,
width 50 Da).
One-hundred-microlitre aliquots having three represen-
tative concentrations of AMFLEA (100, 250 and 400 µM) in
HBS-N buffer were put in contact with the cdMMP-1 mod-
ified sensor-chip surface, and 2-µl aliquots were sampled
every minute. Every aliquot was then added with 450 µl of
methanol, and 25 µl of the resultant solution was injected
into the ESI-MS apparatus. This large dilution of the orig-
inal aliquot was found to be necessary in order to avoid
experimental problems such as capillary obstruction and
high-spray current values.
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Figure 5. The decrease of the initial concentration of AMFLEA
(250 µM was the initial concentration in this graph) is used to
calculate the increased amount of AMFLEA cleaved by
cdMMP-1. The cdMMP-1 activity was thus monitored, and it is
possible to see that for this concentration and for time <10 min
the curve can be approximated to a straight line (as shown in
the insert).
The calibration curve generated from the standard
solutions (Experimental Section) allowed us to convert the
m/z 766.4 peak intensity values into peptide concentration
([AMFLEA]) of the different aliquot samples, so that we were
able to obtain progress curves of the reaction, such as the
one shown in Fig. 5. The progress curves were obtained by
plotting the amount of cleaved AMFLEA versus time and
were used to determine the optimum enzyme concentration
and reaction time for the kinetic study. From Fig. 5, it is
possible to verify that for a reaction time <10 min the
curve obtained can be approximated to a straight line.
An optimal reaction time of 5 min was determined. Since
the chosen optimal reaction time resided in the linear
region of the progression curve, the initial velocity (Vi)
was simply calculated by dividing the difference between
the ESI-MS determined AMFLEA amounts at t D 0 min
and t D 5 min by the reaction time. The values of Vi
for different initial concentrations of AMFLEA in contact
with the cdMMP-1 chip were also obtained in the same
way.41 It was previously demonstrated that MMPs follow
a Michaelis–Menten kinetics,42 so the KM and Vmax values
can be estimated from the double-reciprocal plot of 1/Vi vs
1/[AMFLEA]. A representative Lineweaver–Burk plot for
the cdMMP-1 on chip/AMFLEA reaction is shown in Fig. 6.
Three independent measurements of cdMMP-1 activity
were carried out and the average values of KM D 3.5 š2 ð
103 (µM) and Vmax D 1.8 š 0.2 ð 102 (µM/min) were
obtained. The high error affecting the KM value is mainly
attributed to uncontrolled dilution of the initial substrate
concentration in contact to the enzyme chip surface caused
by the necessity to avoid the drying of the surface. The drying
of the cdMMP-1 chip surface was observed to significantly
affect enzyme activity. Nevertheless, it can be seen that
the KM and Vmax values obtained are relatively large in
comparison with the values reported in the literature for
MMP-1/substrate interaction in solution.43
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Figure 6. Lineweaver–Burk plot for cdMMP-1/AMFLEA at
room temperature (r2 D 0.977).
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Figure 7. ESI-MS spectrum of P125 in HBS-N buffer, full scan
range 200–1000 Da. The peak at m/z 678.7, attributed to the
mono-sodiated ion species, is visible together with many other
peaks generated from species present in the HBS-N buffer.
This is due to the higher number of enzyme molecules
per substrate molecules required for the proposed activity
assay compared to the usual enzyme/substrate ratio used
in spectrophotometric methods. Nevertheless, the kinetic
results can be compared with those reported in the literature
by looking at the kcat value. This last parameter takes into
account the enzyme concentration (kcat D Vmax/E0, where
E0 is the enzyme concentration) and it is possible to note
that the kcat D 4.6 š 0.6 sec1) value obtained from our
experiments is similar to those reported in the literature
for similar systems.43
By following the described procedure, kinetic assay was
also carried out by using the commercially available P125
substrate (MW D 656 Da). In this case, kinetic analysis was
monitored by following the intensity of the mono-sodiated
peak at m/z 678.7, (Fig. 7) and statistically equivalent kinetic
parameters were obtained.
The same experimental procedure was carried out after
inhibition of cdMMP-1 by NNGH inhibitor. A lack of activity
by cdMMP-1 with both substrates (AMFLEA and P125)
was observed (Fig. 8). The same result was obtained in two
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Figure 8. There is no progression in the reaction between
NNGH-inhibited cdMMP-1 and the AMFLEA substrate. No
appreciable variation with time is detected for the
ESI-MS-determined AMFLEA concentration of the substrate
solution in contact with NNGH-inhibited cdMMP-1. The graph
shown refers to an experiment carried out with a
[AMFLEA] D 450 µM.
different cases, where cdMMP-1 incubation with NNGH was
carried out prior to or after the enzyme immobilization.
CONCLUSIONS
A new experimental protocol was developed that enabled
us to anchor cdMMP-1 enzyme on gold surface. The
immobilization did not affect cdMMP-1 activity, which could
be monitored by ESI-MS. The feasibility of this approach was
demonstrated for two different cdMMP-1 substrates, and
inhibition with NNGH of the anchored cdMMP-1 was also
proved.
These results demonstrate the possibility of monitoring
cdMMP-1 inhibition on solid-state support. By coupling the
FT-SPR and ESI-MS techniques, a comprehensive study of
the kinetics of inhibition and of the possibility to determine
the activity of MMPs is shown to be feasible.
We believe that the new solid-state activity assay opens
the doors to a wide range of applications where the activity
of an enzyme has to be monitored in the presence of possible
inhibitors. In our new experimental protocol, substrates do
not need to have fluorescent groups and one requires only
a small amount of enzyme to carry out several different
screenings.
Other MMPs together with other enzymes are currently
being studied in our laboratory in order to expand the
applicability of this new methodology. Efforts are also on to
improve accuracy and precision of the assay.
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Several different procedures are available for the immobilization of proteins on solid supports, as many
advantages derive from this approach, such as the possibility to develop new protein solid-state assays.
Enzymes that are anchored on gold surfaces can interact with several different molecules in a tag-free
environment, opening the way to surface plasmon resonance (SPR) investigations. Nevertheless, it is often
important to know the identity of the affinity-retained analyte, and mass spectrometric analysis, via its
unique molecular mass identification, represents a very valuable complementary method.
There are many pieces of evidence to suggest that matrix metalloproteinases (MMPs) are involved
in normal and pathological processes, including embryogenesis, wound healing, inflammation, arthritis
and cancer, but presumably also exhibiting other functions. The search for new inhibitors of MMPs has
prompted research towards the development of new solid-state assays for the rapid evaluation of MMP
activity. We have already reported the possibility of measuring the activity of MMP-1 anchored on solid
support by coupling SPR with ESI-MS analysis. In this work, we show the in situ atmospheric pressure
(AP) MALDI-MS characterization of MMPs anchored on a gold chip with known surface coverage. The
study extends the MS analysis to different proteins, and sequence coverage is reported for different
digestion and MS procedures. Copyright  2006 John Wiley & Sons, Ltd.
KEYWORDS: matrix metalloproteinases; AP/MALDI-MS; SPR; solid-state assay; MMP immobilization
INTRODUCTION
Solid-state assays represent a very powerful approach for
protein studies,1,2 and in the past few years some attempts
to develop high-throughput and low-volume enzyme assays
on solid supports have been carried out.3 – 5 This approach
offers some important advantages that are not available
in the standard solution assays, such as the possibility to
recycle the studied enzymes, a tag-free working environment
that allows simple and rapid on-spot protein profiling,6
high throughput,7 improved discovery of protein binding
partners through protein-affinity interactions,8 and, most
importantly, a multiplexed approach for the investigation
of proteins, allowing the coupling of different techniques
such as, for instance, surface plasmon resonance (SPR)
and mass spectrometry (MS).9 – 11 The latter multiplexed
approach is particularly advantageous in the case of
protein arrays12 and they are poised to become a central
proteomics technology important both in basic research
ŁCorrespondence to: Giuseppe Spoto, Dipartimento di Scienze
Chimiche, Universita` di Catania, Viale Andrea Doria 6, 95125,
Catania, Italy. E-mail: gspoto@dipchi.unict.it
†Paper presented at the 24th Informal Meeting on Mass
Spectrometry, Ustron˜, Poland, 14–18 May 2006.
and commercially for biotechnology enterprises. In recent
years many studies have been addressed toward the
development of different experimental protocols aimed
at improving the efficiency and applicability of such an
approach.13
Laser desorption ionization MS-based methods play a
central role in the above-mentioned scenario. They do not
require analytes to be labeled and therefore are applicable
to the study of a broad range of biological molecules. High
sensitivity is another typical advantage offered by MS-based
methods, while the use of lasers guarantees the spatial
resolution of the analysis and the suitability for solid-state
assays on the array format.
Surface-enhanced laser desorption ionization (SELDI)14
is one of the above-mentioned MS-based methods that has
seen rapid development15 – 17 recently for a broad range of
applications.18 – 20 The reason for such success lies mainly in
the new research opportunities and advantages that SELDI
investigations offer for on-chip protein characterization,
including on-spot deglycosylation or dephosphorylation,
with subsequent identification through peptide mapping
or MS/MS sequencing.21
Desorption/ionization on silicon mass spectrometry
(DIOS-MS)22 and self-assembled monolayers for MALDI
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(SAMDI)23 offer further MS-based tools for solid-state assays
of proteins.
Unfortunately, one of the limiting factors of most of the
above-mentioned approaches is the difficulty in obtaining
good quality MS data, mostly due to the mixing of
the sample of interest with salt and buffer impurities,
the presence of which is often necessary when dealing
with biological molecules.24,25 As a direct consequence of
this problem, several papers focusing on all the practical
considerations in biomolecular interaction analysis mass
spectrometry (BIA/MS) have been recently published.26
Purification of contaminated peptides and proteins,27,28
choice of matrix molecules and MALDI sample platform
used,29,30 appropriate MALDI spotting procedure,31 addition
of special molecules32 and interpretation of salt-affected
MS spectra33,34 are all examples that show the difficulties
normally encountered in this field.
In a previous paper,35 we have already mentioned the
important role that matrix metalloproteinases (MMPs)36 have
in normal and pathological processes, including embryoge-
nesis, wound healing, inflammation, arthritis and cancer.37 It
is clear that while in vivo the degrading actions of MMPs are
limited by the tissue inhibitors of metalloproteinase (TIMP)
family of natural macromolecular inhibitors, in diseases such
as cancer MMPs are often overexpressed.38 For this reason,
only very recently, much effort has been put in the develop-
ment of inhibitors capable of selectively targeting MMPs for
therapeutic intervention in a variety of pathological events.39
In this perspective, the development of new solid-state assays
for a rapid evaluation of MMP activity and characterization
is of great interest.
We have already showed the possibility to study the
activity of the catalytic domain of MMP-1 (cdMMP-1) by
using a solid-state assay based on both Fourier transform
(FT)-SPR and electrospray ionization (ESI)-MS techniques.35
cdMMP-1 was anchored on a pre-functionalized gold sur-
face, and it was demonstrated that the immobilization proce-
dure did not affect the enzyme activity. Although in principle
such an approach could be applied to other enzymes, there
was no easy way of unambiguously identifying the protein
immobilized on the gold surface.
The need for reliable procedures for the characterization
of immobilized proteins is strictly related to the development
of protein arrays. Protein array fabrication requires different
steps to be used. Roughly, (1) proteins are immobilized
on a solid surface after reaction with suitable chemical
compounds previously anchored to the solid surface,
(2) unreacted chemical compounds present on the solid
surface are deactivated and (3) regions of the solid surface
not involved in the protein immobilization are modified
with specific compounds capable of improving the surface
resistance to nonspecific interactions. Accurate washing with
appropriate solvents are imperative after each step. It is
evident that the removal of proteins from each array region
and their re-binding in the surrounding areas is possible,
thus resulting in a mixing of proteins. The development
of protein arrays requires the optimization of the above-
mentioned procedures and it is not possible without methods
for identifying the proteins immobilized on the gold surface.
Moreover, such methods must be able to identify the
presence of unwanted mixing caused by the re-binding
of proteins coming from close regions of the array. In
order to contribute to the development of suitable methods
to be used in the characterization of protein arrays, we
present a method to characterize anchored MMPs here. The
method is based on the experimental procedure of in situ
digestion and atmospheric pressure (AP) MALDI-MS40
characterization of the covalently immobilized enzymes.
In order to demonstrate the suitability of the method
for immobilized MMPs characterization, different cdMMPs
(cdMMP-1, cdMMP-8, cdMMP-12) and their mixtures, as
well as control samples such as bovine serum albumin
(BSA), are used as examples, and the strict control over
the experimental procedures used for the immobilization
and characterization of the enzyme is highlighted. In
order to avoid MMP degradation and deactivation, such
procedures require the use of buffers with an appropriate
salt content.35 The proposed approach is able to overcome
some experimental difficulties related to the presence of salts
and buffers, and the results represent a further example of
the high impact that such contaminants can have on the
appearance of AP/MALDI-MS spectra.41
EXPERIMENTAL
Protein cloning and purification
The synthesis and purification of cdMMP-1 has already been
described elsewhere.35
The cDNA encoding the cdMMP-12 (Gly106-Gly263)
and cdMMP-8 (100M-G262) was amplified by a polymerase
chain reaction (PCR) from the IMAGE consortium clone (ID
196 612) and human cDNA clone (ORIGENE), respectively,
using two synthetic oligonucleotides as primers. The cDNA
obtained was cloned into the pET21a vector (Novagen)
between the restriction sites NdeI and BamHI. For cdMMP-
12, the single amino acid substitution, to obtain the F171D
mutant, was created using the QuickChange Site-directed
mutagenesis kit from Stratagene. For both cdMMP-12 and
cdMMP-8, the construct was transformed into the BL21Gold
(DE3) strain for expression of the recombinant protein. The
cells were grown in 2 ð YT media at 37 °C. The protein
expression was induced during the exponential growth
phase with 0.5 mM of isopropyl ˇ-D-1-thiogalactopyranoside
(IPTG). Cells were harvested for 4 h after induction. After
lysis of the cells, the inclusion bodies containing the protein
were solubilized in 8 M urea and 20 mM sodium acetate (pH
5.0 for cdMMP-12, pH 8.0 for cdMMP-8). The protein was
purified on the Hitrap (SP for cdMMP-12, Q for cdMMP-
8) column (Pharmacia) with a buffer containing 6 M urea,
20 mM sodium acetate (pH 5.0) (cdMMP-12) and 20 mM Tris
(pH 8.0) (cdMMP-8). The elution was performed using a
linear gradient of NaCl up to 0.35 M. The purified protein
was re-folded by using a multistep dialysis against a solution
containing 50 mM Tris-HCl pH D 7.2, 10 mM CaCl2, 0.1 mM
ZnCl2, 0.3 M NaCl and 500 mM acetohydroxamic acid (AHA),
and decreasing the concentration of urea (from 4 M down
to 2 M). The re-folded protein was concentrated up to 50 µM
using an Amicon stirrer and Centriprep concentrator, fitted
with a YM10 membrane, at 4 °C.
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cdMMP-1 and cdMMP-12 were 15N enriched (95%), and
this was taken into account for the MS analysis.
Surface plasmon resonance imaging (SPRI)
apparatus
SPRI experiments were carried out at room temperature by
using an SPR imager apparatus (GWC Technologies, USA)
equipped with a white light source and an SF-10 prism. A
narrow bandpass filter (800 nm) was placed before the CCD
camera used as a detector for SPR images.
SPR images were analyzed by using the V C C software
(version 4.0, Digital Optics Limited, New Zealand). SPRI
provides data as pixel intensity units on a 0–255 scale.
As specified by the manufacturer, data are converted into
percentage of reflectivity (%R), or %R in the case of
difference images, by using the formula:
%R D 100 ð 0.85Ip/Is
where Ip and Is refer to the reflected light intensity detected
using p- and s-polarized light, respectively.
PDMS microfluidic channels fabrication and
protein array
Microfluidic channels were fabricated in poly(dimethylsil-
oxane) (PDMS) polymer as described elsewhere.42 Briefly,
PDMS microchannels were created by replication from
a master in polyvinyl chloride (PVC), with a pattern of
three (80 µm depth, 1.4 cm length, 400 µm width) parallel
channels, featuring circular reservoirs (diameter D 0.4 mm)
at both ends of each channel. PEEK tubes (0.5 mm, UpChurch
Scientific) were inserted in such reservoirs in order to connect
the PDMS microfluidic cell to a Masterflex L/S (Cole-Parmer,
USA) peristaltic pump,43 operating at 100 µl/ min. Replicas
were formed from a 1 : 10 mixture of PDMS curing agent and
prepolymer (Sylgard 184, Dow Corning, Midland, MI). The
mixture was degassed under vacuum and then poured onto
the master in order to create a layer with a thickness of about
3–4 mm. The PDMS replica was then cured for at least 2 h at
60 °C before it was removed from the master.
An array of cdMMPs was obtained by flowing three
different cdMMP solutions into the three PDMS microchan-
nels in contact with a prefunctionalized gold substrate.35
In Fig. 1(a) an SPR image of the protein array so formed
is shown, while in Fig. 1(b) the change of percent reflec-
tivity over time for the immobilization of cdMMP-1 is also
reported as a representative example, where the difference
in the signal intensity between the first and the last parts
of the graph is proportional to the amount of immobilized
enzyme (indicated as a double arrow in Fig. 1(b)).
Surface coverage: FT-SPR measurements
The FT-SPR apparatus and the procedure used to anchor
BSA, cdMMP-1, cdMMP-8 and cdMMP-12, as well as the
equations used to calculate the protein surface coverage,
were the same as described previously.35 Surface coverage
is governed by two main factors: the initial protein concen-
tration and the contact time of the protein solution with
the surface. The latter experimental parameters were opti-
mized in order to obtain the best quality MS spectra, so
(a)
(b)
Figure 1. Difference SPR image of a cdMMPs array
(a) obtained by flowing cdMMP-1, cdMMP-8 and cdMMP-12 in
three different PDMS microchannels (bottom, middle and top,
respectively) in contact with a prefunctionalized gold surface
as described in the text. (b) The change in percent reflectivity
over time obtained for the immobilization of cdMMP-1 reported
as an example. The difference between the % R values
before and after the protein transit in the microchannel is
proportional to the amount of immobilized cdMMP-1.
that a surface coverage of about 4 ð 1013 molecules/cm2 was
generally used. For each different protein, 60 µl of N-(2-
hydroxyethyl)piperazine-N0-(2-ethanesulfonic acid) sodium
salt (0.01 M HEPES, 0.15 M NaCl, pH 7.4; HBS-N, Biacore
International AB) (HBS-N buffer hereafter) was mixed with
the appropriate volume of protein mother solution in order to
obtain a final concentration of 4.5 µM. This solution obtained
was then left in contact with the prefunctionalized35 gold
surface for about 10 min.
In situ protein digestion and AP/MALDI-MS
Structure, stability and orientation of BSA adsorbed to sil-
ica has already been investigated in order to draw some
conclusions on the structural changes that such protein
undergoes when it is adsorbed on a solid support.44 For
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this reason, although in our case cdMMPs were immobilized
on a gold surface, BSA was chosen as a model protein for
optimizing our experimental procedure by maximizing the
sequence coverage value. Several parameters were consid-
ered (protein surface coverage, digestion time, immobilized
protein/peptidase ratio, use of ZipTipSCX pipette tips (Milli-
pore), sample/matrix solution ratio, etc.), and in Table 1 the
results for the highest sequence coverage values obtained
for BSA immobilized on gold are reported. Generally, for
the digestion of the anchored enzymes, 20 µl of HCl 103 M
(Sigma–Aldrich) was added to a vial containing 20 µg of
either trypsin from porcine pancreas (Sigma–Aldrich, Pro-
teomics grade) or, alternatively, endoproteinase Glu-C from
Staphylococcus aureus V8. Two microliters of the obtained
solution was diluted with 500 µl of NH4HCO3 100 mM, pH
7.8 (both Sigma–Aldrich) and the resulting solution was
spotted on the protein arrayed surface. The latter was then
left in contact with the trypsin solution in a humid chamber
at 37 °C for about 6 h (longer digestion times did not improve
spectra quality). The final solution (0.5 µl) (hereafter, super-
natant) was then collected and spotted on a MALDI plate.
Before allowing total evaporation of the drop, 0.5 µl of the
matrix solution was applied on top. The best results in
terms of spectra quality were achieved by using ˛-cyano-4-
hydroxycinnamic acid (CHCA) in 30% trifluoro acetic acid
(TFA) (0.1%) and 70% acetonitrile C2H3N as the matrix solu-
tion at a concentration of 1 mg/ml (all the above material
was purchased from Sigma-Aldrich. CHCA was purified by
recrystallization from ethanol solution). Any further wash-
ing steps of the obtained matrix crystals did not seem to
improve the MS spectra quality.32 The use of ZipTipSCX
pipette tips (Millipore) in the spotting procedure helped to
improve spectra quality and sequence coverage (Table 2).
All the AP/MALDI-MS measurements were carried out
by using a Finnigan LCQ Deca XP PLUS (Thermo Electron
Corporation, USA) ion trap spectrometer that was fitted
with a MassTech Inc. (USA) AP/MALDI source.45 The latter
consists of a flange containing a computer-controlled X–Y
positioning stage and a digital camera, and is powered by a
control unit that includes a pulsed nitrogen laser (wavelength
337 nm, pulse width 4 ns, pulse energy 300 µJ, repetition
rate up to 10 Hz) and a pulsed dynamic focusing (PDF)
module that imposes a delay of 25 µs between the laser pulse
and the application of the high voltage to the AP/MALDI
target plate. PDF has been shown to improve S/N ratios
in the AP-MALDI spectra.40 Laser power was attenuated
to about 55%. The target plate voltage was 1.8 kV. The
ion trap inlet capillary temperature was 200 °C. Capillary
and tube lens offset voltages of 30 and 15 V, respectively,
were applied. Other mass spectrometer parameters were as
follows: multipole 1 offset at 3.75 V, multipole 2 offset at
9.50 V, multipole RF amplitude 400 V, lens at 24.0 V and
entrance lens at 88.0 V. Automatic gain control (AGC) was
turned off and instead the injection time was set to 220 ms
and 5 microscans per scan. About 4 min acquisition per
sample was usually performed.
Spectra of the in situ trypsin digested cdMMPs were
acquired in a data-dependent fashion by first acquiring full
MS scans from m/z 200 to 2000, followed by MS/MS scans of
the most intense ions of the previous full MS scan. MS/MS
scans were acquired using an isolation width of 5 m/z,
activation qz of 0.250, activation time of 30 ms and normalized
collision energy (NCE) in the range 30–40% depending on
the ion. (NCE is the amplitude of the resonance excitation
RF voltage scaled to the precursor mass on the basis of
the formula: RF amplitude D NCE%/30% (precursor ion
mass ð tick amp slope C tick amp intercept), where the tick
amp slope and tick amp intercept are instrument-specific
values. For our LCQ Deca, 35% NCE for m/z 1000 D 1.8 V.)
Spectral assignment was obtained by comparing the
experimental peaks with the theoretical ones obtained
by introducing the three different sequences for cdMMP-
12,46 cdMMP-8 (UniProtKB/Swiss-Prot Accession Number:
P22894 Met100-Gly262) and cdMMP-1 (UniProtKB/Swiss-
Prot Accession Number: P03956, Val101-Pro269) into the
MS-Digest protein digestion simulator (http://prospector.-
Table 1. Experimental peaks of digested BSA previously immobilized on a gold surface reported together with the expected peaks
and the sequence coverage value obtained for this model protein. Experimental parameters were: protein surface coverage
³4 ð 1013 molecules/cm2; digestion time D 6 h; trypsin/BSA ratio ³1/5; use of ZipTip; matrix solution: CHCA
m/z
submitted
MHC
matched
Delta
Da
Missed
cleavages Sequence
%
Coverage
634.1 634.3789 0.28 1 (R) GVFRR (D) 23.0
656.3 656.3480 0.048 1 (R) RDTHK (S) –
712.7 712.3742 0.33 0 (K) SEIAHR (F) –
927.6 927.4940 0.11 0 (K) YLYEIAR (R) –
1163.6 1163.6312 0.031 0 (K) LVNELTEFAK (T) –
1283.7 1283.7112 0.011 0 (R) HPEYAVSVLLR (L) –
1305.6 1305.7167 0.12 0 (K) HLVDEPQNLIK (Q) –
1479.7 1479.7960 0.096 0 (K) LGEYGFQNALIVR (Y) –
1504.6 1504.9215 0.32 1 (K) QTALVELLKHKPK (A) –
1567.7 1567.7433 0.043 0 (K) DAFLGSFLYEYSR (R) –
1639.9 1639.9383 0.038 1 (R) KVPQVSTPTLVEVSR (S) –
1890.7 1890.8036 0.10 1 (K) VASLRETYGDMADCCEK (Q) –
1955.9 1955.9602 0.060 0 (K) DAIPENLPPLTADFAEDK (D) –
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Table 2. Experimental peaks observed after digestion with trypsin of cdMMP-8. There are no differences between the spectra
obtained from the solution or the supernatant liquid, showing that the immobilization of the enzyme does not affect the peptidase
access to the enzyme. Furthermore, the presence of a strong inhibitor (NNGH) does not have a large impact on the sequence
coverage. On the contrary, the latter is improved considerably by the use of ZipTipSCX pipette tips. Similar results were found also
for cdMMP-1 and cdMMP-12
Expected
fragments
Supernatant
ZipTip
Supernatant, no
ZipTip
Solution
ZipTip
Solution, no
ZipTip
Solution C
NNGH
ZipTip
Supernatant C
NNGH
ZipTip
490.2
p p p p p p
767.4
p p p p p p
857.5
p
–
p
–
p
–
873.5 – – – – – –
1036.6 – – – – – –
1238.6
p
–
p
–
p
–
1328.7
p
–
p
–
p
–
1344.7 – – – – – –
1507.8 – – – – – –
1535.7
p p p p p p
1724.9
p p p p p p
1804.9 – – – – – –
1847.9 – – – – – –
1852.0
p p p p
–
p
Coverage % 37.4 32.5 37.4 32.5 27.6 32.5
ucsf.edu/ucsfhtml4.0/msdigest.htm). In the case of cdMMP-
12 and cdMMP-1, 15N enrichment was also considered.
RESULTS AND DISCUSSION
The immobilization of cdMMPs on solid substrates repre-
sents a fundamental step for the development of solid-state
MMP assays. It has already been highlighted35 how an
improper surface packing density of cdMMPs facilitates
the autodegradation of the enzyme and affects the activ-
ity of the immobilized enzyme itself. At the same time, a
higher protein density at the solid surface is desirable for
analytical purposes owing to the resulting increase in the
MS signals of the species formed after the in situ tryptic
digestion. For these reasons, AP/MALDI-MS experiments
have been carried out by using gold substrates on which
cdMMP-1, cdMMP-8 and cdMMP-12 were immobilized at
the maximum surface density that preserved the enzyme
activity. Both the cdMMPs surface coverage and the immo-
bilized cdMMPs activity have been evaluated by following
the already described procedures.35 In particular, for all the
experiments discussed below, a surface coverage of about
4 ð 1013 molecules/cm2 was used.
The use of MALDI-MS for detecting chemical processes
that involve MMP molecules is not something completely
new.47 Nevertheless, in almost all the works available in
the current literature,48 it is common practice to detect only
the products of MMP proteolytic activity by MALDI-MS,
while the tryptic digestion of the enzyme itself has never
been reported.49,50 This is probably due to the difficulties in
obtaining detectable amounts of purified enzyme not being
mixed with buffer and salt-contaminated solutions, as it
is known that MMPs require a buffer containing specific
amounts of zinc and calcium cations, as well as proper
pH values, in order to maintain their structural integrity
and biological activity.51,52 Even for our stabilized forms of
cdMMP-1, cdMMP-8 and cdMMP-12,46 the starting solutions,
respectively 90 µM (1), 50 µM (2) and 270 µM (3) in enzyme,
were also 20 nM in the Tris buffer, 10 mM in CaCl2, 0.1 mM in
ZnCl2 and 200 mM in AHA. It is then clear that the amount
of salts added in order to have a stabilized and active form
of the enzymes is larger than the enzymes themselves. This
can cause problems in the MALDI-MS spectrum in terms of
both sensitivity and peak detection.
In Fig. 1(a), the SPR image of a gold surface arrayed
with the three different cdMMPs is reported, together with
a representative graph showing the change in percent reflec-
tivity over time obtained for the cdMMP-1 immobilization
(Fig. 1(b)). Appropriate separate spotting of the trypsin solu-
tion on each different channel (Fig. 2) allowed the spatially
resolved recognition of the three proteins, producing the MS
spectra in the m/z 200–2000 range reported in Fig. 3 (the MS
spectrum for the same samples in the range 2000–4000 are
not shown as they are not informative for our purpose). It is
possible to see that some peaks are detected in the sodiated
form34 (m/z 865.6, 1271.7 and 1591.7 in Fig. 3(a), m/z 1260.6
in Fig. 3(b)) and, in some cases, the peak assignments had
to be confirmed by MS/MS experiments in order to avoid
ambiguity (Fig. 4). In the case of cdMMP-8 (Fig. 3(b)), sev-
eral other unassigned peaks are also observed and this is due
to the fact that the problem of auto-hydrolysis, commonly
encountered for all metalloproteinases,53 is more severe for
this member of the MMP family.
The presence of contaminants is easily revealed by
performing MS analyses of blank areas treated as above but
without the presence of cdMMPs. In this case several peaks
originating from matrix clusters with NaC are observed, as
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Figure 2. Scheme of the procedure applied for in situ tryptic
digestion and AP/MALDI-MS characterization. Enzyme
molecules previously immobilized on the gold surface
(cdMMP-12 in this particular case) are put in contact with the
tryptic solution in a humid chamber at 37 °C overnight. The
supernatant solution (0.5 µl) is sampled after 6 h for
AP/MALDI-MS analysis. The same experimental procedure
was applied also using a different peptidase, endoproteinase
Glu-C, and the results are discussed in the text.
shown in Fig. 5. In our case, the use of ZipTip helped to
remove some of the contaminants and it gave an important
contribution for the acquisition of the less salt-affected MS
spectra.
It has been reported that when immobilized to a solid
support, some proteins are less accessible to the action
of peptidases, producing a smaller sequence coverage.44
In most cases, by reducing the degrees of freedom, both
activity and structure of the immobilized protein are usually
affected and the general trend is that structurally less
stable proteins lose more native structure upon adsorption
than more stable proteins.54 Nevertheless, the impact that
adsorption to a solid support has on the properties of a
protein depends greatly on the nature of such adsorption.
Usually, in order to study biological molecules by SPR,
a low-impact adsorption is highly desirable. Ideally, it
should be possible to array proteins on a surface and the
anchored biomolecules should preserve their properties
as in the solution state, so that interaction with other
molecules is meaningful. We have already proved that
anchored cdMMP-1 has the same activity as in the solution
state,35 and here the immobilization procedure is expanded
to two other cdMMPs and it is shown that it does not
affect the action of peptidases for protein degradation
and recognition by peptide fingerprint. We also inhibited
(a)
(b)
(c)
Figure 3. AP/MALDI-MS spectra of three different proteins,
cdMMP-1 (a), cdMMP-8 (b) and cdMMP-12 (c), after
immobilization on a gold substrate and on-chip digestion with
trypsin solution. The assignment of the most intense peaks is
reported. Peaks attributed to the matrix crystals are labelled
with Ł, and the positive charge is omitted for simplicity. Some
of the peaks (m/z 865.6, 1271.7 and 1591.7 in (a), m/z 1260.6
in (b)) were assigned to sodiated peptides that form because of
the high salt content of the initial protein solution. Although
many unassigned peaks are present in (b) owing to protein
auto-hydrolysis, even in this case the sequence coverage has
an acceptable value, which ensures unambiguous
characterization of the protein (Table 3).
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Figure 4. MS/MS fragmentation pattern for the m/z 993.4 peak
of the cdMMP-12 spectrum. Because of the 15N enrichment,
the peak is assigned to the fragment KHYITYR having m/z
980.5 without the 15N enrichment. The observed fragmentation
pattern confirmed our assignment, excluding the possible
presence of the fragment EDVDYAIR, having m/z 980.4 without
the 15N enrichment, but a different fragmentation pattern.
Figure 5. AP/MALDI-MS spectrum obtained by sampling the
supernatant solution from an area of the gold surface where no
enzyme was immobilized. Many peaks that could be assigned
to CHCA clusters containing NaC ions are visible, confirming
that a salt-free MS spectrum can be a challenging task in such
experimental conditions. In fact, the presence of buffered
solutions is necessary to maintain enzyme activity, as
discussed in the text.
the cdMMPs with a strong inhibitor, N-isobutyl-N-(4-
methoxyphenylsulfonyl)-glycylhydroxamic acid (NNGH),
and only negligible differences were observed in terms of
peptide appearance in the mass spectra of the immobilized
enzyme (Table 2). The use of Glu-C as peptidase lowered the
sequence coverage values for all of the cdMMPs investigated,
so trypsin was selected as optimal peptidase in these
conditions (Table 3). Generally, the high sequence coverage
values obtained when trypsin was used confirmed the idea
that our immobilization procedure does not have any MS-
measurable impact on protein properties.35 This is probably
due to the fact that, by using amine coupling chemistry,
anchored proteins are randomly oriented on the surface
(interacting –NH2 groups in cdMMPs are equally distributed
on protein surfaces), so that, overall, all the sides of the
biomolecules are equally exposed to the action of peptidases.
In order to extend the applicability of our multiplexed
approach to real biological samples,55 we applied the
same experimental procedure to a 1 : 1 mixture of cdMMP-
1/cdMMP-12 immobilized on the solid surface. From the
results shown in Fig. 6, it is possible to see that almost all the
MS peaks detected for single protein solutions are found also
in this case. The same result was obtained also for cdMMP-
8/cdMMP-12 mixture (data not shown) and this confirms
that the experimental protocol is applicable to protein
mixtures. The same MS spectra were recorded with the
Table 3. Sequence coverage values for the digestion of
cdMMP-1, cdMMP-8, cd-MMP-12 and BSA with two different
peptidases, trypsin and endoproteinase Glu-C. The latter gives
usually lower sequence coverage values in the experimental
conditions used, so that trypsin was chosen as the optimal
enzyme for our experimental protocol
Protein Sequence coverage (%)
Trypsin Endoproteinase Glu-C
cdMMP-1 31.1 20.5
cdMMP-8 37.4 31.9
cdMMP-12 47.7 25.5
BSA 30.6 20.6
Figure 6. AP/MALDI-MS spectrum obtained by sampling the
supernatant solution from an area of the gold surface where
both cdMMP-1 and cdMMP-12 were previously immobilized
and digested with trypsin solution as described in the text. The
same MS spectrum was recorded with the protein molecules
mixed before or after the immobilization on the gold surface.
Although the spectrum is more complicated because it is
crowded with peaks derived from the tryptic digestion of both
cdMMPs, a meaningful assignment is also possible in this
case, confirming the applicability of the experimental
procedure to protein mixtures.
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protein molecules mixed before or after the immobilization
on the gold surface, proving once again that the anchorage
on the solid support does not alter the protein interaction
properties.
From all the results shown above, we therefore think that
the new experimental procedure is particularly suitable for
SPR/MALDI-MS coupled investigation of enzyme activity
and/or interactions with other molecules, and it can be
developed further in order to extend its applicability to real
complex biological samples.
CONCLUSIONS
The obtained results for cdMMP-1, cdMMP-8 and cdMMP-
12 show that it is possible to characterize an enzyme that
had been previously anchored on a gold surface by in situ
AP/MALDI-MS. Although such experimental protocol can
have many different applications, we believe that the
new approach could be particularly advantageous for the
development of solid-state MMP assays. Moreover, it could
be of help to SPR users, as the necessity to unambiguously
characterize biomolecules that have been previously studied
by SPR is often an important issue in the BIA field. Finally,
the obtained results are a further proof of the importance
that buffer- and salt-contaminated solution has in the MS
analysis, not only in diminishing the sensitivity but also in
affecting the appearance of the MS spectrum.
The applicability of the above-described experimen-
tal approach to more complicated samples (mixture of
cdMMPs), as well as to protein arrays, has also been
demonstrated, proving that the experimental protocol can be
generally used for unambiguously identifying immobilized
proteins on solid supports.
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Matrix metalloproteinases (MMPs) are a family of proteins
involved in tissue remodeling and cell signaling.[1–3] As such,
they are validated drug targets.[4, 5] MMPs are endopeptidases
with zinc at the active site of a catalytic domain.[6]
The enzymology of peptidases has been a popular area of
research since the investigation of carboxypeptidase A
(CPA)[7–11] and thermolysin (TLN)[12–15] in the 1980s. Both
proteins are rich in charged and ionizable groups, such as Glu,
Arg, and His, in the active site. A role for these residues in
catalysis was proposed. In contrast, MMPs are simple proteins
with only one Glu residue in the active site besides the three
His residues coordinated to the catalytic zinc ion. In the most
widely accepted mechanism, which is similar to that proposed
for CPA and TLN, this Glu residue assists in the nucleophilic
attack at the relevant peptide carbonyl group of the substrate
by a zinc-coordinated water molecule.[16] The interest in
MMPs has grown again because of the need for inhibitors that
are as specific as possible for each of the 23 human
proteins.[17–22]
We have now solved a series of X-ray crystal structures
under a variety of conditions in an attempt to obtain models
of the various steps of the reaction mechanism of MMPs. The
protein tends to digest itself, so crystallization is always
carried out in the presence of an inhibitor. By experimenting
with various crystals under crystal-washing conditions we
could solve the structure of the uninhibited form of MMP-12
at a resolution of 1.2 8 (Figure 1a; see also the Supporting
Information) and that of MMP-8 at a resolution of 1.7 8 (see
the Supporting Information). These are the first X-ray crystal
structures of the uninhibited, active form of MMP. In MMP-
12, the active site contains three water molecules coordinated
to zinc, one of which is hydrogen bonded to Glu219, in an
almost regular octahedral geometry. In the case of MMP-8,
only the water molecule that is hydrogen bonded to Glu219
has full occupancy, whereas the other two water molecules
have occupancies of only about 20%. Despite the lower
resolution of the MMP-8 structure, the electron densities of
the latter water molecules are clearly appreciable (see the
Supporting Information). If these two water molecules are
neglected, the resulting geometry is a flattened tetrahedron,
with ample room for the binding of an exogenous ligand.
We then attempted to soak the 204–209 peptide fragment
of type I/III of the alpha-1 collagen chain, ProGlnGlyIle-
AlaGly, which is known to be cleaved at the GlyIle bond,
into the active MMP-12 and MMP-8 crystals. No peptide-
bound form could be identified, as a result of rapid hydrolysis.
Even with the mutation Glu219Ala, which had been reported
to lower the enzymatic activity of MMP-7 by three orders of
magnitude,[23] the substrate underwent hydrolysis. On the
other hand, well-resolved X-ray crystallographic structures
that show a hydrolysis product inside the active site could be
obtained for both MMP-12 (resolution: 1.1 8; Figure 1d) and
MMP-8 (resolution: 1.5 8; see the Supporting Information),
and for the former even a structure with both hydrolysis
products was obtained (resolution: 1.8 8; Figure 1c). We then
modeled the substrate in the form of a tetrahedral gem-diol
intermediate (in analogy to the structure of a pseudosubstrate
described in the literature[24]) by taking the uninhibited form
of MMP-12 and that with two peptides in the active site as the
starting points (Figure 1b). Figure 1a–d show a plausible
series of events in the catalytic cycle of MMPs, as discussed
below. A four-snapshot movie of the steps illustrated in
Figure 1a–d can be downloaded as Supporting Information
for this article.
The cycle starts with the uninhibited MMP-12 enzyme
(Figure 1a). Figure 1b shows that one of the two oxygen
atoms of the gem-diol that results from substrate binding
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indeed sits in the position previously occupied by the
catalytically relevant water molecule and is also hydrogen
bonded to Glu219, whereas the other occupies a coordination
site between the positions of the other two more external
water molecules in Figure 1a. The peptide NH group of the
scissile bond is hydrogen bonded to the carbonyl oxygen atom
of Ala182, and the side chain of Ile207 partially enters the S1’
cavity, whereas the rest of the body of the peptide is stabilized
by four hydrogen-bonding interactions with the backbone of
the protein. The latter interactions involve the carbonyl
oxygen atom of Ile207 and the nitrogen atom of Leu181, the
nitrogen atom of Ala208 and the carbonyl oxygen atom of
Pro238, the carbonyl oxygen atom ofAla208 and the nitrogen
atom of Tyr240, and the nitrogen atom of Gly209 and the
carbonyl oxygen atom of Gly179. As the modeling did not
provide a convincing conformation for the Pro and Gln
residues of the peptide, they are omitted from Figure 1b.
After peptide-bond cleavage, both hydrolysis fragments,
ProGlnGly and IleAlaGly, sit in the active-site cavity, as
shown in Figure 1c. The peptide ProGlnGly, for which a clear
electron density is observed only for the whole Gly206
residue and part of Gln205, is apparently not involved in any
significant stabilizing interaction with the protein backbone.
The carboxylate end of Gly206 binds the zinc ion in an anti-
monodentate fashion. A water molecule is also semicoordi-
nated to zinc (Zn–O distance: 2.8 8) and hydrogen bonded to
the catalytically relevant Glu219 residue; it acts as a “spacer”
between Glu219 and the coordinated carboxylate end of
Gly206. The zinc ion is thus five-coordinated in this
intermediate. The semicoordinated water molecule occupies
a position similar to that of the catalytically relevant water
molecule observed in the free uninhibited enzyme. The full
IleAlaGly fragment can be detected clearly. Its orientation in
the active site is such that the side chain of Ile207 partially
enters the S1’ cavity, whereas the rest of the body of the
peptide is stabilized by four hydrogen-bonding interactions
with the backbone of the protein. The hydrogen-bonding
distances are 2.91 8 between the carbonyl oxygen atom of
Ile207 and the nitrogen atom of Leu181, 3.16 8 between the
nitrogen atom of Ala208 and the carbonyl oxygen atom of
Pro238, 2.81 8 between the carbonyl oxygen atom of Ala208
and the nitrogen atom of Tyr240, and 2.71 8 between the
nitrogen atom of Gly209 and the carbonyl oxygen atom of
Gly179. The N-terminal nitrogen atom of the IleAlaGly
fragment is involved in two strong hydrogen-bonding inter-
actions with the water molecule coordinated to the zinc atom
(2.69 8) and with one oxygen atom of Glu219 (2.24 8),
whereas there are no hydrogen-bonding interactions of this
nitrogen atom with the protein backbone. It is difficult to
ascertain whether the N-terminal nitrogen atom is part of a
neutral NH2 group or a positive NH3
+ group. Overall, the
active-site crevice is slightly more open than in the active
uninhibited enzyme, in contrast to what was observed for
thermolysin and astacin.[25,26]
The ProGlnGly fragment, which is coordinated to zinc
through the carboxylate group of the C-terminal Gly206
residue, is the first to leave the cavity, whereas the IleAlaGly
fragment remains in the cavity (Figure 1d; see also the
Supporting Information). The zinc ion appears in this case to
Figure 1. a) Active, uninhibited form of MMP-12. b) A plausible gem-
diol intermediate[24] of MMP-12 modeled by using the structures of the
uninhibited (a) and two-peptide (c) forms as templates. c) Two-peptide
intermediate observed upon soaking the active uninhibited MMP-12
crystals with the collagen fragment ProGlnGlyIleAlaGly. d) IleAlaGly
adduct of MMP-12.
Angewandte
Chemie
7953Angew. Chem. Int. Ed. 2006, 45, 7952 –7955  2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
be tetracoordinated, with a more strongly bound water
molecule (2.28 8), which is in turn hydrogen-bonded to
Glu219. The interaction between this water molecule and
Glu219 is still very strong; they are separated by a distance of
2.60 8. This water molecule occupies roughly the same
position as in the free uninhibited enzyme, but the other
two coordinated water molecules are not present, so that the
zinc ion has a flattened tetrahedral coordination sphere.
Given the high resolution of the structure, the existence of
other immobilized water molecules in the zinc coordination
sphere can be safely ruled out (see the Supporting Informa-
tion). The bond lengths around the zinc ion (see the
Supporting Information) are also consistent with a lower
coordination number of the zinc center. The amino terminus
of the IleAlaGly fragment moves away from the zinc center
and loses the strong hydrogen-bonding interaction with the
zinc-coordinated water molecule, whereas the interaction
with one of the oxygen atoms of Glu219 (2.74 8) is retained.
The side chain of Ile207 alters its position and increases its
interactions with the S1’ cavity. The rest of the body of the
peptide is stabilized by three of the four hydrogen-bonding
interactions with the backbone of the protein that were
observed when two peptides occupied the active site (car-
bonyl oxygen atom of Ile207 with the nitrogen atom of
Leu181, 2.77 8; carbonyl oxygen atom of Ala208 with the
nitrogen atom of Tyr240, 2.74 8; nitrogen atom of Gly209
with the carbonyl oxygen atom of Gly179, 3.03 8). However,
the interaction between the nitrogen atom of Ala208 and the
carbonyl oxygen atom of Pro238 no longer exists, and this
carbonyl bond is itself reoriented by almost 908 away from the
center of the active crevice, as observed in several inhibitor
adducts with hydrophobic groups in the S1’ cavity.
[27] Overall,
the active-site crevice is more open with respect to the
previous snapshot (Figure 1c). The observation of a similar
adduct with MMP-8[*] (see the Supporting Information) and
in a self-interacting form of MMP-12[28] confirms the general-
ity of our findings.
Based on the details of the structures shown in Figure 1a–
d and in the corresponding movie, a consistent sequence of
events emerges:
1) The uninhibited enzyme has a coordinated water molecule
whose position is determined by a strong hydrogen bond
with Glu219. The position of this water molecule suggests
that the Zn-H2O-Glu219 moiety has lost at least one
proton, as has already been proposed for CPA and TLN.
During catalysis the water hydrogen atom in the hydrogen
bond to the carboxylate group of Glu219 may actually
move to Glu219 as a proton; the coordinated water
molecule is thus transformed into a hydroxide ion and its
nucleophilicity increased.[29] The active-site crevice is in a
“closed” form; that is, it is somewhat narrower than when
observed in the presence of the hydrolysis products or
inhibitors.
2) The incoming substrate binds zinc with the carbonyl group
ofGly206 (replacing the additional labile water molecules
when present), and establishes a number of stabilizing
interactions with the protein through its C-terminal
section (IleAlaGly). It is thought that the N-terminal
section may not be involved in relevant interactions with
the protein on the basis of the bent conformation observed
for the Gln side chain in the product (Figure 1c). The
strongly coordinated water molecule (hydroxide ion)
performs a nucleophilic attack on the Gly206 carbonyl
group to give the gem-diol intermediate modeled in
Figure 1b.
3) After the peptide bond has been broken, both peptide
fragments remain bound to the protein initially. However,
the ProGlnGly fragment is only held in place by mono-
dentate coordination of the Gly206 carboxylate group to
the zinc center, whereas the IleAlaGly fragment is strongly
bound to the protein (Figure 1c). An incoming water
molecule loosely binds zinc and separates the bound
carboxylate group from the Glu219 residue. The forma-
tion of this five-coordinate intermediate facilitates the
detachment of the ProGlnGly fragment through an
associative ligand-exchange mechanism.
4) The remaining protein-bound fragment IleAlaGly (Fig-
ure 1d) undergoes a relatively small but significant
rearrangement in the active-site cavity. The driving force
for this rearrangement could rest in the possibly strained
pose of this fragment in the two-peptide adduct as a result
of several interactions that still exist between the two
fragments; these interactions are mediated by the zinc-
coordinated water molecule and the Glu219 residue.
After the release of the ProGlnGly fragment, the
increased repulsion between the positively charged zinc
ion and the incipient NH3
+moiety cause the Ile side chain
to enter deeper into the S1’ cavity and optimize its
hydrophobic interactions with the cavity. The change in
the position of the Ile side chain occurs at the expense of
the interaction between the nitrogen atom of Ala208 and
the carbonyl oxygen atom of Pro238; this interaction is
lost as a result of the opening up of the cavity. The release
of the IleAlaGly fragment would from this point follow the
same pathway as that of any S1’-directed inhibitor.
This model may also provide some clues on the pH
dependence of the catalytic activity of MMPs. The kcat/KM
profile is bell-shaped, as it is for CPA and TLN, with
pKa values of 4.3 and 9.6. In the absence of any other
ionizable groups in the active-site cavity, the simplest
interpretation would be that the two pKa values apply to the
successive deprotonations of the coordinated water–Glu219
system. However, mutations in which Glu219 is replaced by a
nonionizable residue decrease but do not abolish activity, and,
more importantly, the bell-shaped activity profile is main-
tained.[23] For example, the Glu219Ala mutation in MMP-7
reduces the activity to 0.1%, shifts the first pKa value to 5.4
(an increase of 1.1 pH units), and does not change the second
pKa value appreciably.
[23] In this mutant, the only ionizable
residue is the coordinated water molecule, which itself can not
account for two pKa values. One possibility is that one of the
[*] In the MMP-8 adduct the orientation of the IleAlaGly fragment is
more similar to that observed in the two-peptide adduct of MMP-12,
and two water molecules are coordinated to zinc; these water
molecules occupy similar positions to those of the two gem-diol
oxygen atoms in the modeled structure in Figure 1b.
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two pKa values is product-linked. Our mechanism might
suggest that the high pKa value of 9.6 corresponds to the
deprotonation of the IleAlaGly product. A neutral NH2
amino terminus could stabilize the IleAlaGly adduct, thereby
preventing the clearance of the active site for the next
enzymatic reaction.
Experimental Section
The catalytic domains of MMP-12 (Gly106–Gly263, F171D mutant)
and MMP-8 (Asn85–Gly242) were expressed and purified as
reported previously.[30] Crystal growing, data collection, and structure
refinement are described in the Supporting Information. The follow-
ing structures have been deposited to the PDB: Uninhibited MMP-
12; the adduct of MMP-12 with two peptides; the adduct of MMP-12
with one peptide; uninhibitedMMP-8; the adduct of MMP-8 with one
peptide. The PDB file of the model of the MMP-12–gem-diol adduct
is available as Supporting Information.
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C 
Figure S1. 2Fo-Fc electron density map contoured at 1s level showing zinc and its 
coordinated water molecules in A) Active MMP-8, B) Active MMP-12 and C) One 
peptide MMP-12 adduct.  
 3
 
 
 
 
 
Figure S2. Active, uninhibited form of MMP-8 (A) and its IleAlaGly adduct (B). 
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Figure S3. 2Fo-Fc electron density map contoured at 1s level showing zinc and its 
coordinated water molecules and the bound peptide(s) in A) Two-peptide MMP-12 
adduct, B) One peptide MMP-12 adduct and C) One peptide MMP-8 adduct. 
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  (set the player repeat option on)  
Movie S1. A four-frame movie of 1) active MMP, 2) its modelled gem-diol intermediate 
with the central part of the ProGlnGlyIleAlaGly peptide; 3) the two-peptide intermediate; 
4) the one-peptide intermediate. The movie is based on the MMP-12 structures, where the 
gem-diol intermediate[29] in frame (B) is modelled after the uninhibited (Figure 1A) and 
two-peptide (Figure 1C) forms. Atom colors are CPK except zinc (cyan), its histidine 
ligands (yellow = N, limon = C), and coordinated water molecules (magenta). Hydrogens 
are not shown. 
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Crystallization, Data Collection and Structure Solution 
Crystals of human MMP-12 were obtained as previously reported.[1] Crystals of human 
MMP-8 grew using the same technique at 20° C from a solution containing 0.1 M Tris-
HCl, 20% PEG-3350, 200 mM AHA, 0.2 M MgCl2 at pH 8.0. The final protein 
concentration was 0.4 mM. The crystallization buffer contained 200 mM of the weak 
inhibitor acetohydroxamic acid (AHA). To obtain the active uninhibited enzymes, MMP 
crystals were then extensively dialyzed against the same crystallization buffers lacking 
AHA. The ProGlnGlyIleAlaGly peptide (INBIOS s.r.l., Naples) was soaked into the 
crystals for 1-3 days in order to obtain the two- or the one-peptide adducts. 
The peptide was added, in powder form, directly into the drop using a needle and was left 
incubating for 1-3 days. MMP-12 two-peptide complex (A) was measured in-house, 
using a PX-Ultra copper sealed tube source (Oxford Diffraction) equipped with an Onyx 
CCD detector, whereas the single-peptide complex (B) was measured using synchrotron 
radiation at ID-29 beamline (ESRF, Grenoble, France). Active MMP-12 (C) and the 
MMP-8 one-peptide complex (D) were measured at beamline BW7B (DESY, Hamburg, 
Germany), whereas active MMP-8 (E) was measured at beamline ID23-1 (ESRF, 
Grenoble, France). All datasets were collected at 100 K and the crystals used for data 
collection were cryo-cooled without any cryo-protectant treatment.  
A diffracted to 1.9 Å resolution, B diffracted to 1.2 Å and C to 1.3 Å; they all belong to 
spacegroup C2 with one molecule in the asymmetric unit, a solvent content of about 50% 
and a mosaicity of 0.7°-0.8°. D diffracted to 1.5 Å resolution in space group P21 with two 
molecules in the asymmetric unit whereas E diffracted to 1.7 Å resolution in space group 
P1 with two molecules in the asymmetric unit. Solvent content and mosaicity values for 
D and E are roughly 50% and 0.8°-0.9° respectively. 
The data were processed in all cases using the program MOSFLM[2] and scaled using the 
program SCALA[3] with the TAILS and SECONDARY corrections on (the latter 
restrained with a TIE SURFACE command) to achieve an empirical absorption 
correction. Table 1 shows the data collection and processing statistics for all datasets. The 
structures were solved using the molecular replacement technique; the model used for all 
MMP-12 datasets was 1Y93 whereas the one used for MMP-8 datasets was 1I73; in all 
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cases inhibitors, water molecules and ions were omitted from the models. The correct 
orientation and translation of the molecule within the crystallographic unit cell was 
determined with standard Patterson search techniques[4,5] (as implemented in the program 
MOLREP.[6;7] The isotropic refinement was carried out using REFMAC5[8] on A and E 
datasets but metal ion B-factors were refined taking anisotropy into account; conversely, 
datasets B, C and D were refined taking anisotropy into account for all atoms. REFMAC5 
default weights for the crystallographic term and the geometrical term have been used in 
all cases. 
In between the refinement cycles the models were subjected to manual rebuilding by 
using XtalView.[9] The same program was used to model ligands. Water molecules have 
been added by using the standard procedures within the ARP/WARP suite.[10] The 
stereochemical quality of the refined models was assessed using the program 
Procheck.[11] The Ramachandran plot is in all cases of very good quality.  
Table 1 reports the data collection and refinement statistics for all datasets.  
 
Modelling of the gem-diol 
 
The gem-diol adduct of MMP-12 was modeled using the experimental structures of the 
active enzyme (Figure 1A) and of the two-peptide adduct (Figure 1C) as the starting point 
and the gem-diol coordination geometry experimentally observed for a transition state 
analog.[29] 
The model was refined using the local search option of Autodock.[12] The standard, 
validated Autodock zinc parameters for MMP were used.[13;14] A final minimization of 
both models using Amber[15] converged to the single structure of Figure 1B. 
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 His218 His222 His228 HOH1 
(Glu219) 
HOH2 HOH3 
Active 
MMP-12 
2.13 2.12 2.09 2.40 2.38 2.10 
Two-
peptide 
MMP-12 
2.11 2.00 2.02 2.83 2.37 - 
One-
peptide 
MMP-12 
2.04 2.08 2.04 2.28 - - 
Active 
MMP-8 
(two 
molecules) 
2.06 
 
2.09 
2.22 
 
2.06 
2.14 
 
2.20 
2.84 
 
2.69 
2.70 
 
- 
2.79 
 
- 
One-
peptide 
MMP-8 
(two 
molecules) 
2.07 
 
2.06 
2.10 
 
2.12 
2.04 
 
2.00 
2.27 
 
2.19 
2.35 
 
2.48 
- 
 
- 
 
Table S1. Distances between Zn and the three coordinated histidines, between the Glu-
activated water molecules and zinc and between Zn and the other water molecules 
coordinated to it. 
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Table S2. 
Table 1.              DATA COLLECTION AND REFINEMENT STATISTICS 
 Two-peptide-
MMP12 
complex 
(A) 
Active MMP-12 
 
 
(C) 
One-peptide-
MMP12 
complex 
(B) 
Active MMP-8 
 
 
(E) 
One-peptide-
MMP8 complex 
 
(D) 
Spacegroup C2 C2 C2 P1 P21 
Cell dimensions (Å, °) a= 51.54  
b= 60.37 
c= 54.45 
b= 115.41 
a= 51.54   
b= 60.75  
c= 54.26 
b= 115.64 
a= 51.89 
b= 60.36  
c= 54.52 
b= 115.73 
a= 33.29 
b= 47.11 
c= 61.32 
a= 77.73  
b= 80.03  
g= 77.01 
a= 33.21  
b= 68.53 
c= 78.28 
b= 98.10 
Resolution (Å) 30.2 – 1.9 25.8 – 1.2 49.0 – 1.1 39.5 – 1.7 38.7 – 1.5 
Unique reflections 11726 (1505) 41969 (5315) 50850 (7153) 30329 (4603) 55607 (8108) 
Overall completeness (%) 98.1 (86.9) 97.2 (84.8) 94.6 (91.1) 90.3 (88.3) 99.9 (99.9) 
R
sym (%) 13.7 (32.7) 7.9 (12.6) 5.9 (15.6) 10.3 (24.5) 8.2 (31.4) 
Multiplicity 5.6 (3.0) 5.8 (5.2) 6.8 (6.8) 1.5 (1.5) 6.7 (6.0) 
I/(sI) 4.7 (2.3) 5.1 (3.8) 4.2 (4.1) 4.7 (2.6) 6.6 (2.2) 
Wilson plot B-factor (Å2) 7.69 7.17 11.08 16.14 10.21 
Rcryst  / Rfree (%) 20.6 / 28.7 19.6 / 21.6 19.7 / 22.2 22.5 / 29.3 16.3 / 19.2 
Protein atoms 
1238 1238 1238 
2480 (two 
molecules) 
2480 (two 
molecules) 
Ions 5 5 5 8 8 
Ligand atoms 31 0 17 0 17 
Water molecules 119 238 206 303 591 
RMSD bond lengths (Å) 0.021 0.007 0.007 0.020 0.008 
RMSD bond angles (º) 1.8 1.0 1.1 1.6 1.1 
Mean B-factor  (Å2) 9.80 11.00 14.16 17.17 12.39 
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B
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C
 13
D
 14
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Figure S4. Ramachandran plots for A) Active MMP-12, B) One peptide MMP-8 adduct, 
C) Active MMP-8, D) Two peptide MMP-12 adduct and E) One peptide MMP-12 
adduct. 
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Abstract 
By solving high resolution crystal structures of a large number (14 in this case) of 
adducts of matrix metalloproteinase 12 (MMP12) with strong, nanomolar, inhibitors 
all derived from a single ligand scaffold, it is shown that the energetics of the ligand-
protein interactions can be accounted for directly from the structures to a level of 
detail that allows us to rationalize for the differential binding affinity between pairs of 
closely related ligands. In each case, variations in binding affinities can be traced 
back to slight improvements or worsening of specific interactions with the protein of 
one or more ligand atoms. Isothermal calorimetry measurements show that the 
binding of this class of MMP inhibitors is largely enthalpy driven, but a favorable 
entropic contribution is always present. The binding enthalpy of acetohydroxamic 
acid (AHA), the prototype zinc-binding group in MMP drug discovery, has been also 
accurately measured. In principle, this research permits the planning of either 
improved inhibitors, or inhibitors with improved selectivity for one or another MMP. 
The present analysis is applicable to any drug target for which structural information 
on adducts with a series of homologous ligands can be obtained, while structural 
information obtained from in silico docking is probably not accurate enough for this 
type of study. 
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Introduction 
Drug discovery projects aim at finding small molecules that bind a selected 
protein target with high binding affinity. High selectivity is also a desirable property 
especially when the selected target belongs to a protein family. In the case of matrix 
metalloproteinases (MMP), a family of closely related zinc-containing extracellular 
proteases, numerous high affinity inhibitors are available.1 Well-known examples are 
batimastat and marimastat belonging to the class of succinate peptidomimetic 
inhibitors,2,3 the class of succinate macrocyclic inhibitors,4 the class of sulfone 
hydroxamate,5 the class of the reverse hydroxamic acid inhibitors6 and the class of 
sulfonamidic inhibitors such as NNGH.7 Their dissociation constants are in the low 
nanomolar range. However, the selectivity versus one or another MMP is often 
modest and this is at the origin of several side-effects discovered during the clinical 
trials.8 Several approaches have been proposed in order to design selective ligands for 
protein targets.9-12 Three-dimensional structures of enzyme-inhibitor adducts for 
several ligands, belonging to the various classes, with several different MMPs are 
available.3,5,13-22 Given the active site topology of MMPs, most inhibitors share 
similar features, i.e. the ability to bind to the metal ion, to the hydrophobic pocket 
termed S1’, and to the substrate binding groove (Figure 1A). In such a situation, to 
attempt planning ligands with increased selectivity requires an understanding of the 
energetics of the inhibitor interactions with each of these active site regions to an 
unprecedented level of detail. The existing structural data for various MMP-inhibitor 
adducts are many but scattered, and structure-affinity relationships at the level of a 
meaningful dissection of the various contributions can be hardly attempted.23 
Furthermore, the catalytic domains of MMPs undergo non-negligible conformational 
equilibria in solution,17,24,25 which also involve the active site pocket. A flexible 
active site is a serious drawback for the use of in silico docking programs to design 
inhibitors,26 and even more to refine them to increase selectivity.27 
With this in mind, we felt it would be important to ascertain whether, in case a 
large number of structures of MMP adducts with a homologous series of ligands were 
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available,  structure-affinity relationships can be established; and, if so, whether these 
relationships are accurate enough to enable meaningful protein-specific ligand-
refinement strategies. Thus, we collected structural data for a large number of adducts 
of a homologous series of ligands with one particular MMP. We selected MMP12, a 
validated target for emphysema28 and multiple sclerosis,29 because a crystalline form 
of its catalytic domain is available17 that allows easy soaking of inhibitors. High-
resolution crystal structures of as many as sixteen different adducts of the protein 
with structurally related inhibitors were obtained. In parallel, the free energies of 
binding (ΔG0) through enzyme activity inhibition experiments were measured for the 
same ligands. It is shown that, indeed, a careful analysis of the structural data, 
performed with the aid of structure-based computed interatomic interaction energies, 
can provide a detailed description of how different substituents on the same scaffold 
can interplay to improve or worsen affinity and selectivity. It is proposed that this 
strategy is of general validity for any drug target, provided structural information on a 
number of homologous ligand-protein adducts can be obtained. 
 
Materials and Methods 
Synthesis, characterization and inhibitory assays of compounds 1-11 and 13-14 will 
be described elsewhere. Compound 12 has been already described.7 
Expression and purification of human MMP12 and MMP13 catalytic domain. 
Cloning, expression and purification of MMP12 catalytic domain have been 
previously described.17 The cDNA of proMMP13 (Leu20-Pro268) was cloned into 
the pET21 vector (Novagen) using Nde I and Xho I as restriction enzymes. One 
additional methionine at position 19 was present in the final expression product. The 
E. coli strain BL21 Codon Plus cells, transformed with the above plasmid, were 
grown in LB medium at 310 K. The protein expression was induced during the 
exponential growth phase with 0.5 mM of IPTG. The cells were harvested 3 hours 
after induction. After lysis of the cells the inclusion bodies, containing the 
proMMP13, were solubilized in 6 M urea; 20 mM Tris (pH 8.0). The protein was 
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purified on the Hitrap Q column (Pharmacia) with a buffer containing 6 M urea; 20 
mM Tris (pH 8.0). The elution was performed using a linear gradient of NaCl up to 
0.6 M. The purified protein was then refolded  using multi-step dialysis against 
solutions containing 50 mM Tris (pH 7.2); 10 mM CaCl2; 0.1 mM ZnCl2; 0.3 M NaCl 
and decreasing concentration of urea. The refolded protein was exchanged, by 
dialysis, against a buffer with 50 mM Tris (pH 7.2); 5 mM CaCl2; 0.1 mM ZnCl2; 0.3 
M NaCl. The protein was concentrated at room temperature using an Amicon up to a 
concentration of about 30 μM. The active protein is left overnight in these conditions 
to allow the autoproteolysis of the prodomain. After addition of Acetohydroxamic 
acid (AHA) to a final concentration of 0.5 M, the catalytic domain of MMP13 (Tyr 
104- Pro 268) was purified using size-exclusion chromatography with the buffer 50 
mM Tris (pH 7.2); 5 mM CaCl2; 0.1 mM ZnCl2; 0.3 M NaCl, 0.2 M AHA and then 
concentrated using a Centriprep concentrator at 277 K to a final concentration of 0.3 
mM. 
Fluorimetric assays. The inhibition constants for the compounds here 
investigated were determined evaluating their ability to prevent the hydrolysis of the 
fluorescent-quenched peptide substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 
(Biomol Inc.). All measurements were performed in 50 mM HEPES buffer, with 10 
mM CaCl2, 0.05% Brij-35, 0.1 mM ZnCl2 (pH 7.0), using 1 nM of enzyme and 1 μM 
of peptide at 298 K.  
Crystallization, Data Collection and Resolution of the Crystal Structures. 
Crystals of human MMP12, already containing AHA from the refolding process, 
grew at 293 K from a 0.1 M Tris-HCl, 30% PEG 8000, 200 mM AHA, 1.0 M LiCl2 
solution at pH 8.0 using the vapor diffusion technique. The final protein 
concentration was about 10 mg/ml. 
The complexes were obtained through soaking MMP12-AHA crystals with a solution 
containing the inhibitor itself in the presence of LiCl2. Crystals of MMP12-AHA 
were obtained in the presence of LiCl2 as well.17 
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The data were measured in-house, using a PX-Ultra copper sealed tube source 
(Oxford Diffraction), for 3, 6, 7, 9, 13 and 14, at ID29 ESRF (Grenoble, France) for 4 
and 8, at BW7A DESY (Hamburg, Germany) for 1, 2, 5, 10 and 11 complexes and at 
XRD-1 ELETTRA (Trieste, Italy) for 12. 
All the datasets were collected at 100 K and the crystals used for data collection were 
cryo-cooled without any cryo-protectant treatment. The crystals of all complexes had 
a mosaicity ranging from 0.3° to 0.8° and diffracted to a maximum resolution of 1.1 
Å.  
All the soaked adducts crystallize in the C2 space group with one molecule in the 
asymmetric unit while co-crystallized complex of 12 crystallizes in P21212 space 
group with one molecule in the asymmetric unit.  
The data were processed in all cases using the program MOSFLM30 and scaled using 
the program SCALA31 with the TAILS and SECONDARY corrections on (the latter 
restrained with a TIE SURFACE command) to achieve an empirical absorption 
correction. Table 1S (in Supporting Information) shows the data collection and 
processing statistics for all datasets. 
The structure of the adduct with 12 was previously solved17 using the molecular 
replacement technique; the model used was that of a molecule of human MMP12 
(1OS9) while the structure of all other adducts were solved using the MMP12-AHA 
adduct (1Y93) as the model from where the inhibitor, all the water molecules and 
ions were omitted. The correct orientation and translation of the molecule within the 
crystallographic unit cell was determined with standard Patterson search 
techniques32,33 as implemented in the program MOLREP.34,35 The refinement was 
carried out using REFMAC536 and for the atomic resolution datasets anisotropic B-
factors were also refined. In between the refinement cycles the models were subjected 
to manual rebuilding by using XtalView.37 The same program has been used to model 
all inhibitors. Water molecules have been added by using the standard procedures 
within the ARP/wARP suite38 and for the atomic resolution datasets hydrogens were 
added at the riding positions and refined. 
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The stereochemical quality of the refined models was assessed using the program 
Procheck.39 The Ramachandran plot for all structures is of very good quality. 
The coordinates for all adducts are under deposition at the ProteinDataBank. 
Energy calculation. Autodock 3.05 was used to calculate the protein ligand 
binding-energy.40 The calculation was performed starting from the x-ray crystal 
structure using reliable Zn(II) parameters.41 A box of 70x70x70 point with grid 
spacing of 0.375 Å  was created on the protein side, and centered near the catalytic 
Zn(II) ion. The ligands were extracted from the x-ray structure and hydrogen atoms 
were added considering the hydroxamic group deprotonated; Gaister-Marsili partial 
atomic charges were calculated using BABEL.42 The ligands were modelled based on 
the X-ray structures which were already minimized against the experimental 
diffraction data. Energy contributions for individual atoms were extracted  from the 
Autodock energy output.  
Calorimetry. Isothermal Titration Microcalorimetry experiments were 
performed at 298 K with a VP-ITC microcalorimeter (MicroCal, Inc., Northampton, 
MA). After an initial injection of 1 μL, aliquots of 9 μL of 200 μM inhibitor were 
stepwise injected into the sample cell containing a solution 20 μM of MMP12 
catalytic domain until complete saturation. All experiments were performed in 20 
mM Tris (pH 7.2), 5 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl, AHA 4 mM with 0.1% 
(v/v) DMSO. Heats of dilution were measured by injecting the ligand into buffer and 
then subtracted from the binding heats. The thermodynamic parameters and KA values 
were calculated fitting data to a single binding site model with ORIGIN 7.0 sofware 
(Microcal, Inc.).43 
 
Results and Discussion 
Crystal structures and dissociation constants of ligand-MMP12 adducts. The 
crystal structures of the complexes of the catalytic domain of MMP12 with 14 closely 
related inhibitors have been solved. Figure 1B shows the scaffold common to all 
these inhibitors, and the three positions on which different functionalizations have 
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been tested. The general formula contains a hydroxamic group targeted to bind the 
catalytic zinc ion, and an aromatic moiety bearing the R1 substituent targeted to the 
hydrophobic S1’ pocket. The two groups are tethered by a sulphonamide moiety 
interacting with the substrate binding groove and containing substituents R2 and R3, 
potentially able to give rise to further interactions. R1 ranges from H to F to OCH3 to 
C6H5. These variations were planned to monitor their relative effects on the strength 
of the interaction with S1’. R2 and R3 are either H or aliphatic groups with various 
degrees of hydrophobicity/hydrophilicity. 
A close up of the arrangement of the various ligands in the active site of MMP12 
is shown in Figures 2-6. All the inhibitors share the same binding mode, as expected, 
and to a first inspection all relevant interactions (with the S1’ pocket, the metal and 
the substrate binding groove) are in place. To emphasize the similarities, all 
structures are reported with the same orientation, obtained by least square fits of all 
the coordinates of the adducts to one another. The left-hand column of Figures 2-6 
shows the structures of each adduct, and the central column reports the structure of 
the adduct with the closest ligand homologue. 
Despite the similarities of the ligand-protein interactions, the dissociation 
constants, measured as inhibition constants through fluorimetry under non-saturating 
substrate concentration conditions at 298 K (see materials and methods), span two 
orders of magnitude. The associated ΔG0 values are reported in Table 1.† It can be 
seen that there are relevant differences in binding affinities even between ligands that 
are very close homologues, i.e. are next to one another in Figures 2-6. 
These results illustrate well the nature of the problem: as large differences in the 
binding modes can be immediately ruled out by visual inspection, the point is to 
ascertain whether small differences in the binding mode are at all detectable‡ and, if 
                                                 
†As described in the Materials and methods Section, the protein was used as an adduct with the weak inhibitor 
acetohydroxamic acid (AHA). Stock protein solutions contained 200 mM AHA. At the final dilution for the fluorimetric 
assays (1 nM of enzyme), the AHA concentration was 5 μM at most, which is well below the dissociation constant of 
6.2 mM estimated through the same fluorimetric assay. Therefore, it may be concluded that AHA does not appreciably 
interfere with the assays. 
‡ The nominal resolution for the adduct structures obtained in this work range between 1.2 and 1.7 Å, which 
corresponds to indeterminations in interatomic distances of ±0.10 to ±0.15 Å. 
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so, whether these small differences are consistently related with the differences in 
binding affinity. 
Careful examination of key interatomic distances and angles does suggest that 
indeed not all interactions, despite being all in place, may be energetically equivalent. 
For example, on passing from R1 = -H (1) to R1 = -F (2), -OCH3 (3), -C6H5 (4), Van 
der Waals contacts are of course gained in the S1’ pocket, but less optimal H-bond 
interactions of the SO2 group are seen in all cases, a slight worsening is apparent in 
the hydroxamic acid coordination mode in the -OCH3 derivative, and a less deep 
penetration of the first phenyl ring in the S1’ pocket is seen in the -C6H5 derivative. 
As another example, by comparing the R1 = -C6H5, R2 = -CH2CH2OH, R3 = -H 
derivative (7) with the R1 = -C6H5, R2 = -H, R3 = -H derivative (4) on one side, and 
the R1 = -OCH3, R2 = -CH2CH2OH, R3 = -H derivative (6) with the R1 = -OCH3, R2 = 
-H, R3 = -H derivative (3) on the other side, we notice that the addition of the R2 = -
CH2CH2OH substituent may have opposite effects: it modestly improves the overall 
binding of the R1 = -OCH3 compound, and strongly worsens the binding of the R1 = -
C6H5 compound. Inspection of the structures suggests that the worsening of the 
affinity of the -C6H5 derivative may be qualitatively explained by the less optimal 
binding mode of the hydroxamic moiety, with an average distance of the two oxygens 
of 0.03 Å longer, respectively, in the -C6H5 with respect to the -OCH3 case. While an 
increase in binding affinity upon increasing the R1 substituent in the first example 
could have been expected, the reversal in behavior of the R2 = -CH2CH2OH 
substitution between the -OCH3 and the -C6H5 derivatives was unexpected. 
Differential interaction energies of homologous ligand pairs. From careful 
inspection of the structures a qualitative correlation seems to exist between good 
intermolecular interactions and binding affinity. It is difficult, however, to extend 
these considerations to all molecules, especially when some interactions seem to have 
improved and other to have been worsened in the same adduct. In other words, it 
would be desirable to have a simpler but reliable way to translate these observations 
in contributions to binding. As the individual interaction strengths can be ultimately 
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traced down to either hydrophobic or electrostatic effects, we decided to simply 
evaluate the hydrophobic and electrostatic contributions to the overall intermolecular 
interaction energy by each ligand atom using standard parameter sets such as those 
employed in popular docking programs. Among them, the parameter set used by 
Autodock was selected because of its simple ad hoc treatment of the ligand metal ion 
interaction.44 It should be immediately stressed that we are not using these parameters 
to estimate overall, absolute binding energies (see however later) but only to attach a 
more quantitative meaning to structural observations by calculating differences in 
interatomic interaction energies between the protein and each atom of different 
homologous ligands. By estimating differences, possible biases originating by crude 
approximations, for instance those used by Autodock to parameterize the strength of 
the zinc-hydroxamic ligand coordination bonds, should largely cancel. Furthermore, 
the differences are taken between ligands that are very close homologues, i.e. are next 
to one another in Figures 2-6. 
The results are reported in pictorial form on the right-hand columns of Figures 2-
6. For each row in these figures, the ligand forming the adduct reported in the left-
hand side of the figure is drawn, and its atoms are color- and size-coded to show 
whether their individual interactions with the protein are stronger (green) or weaker 
(red), and by how much (sphere volume), with respect to those of the corresponding 
atoms in the central column adduct. For ligand atoms that do not have a 
corresponding atom in the homologue compound their interaction strengths with the 
protein are encoded as such. The right-hand columns of Figures 2-6 thus provides an 
immediate perception of which atoms may be relevant in determining the differences 
in affinity when the structures of closely related ligands are compared. We have 
checked that the results of the above procedure are largely independent of the set of 
parameters used, suggesting that the estimated differences in interaction energies are 
reliable. A better way to check their reliability is of course to compare the algebraic 
sum of all the differences with the difference in experimental ΔG0 values (ΔΔG0). 
This comparison is reported in Figure 7. Remarkably, not only are the signs of the 
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ΔΔG0s predicted correctly in most cases, but their magnitudes are also reproduced 
quite well. In only two cases (2-1 and 10-3) the calculated sign is opposite to the 
predicted one, but in both cases the differences are rather close to zero. An entropic 
penalty may be further added to the algebraic sum of the individual energetic terms if, 
between the two ligands, there is a difference in the number of rotatable bonds that 
can be possibly immobilized upon binding to the protein. For instance, in Autodock 
the entropic penalty is assigned a default value of 0.31 kcal/mol per bond. The 
calculated ΔΔG0 in Figure 7 take this contribution into account when deemed present, 
i.e. when the ligands to be compared differ in number of potentially immobilized 
rotatable bonds. The bars extending, inwards or outwards of the calculated ΔΔG0 
values, show the results obtained by neglecting the entropic penalty. It is apparent 
that the general trend is maintained whether or not such contribution is taken into 
account. 
In our opinion, the results in Figure 7 constitute a strong validation of the use of 
energetic considerations to examine the details of the structure-affinity relationships 
in this series of homologous MMP inhibitors. We turn now to describe such details, 
to further show that their information content is high enough to make this approach 
precious in terms of predictive power for the refinement of inhibitors towards a 
particular target. 
R1 groups. The first three pairs of experimental ΔΔG0 values in Figure 7 show 
that the substitution of a hydrogen atom in para position to the phenyl substituent 
targeted to the hydrophobic S1’ pocket with –F (2), -OCH3 (3) or a -C6H5 (4) R1 group 
is essentially neutral, moderately advantageous, and strongly advantageous, 
respectively. The corresponding estimated ΔΔG0 values (Figure 7) agree very well 
with the observations, albeit with a slight tendency to overestimate the improvement. 
From Figure 2A-C it appears that the atoms involved in improving the binding are 
mostly the additional atoms in  the R1 group, as expected. The rest of the molecular 
scaffold is scarcely affected. However, it is interesting to notice that the perturbations 
on the rest of the scaffold are larger in the -OCH3 than in the -F derivative, and that 
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they extend as far as to affect the coordination of the hydroxamic group to the zinc 
ion. It is also interesting to note that individual interactions can both gain and lose 
strength, with a prevalence of the latter. This is to be expected as, the bulkier the R1 
group, the fewer the degrees of freedom available to the rest of the molecule to 
optimize these individual interactions. The worsening of a subset of other interactions 
in the rest of the molecule is particularly apparent for R1 = -C6H5: its presence does 
increase substantially the total hydrophobic interactions in the S1’ pocket, but at the 
same time decreases the hydrophobic interactions of the first phenyl ring (right-hand 
side of Figure 2C). As noticed already by comparing the left and central panels in 
Figure 2C, the presence of the second ring apparently prevents the first phenyl ring to 
enter the S1’ pocket as deeply as in the unsubstituted derivative. Also the other 
qualitative observations made by comparing the structures in panels A-C in Figure 2 
are confirmed: -F introduces the least perturbations, slightly worsening the 
hydrophobic interactions in the S1’ pocket and the hydrogen bonds of the SO2 group, 
while in the -OCH3 derivative an appreciable worsening is transmitted to the 
hydroxamic moiety, and in the -C6H5 derivative there is a modest but clear decrease 
of the hydrophobic interactions of the first phenyl ring with the S1’ pocket. 
R2 = -CH2CH2OH. For three derivatives with R1 = -F (5), -OCH3 (6) and -C6H5 
(7), the effect of substituting the hydrogen atom in position R2 with -CH2CH2OH was 
investigated. The alcoholic substituent in R2 slightly improves the binding to the 
enzyme for the first two derivatives, and sizably worsens the binding for the third. 
Again, the estimated ΔΔG0 values agree very well with the observations (Figure 7). 
Panels A-C in Figure 3 provide a rationale for the different behavior. In summary, in 
all three cases the R2 substituent provides an appreciable contribution to binding, 
especially through hydrophobic interactions of the two additional CH2 groups. For R1 
= -F this is accompanied by a modest worsening of the hydroxamic coordination 
strength. Conversely, for R1 = -OCH3 the hydroxamic coordination is actually slightly 
improved, and a modest worsening of the hydrophobic contact of the phenyl ring is 
seen. Thus, in no case a perfect fit is achieved. It is interesting to note that the non 
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perfect fits for the two different molecules lead to different compromises for the 
interactions with the three enzyme subsites: For R1 = -F, the interaction is optimized 
for the hydrophobic pocket and the substrate binding groove, while the binding to 
zinc is sacrificed. For R1 = -OCH3 the interaction is optimized for the binding to zinc 
and to the substrate binding groove, while the binding to the hydrophobic pocket is 
sacrificed. 
Unexpectedly, the R2 = -CH2CH2OH substitution has a sizable destabilizing 
effect on the R1 = -C6H5 scaffold. In this case, the binding to zinc is strongly 
worsened, and the additional interactions established by the alcoholic R2 group do not 
compensate for the loss of interaction strength of the zinc-binding group. Apparently, 
a sizable steric misfit is being faced in this derivative. Figure 2C shows that there is 
almost no perturbation of the hydrophobic interactions of the biphenyl group with 
respect to those experienced by the same group in the R2 = -H derivative. This 
suggests that the two phenyl rings together are held so tightly in the S1’ pocket that 
the steric perturbation introduced by the R2 substituent on the sulfonamide nitrogen, 
which is apparently tolerated in the R1 = -F and R1 = -OCH3 derivatives, is not 
tolerated by the R1 = -C6H5 derivative. As a consequence, a serious mismatch of the 
hydroxamic moiety in the zinc subsite occurs. It should be recalled that the 
hydroxamic group, if free to optimize its orientation, is very specifically tailored for 
the MMP active site, featuring bidentate binding to zinc together with two strong 
hydrogen bonds, one with the carboxylate side chain of the active site Glu-219 and 
one with the peptide carbonyl group of Ala-182. 
R3 = -D,L-Ser or -D,L-Thr. The effect of these substituents (8-11) has been 
examined on the scaffold having R1 = -OCH3. The D stereoisomers have higher 
affinity, and the L stereoisomers lower affinity for MMP12 with respect to the R3 = -
H scaffold (Figure 7). Examination of Figure 4A-D again provides a full rationale for 
this behavior: The D-isomers, besides providing additional binding interactions with 
the R3 group, also exert a slight stabilizing effect on the hydroxamic moiety. The 
stabilization is somewhat larger for the D-Thr derivative, but is accompanied by a 
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modest weakening of the sulfonamide nitrogen interactions, so that the overall gain in 
affinity is slightly lower for the D-Thr (9) than for the D-Ser (8) derivative. In the L-
Ser stereoisomer (10) the stabilizing effect on the hydroxamic moiety is estimated to 
be essentially lost, leading to a very small overall stabilization effect, while the 
experimental ΔΔG0 indicates an overall modest destabilization. Finally, the behavior 
of the R3 = L-Thr (11) is strikingly different, both the experiment and the 
computational estimate showing a strong destabilization. Figure 5A-B shows that the 
L-Thr group actually has slightly more stabilizing interactions that the D-Thr group; 
however, its stereochemistry causes an appreciable distortion of the scaffold that 
apparently strongly destabilizes both the hydroxamic moiety and the sulfonamide NH 
and SO2 groups. Again, it is remarkable that the experimental ΔΔG0 trend is 
reproduced so well by these simple calculations (Figure 7). 
Figure 7 also shows the direct differences between the L and D isomers, and 
confirm the analysis. In the case of the Ser derivatives (8, 10) the L isomer slightly 
stabilizes the Ser itself and mainly destabilizes the hydroxamic moiety, while in the 
case of the Thr derivatives (9, 11) the Thr itself is slightly stabilized but the 
hydroxamic moiety and the sulfonamide NH and SO2 groups are substantially 
destabilized. This direct comparison between the L and D isomers is of course 
redundant, because the effects could have been deduced from the preceding panels of 
Figure 7. However, it is instructive because the ΔΔG0 values in this latter comparison 
are by definition free from solvent-ligand interactions and essentially free also from 
solvent-protein interactions. In other words, the ΔΔG0 values almost purely reflect 
ligand-protein interactions. 
R2 = -CH2CH(CH3)2; R2 = -CH2CHOHCH2OH with R3 = -H, -CH2OH. Having 
established that the -OCH3 substitution in R1 allows substituents in either R2 or R3 to 
increase the overall affinity for MMP12, the relative effects of hydrophobic vs. 
hydrophilic substituents in R2 was investigated for R1 = -OCH3, both in the absence (-
H) or in the presence (-CH2OH) of a substituent in R3 with a D configuration. The 
experimental and predicted ΔΔG0 values for hydrophobic (12) vs. hydrophilic (13) R2 
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are shown in Figure 7, and the calculated energetics of the individual interactions are 
reported in Figure 6A-D. The estimated sign of the effect is again correct, i.e. both R2 
groups are predicted and found to stabilize the R1 = -OCH3, R2 = -H, R3 = -H 
scaffold, although the stabilizing effect is somewhat overestimated for the 
hydrophobic substituent and underestimated for the hydrophilic substituent. In the 
first case, Figure 6A shows that the hydrophobic substituent has by itself a strong 
stabilizing effect, on top of which a non-negligible stabilization of the hydroxamic 
moiety is also observed. In the second case (Figure 6B), the stabilizing effect of the 
R2 substituent is smaller, but the stabilizing effect on the hydroxamic moiety is 
maintained. These findings are consistent with what observed for the R2 = -
CH2CH2OH case already discussed: it can be concluded that for R1 = -OCH3 (but not 
R1 = -F or R1 = -C6H5) any substituent at R2 improves the binding of the hydroxamic 
group. With this in mind, the derivative with R2 = -CH2CHOHCH2OH and R3 = -
CH2OH simultaneously present (14) was tested. These R2 and R3 groups, taken 
separately, both improved the binding of the starting R1 = -OCH3 scaffold. Figure 7 
shows that the effect is not synergistic, the improvement being of the same order of 
each substituent separately, and actually slightly smaller than that caused by the R3 = 
-CH2OH substituent alone. Again, the calculations are in qualitative agreement in all 
cases. Figure 6C-D surprisingly shows that the hydroxamic moiety and the SO2 
groups are both improved by the simultaneous presence of the two substituents, but 
each substituent adopts a less optimal set of interactions with the protein, essentially 
neutralizing the improvement. 
Implications for drug-design strategies. The above analysis demonstrates that 
the availability of high resolution structures of a series of enzyme adducts with 
homologous ligands provides precious information on the subtle factors that 
modulate ligand affinity, and thus may be of much help in the optimization of such 
ligands. For instance, increasing the size of the hydrophobic group in the S1’ pocket 
increases the affinity, but only provided that no substituents are placed in R2 and R3 
positions. Conversely, a smaller hydrophobic group such as the one with R1 = -OCH3 
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permits the insertion of other groups, including more hydrophilic groups, in R2 and 
R3, provided their local effect is not destabilizing. One could even conceive 
substitutions in R1, R2 and R3 that strongly destabilize the hydroxamic moiety but 
provide enough local stabilization to partially compensate for the loss. Under such 
circumstances, the substitution of the now unfit hydroxamic moiety with a more 
druggable group with a better fit could provide enough extra stabilization to obtain 
nanomolar affinity for a non-hydroxamic ligand. Regarding the R2 and R3 
substituents, the present results also show that hydrophilic substitutions are not 
severely disfavored with respect to hydrophobic substitutions, as commonly assumed 
for this class of molecules. Furthermore, as other MMPs such as MMP13 have a 
larger binding site, one could exploit the present findings to test ligands with 
substituents in e.g. R1, R2 that show more or less pronounced steric misfit in MMP12 
for improved selectivity for MMP13. Indeed, ΔG0 data on binding of selected ligands 
to MMP13 confirm the correctness of the approach (Figure 8): adding an R2 = 
CH2CH2OH to the R1 = OCH3 or R1 = C6H5 scaffolds stabilizes the adduct with 
MMP13 more, or destabilizes it less, than the corresponding adduct with MMP12, 
resulting in both cases in an increased selectivity for MMP13. Of course, if suitable 
crystals for ligand soaking were available for other MMPs, the potential of this 
strategy would be further enhanced. Finally, The degree of prediction achieved with 
the present strategy should help avoiding the extensive screening of substituents in n 
different positions (R1, R2 and R3 in this case) by examining a full n-dimensional 
matrix of compounds. Indeed, once the interplay among a certain set of substituents 
shows that one position is disfavored, examining further substitutions in that position 
with the chosen set of substituents can be avoided. 
It should be stressed that the above findings have only been made possible by the 
availability of experimental structures. While docking programs are able to provide 
reasonable models of ligand binding modes, especially in the presence of existing 
structures with homologous ligands, the accuracy of the resulting models is lower 
than that of experimental structures, and insufficient for the present purpose. This has 
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been tested by taking the high-resolution (1.1 Å) crystal structure of MMP12 and 
using it to dock all the inhibitors described in this work. Despite the overall binding 
mode always resulted correct, the details of the interatomic distances were not 
accurate enough to make any energetic predictions. One drawback is the use of the 
same protein structure for all adducts, while the present work shows that the protein 
structures differ slightly from one another in the various adducts, as a consequence of 
some mutual adaptation or “induced fit”. Attempts to mimic this induced fit, either by 
allowing protein side-chain movements during docking or by overall (i.e. ligand and 
protein) restrained energy minimization of the final adduct did not improve the 
energetic predictions significantly (data not shown). On the other hand, it is 
reassuring that the choice of the set of potentials to extract energetic information from 
the experimental structures is not critical, as different popular potential sets provide 
similar results. 
Thermodynamics of ligand binding. Of course, it is well known that the 
relationship between ΔG0 and intermolecular potential energy calculations is totally 
empirical, although it is often found to hold.45-47 There are two reasons to question its 
applicability. The first reason is that contributions to ΔG0 from solvent-ligand, 
solvent-protein and solvent-adduct interactions are not taken into account. However, 
it can be speculated that, at least in systems of this kind, solvation effects are not so 
strong, and there is always partial cancellation between solvent effects on the 
reactants and the product. Furthermore, in our approach ΔΔG0 values are estimated, 
so the differential solvent-protein effects are zero, and the other two terms are likely 
to be further reduced. In one case, i.e. the comparison between the behavior of the D- 
and L- isomers substituted in R2, solvent effects on the ligands are also zero, and the 
differential solvent-adduct effects are probably negligibly small. It is obvious that the 
striking difference in binding affinity between the R2 = D-Thr and R2 = L-Thr is 
almost entirely due to the difference in protein-ligand interaction. 
The second reason is that, even if the leading term is the free energy of the 
protein-ligand interaction, the latter is still composed by enthalpic and entropic terms, 
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and intermolecular interaction energy calculations only take into account the 
enthalpic term (except for a modest correction for possible differences in number of 
immobilized rotatable bonds). Prompted by these considerations, ΔH0 values for the 
binding of some of the present ligands were measured through isothermal titration 
calorimetry (ITC). Two other well known strong MMP ligands, actinonin and 
galardin (Biomol Inc.), were also studied for comparison purposes. 
ITC measurements. Isothermal titration calorimetry is widely used in drug 
discovery, since it permits an accurate and extensive thermodynamic characterization 
of protein-ligand interactions.48,49 In particular, ITC measurements have already been 
successfully exploited  to design and characterize Stromelysin inhibitors.50,51 
All measurements were performed at 298 K. At variance with fluorimetric 
assays, here the protein concentrations were much higher (20 μM), and the AHA 
concentration was correspondingly higher (4 mM). This concentration is comparable 
with the dissociation constant of AHA itself. Therefore, AHA interferes with the 
binding of the inhibitors, and the experimental ΔH0 values are conditional values. A 
proper estimate of the ΔH0 for AHA was needed, both to obtain the true ΔH0 values 
for the other inhibitors and to obtain thermodynamic parameters of AHA itself. A 
series of ITC measurements on the binding of the 3 (R1 = OCH3, R2 = H) were thus 
performed in the presence of various AHA concentrations in the range 1 to 256 mM. 
By fitting the obtained enthalpy as a function of AHA concentration, a ΔH0 of –3.180 
kcal/mol was found for the binding of AHA. The latter parameter provides an 
experimental estimate of the enthalpic contribution of the metal binding group to the 
overall binding of all the inhibitors investigated here, as well as of all hydroxamic-
based inhibitors in general, to MMP12. Furthermore, the AHA ΔH0 value allowed us 
to estimate the correction to apply to the other ΔH0 values. The corrected 
thermodynamic parameters of some of the inhibitors investigated here, as well as 
those of AHA, are reported in Table 1. 
Although ITC measurements performed at increasing inhibitor concentrations as 
in the present experimental scheme also provide estimates of the dissociation 
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constants, the latter are affected by large errors when the constants approach 
nanomolar values, and so are the derived ΔG0 values. Conversely, the ΔH0 values are 
not affected by such errors. Therefore, estimates of -TΔS0 values were obtained by 
using the corrected ΔH0 values from calorimetry and the ΔG0 values from fluorimetry 
measurements. The -TΔS0 values are also reported in Table 1. The binding constants 
derived from ITC measurements (not shown) were in any case within a factor two 
with respect to the fluorimetric values. 
From the the ΔH0 and -TΔS0 values reported in Table 1 it appears that the free 
energy of binding of all the homologous ligands examined in this work contains an 
important enthalpic contribution, and a less important but sizable entropic 
contribution, both favorable to binding. This appears a general feature for this class of 
ligands, but is by no means general for other inhibitors of MMPs. For instance, 
galardin and actinonin, two well known strong inhibitors of MMPs, show much less 
favorable, or even unfavorable enthalpic contributions, respectively, and much more 
favorable entropic terms (Table 1). 
By examining the ΔH0 values in Table 1 no apparent correlation can be seen 
with the corresponding ΔG0 values, neither with the intermolecular interaction 
energies estimated from the experimental structures in the present homologous series 
of ligands; nor do the differences ΔΔH0 correlate better with the ΔΔG0. Apparently, 
the enthalpies (and entropies) of the ligand-solvent interactions are sizable and vary 
in a rather unpredictable way, while they largely cancel each other to give a modest 
contribution to ΔG0. Apparently, this is yet another manifestation of the well-known 
entropy-enthalpy cancellation phenomenon. 
An interesting finding from ITC measurements is the fact that, as already 
observed for Stromelysin51 the binding of AHA to MMP12 (and thus presumably to 
all others MMPs) is almost exclusively enthalpy-driven. The ΔH0 value of about -3.2 
kcal/mol for this ligand having millimolar affinity is only two-three times smaller 
than the binding enthalpy of nanomolar affinity ligands, which is a relevant 
contribution. The -TΔS value for AHA is close to zero. This relatively strong 
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contribution to the overall binding enthalpy could be even higher if the ligand solvent 
contribution were not unfavorable, as it is expected to be for the very soluble AHA 
molecule. Indeed, in our parameterization, the estimated contribution of the AHA 
moiety to the overall protein-ligand interaction energy has to be as high as -6 
kcal/mol if a reasonable estimate of the overall interaction energy for this class of 
ligands has to be obtained. This is not unespected, as it is well known that, if AHA is 
considered a fragment of a strong binding ligand rather than an independent 
molecule, the loss of rigid body rotational and traslational entropy upon binding 
occurs only once and not twice as it would be for the isolated fragments. The 
corresponding gain in ΔG0, which is parametrically incorporated in the interaction 
energy in our calculations, can easily be of the order of –3 kcal/mol.51-53  
 
Concluding Remarks 
In summary, it is shown here that an analysis of the details of the protein-ligand 
interactions – as they appear from the three-dimensional structures – in terms of 
simple hydrophobic and electrostatic contributions provides a remarkable semi 
quantitative account of i) the ΔG0 values of the adducts, ii) the differences in ΔG0 
(ΔΔG0) between pairs of closely related ligands, and iii) the identity of the individual 
ligand atom-protein atom interactions that contribute in each case to increase – or 
decrease – the affinity of each particular ligand with respect to its closest analog. This 
work demonstrates that this kind of rationalization is possible and reliable, and 
provides hints for the planning of finely tuned inhibitors, originating from the same 
scaffold, for any structurally well-characterized biological target. 
For some of the present ligands, the enthalpies of binding (ΔH0) were also 
measured through isothermal calorimetry. All the ligands from this class are found to 
be characterized by favorable enthalpic as well as entropic contributions. The 
enthalpic contribution of the hydroxamic moiety, a popular zinc-binding group in the 
MMP inhibitor landscape, has been separately evaluated and discussed in terms of its 
relative contribution to the potency of hydroxamic-based MMP ligands. A detailed 
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analysis of the ΔH0 and ΔS0 values, taken separately, is less instructive, due to the 
well-known entropy-enthalpy compensation effects.48 As in many other 
thermodynamic studies, the two terms are found to provide opposite and largely 
canceling contributions to ΔG0. 
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Captions to the Figures 
 
Figure 1. (A) Schematic representation of the active site of MMPs highlighting the 
zinc ion site, the hydrophobic pocket termed S1’, and the substrate binding groove. 
(B) The sulfonamide scaffold used in this work with its R1, R2 and R3 substituents. 
The actual compounds investigated are: 
1 R1 = H, R2 = H, R3 = H 
2 R1 = F, R2 = H, R3 = H 
3 R1 = OCH3, R2 = H, R3 = H 
4 R1 = C6H5, R2 = H, R3 = H 
5 R1 = F, R2 = CH2CH2OH, R3 = H 
6 R1 = OCH3, R2 = CH2CH2OH, R3 = H 
7 R1 = C6H5, R2 = CH2CH2OH, R3 = H 
8 R1 = OCH3, R2 = H, R3 = (D)CH2OH 
9 R1 = OCH3, R2 = H, R3 = (D)CHCH3OH 
10 R1 = OCH3, R2 = H, R3 = (L)CH2OH 
11 R1 = OCH3, R2 = H, R3 = (L)CHCH3OH 
12 R1 = OCH3, R2 = CH2CH(CH3)2, R3 = H 
13 R1 = OCH3, R2 = CH2CHOHCH2OH, R3 = H 
14 R1 = OCH3, R2 = CH2CHOHCH2OH, R3 = (D)CH2OH 
 
Figure 2. Close up of the high resolution 3D structures of the adducts of MMP12 
with ligands 2-4 (left hand column) and 1 (central column, panels A-C). The right 
hand column highlights the improvement (green spheres) and worsening (red 
spheres) of the protein interaction with individual atoms of ligands 2-4 with respect to 
1. The volumes of the spheres are proportional to the size of the interaction energy 
variation. 
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Figure 3. Close up of the high resolution 3D structures of the adducts of MMP12 
with ligands 5-7 (left hand column panels A-C) and 2-4 (central column, panels A-C). 
The right hand column highlights the improvement (green spheres) and worsening 
(red spheres) of the protein interaction with individual atoms of ligands 5-7 with 
respect to 2-4, respectively. The volumes of the spheres are proportional to the size of 
the interaction energy variation. 
 
Figure 4. Close up of the high resolution 3D structures of the adducts of MMP12 
with ligands 8-11 (left hand column panels A-D) and 3 (central column, panels A-D). 
The right hand column highlights the improvement (green spheres) and worsening 
(red spheres) of the protein interaction with individual atoms of ligands 8-11 with 
respect to 3. The volumes of the spheres are proportional to the size of the interaction 
energy variation. 
 
Figure 5. Close up of the high resolution 3D structures of the adducts of MMP12 
with ligands 10 and 11 (left hand column panels A,B) and 8-9 (central column, panels 
A,B). The right hand column highlights the improvement (green spheres) and 
worsening (red spheres) of the protein interaction with individual atoms of ligands 10 
and 11 with respect to 8-9. The volumes of the spheres are proportional to the size of 
the interaction energy variation. 
 
Figure 6. Close up of the high resolution 3D structures of the adducts of MMP12 
with ligands 12-14 (left hand column panels A-D), and 3 (central column, panels A-
C), and 8 (central column, panels D). The right hand column highlights the 
improvement (green spheres) and worsening (red spheres) of the protein interaction 
with individual atoms of ligands 12-14 with respect to 3 and 14 with respect to 8. The 
volumes of the spheres are proportional to the size of the interaction energy variation. 
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Figure 7. Calculated (white bars) and observed (black bars) free energy variations 
(ΔΔG0) on passing from one MMP12 adduct to another with a close analogue ligand. 
The calculated ΔΔG0 values are the algebraic sum of all the intermolecular interaction 
energies plus a entropic penalty term related to immobilization of rotatable bonds as 
described in Materials and Methods. The bars extending, inwards or outwards of the 
calculated ΔΔG0 values, show the results obtained by neglecting the entropic penalty. 
The individual intermolecular interaction energy differences are illustrated in Figure 
2 for ligand pairs 2-1, 3-1 and 4-1, in Figure 3 for ligand pairs 5-2, 6-3 and 7-4, in 
Figure 4 for ligand pairs 8-3, 9-3, 10-3 and 11-3, in Figure 5 for ligand pairs 10-8 and 
11-9, and in Figure 6 for ligand pairs 12-3, 13-3, 14-3 and 14-8. 
 
Figure 8. Experimental free energy of binding to MMP12 (up triangles) and MMP13 
(filled circles) for ligands 1, 3 and 6 (A) and 1, 4 and 7 (B). The increased 
discrimination between MMP12 and MMP13 is highlighted. 
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Table 1. Corrected thermodynamic parameters for the investigated inhibitors. 
 ∆G0 ∆H0 -T∆S0 
1 -9.833 -9.095 -0.738 
2 -9.796 -6.772 -3.024 
3 -10.503 -8.520 -1.983 
4 -11.759 -8.849 -2.910 
5 -10.092 -6.459 -3.633 
6 -11.046 -9.653 -1.393 
7 -10.243 - - 
8 -11.216 -8.391 -2.825 
9 -10.857 -8.124 -2.733 
10 -10.063 - - 
11 -7.775 - - 
12 -11.428 -8.243 -3.185 
13 -11.046 -8.888 -2.158 
14 -11.125 -8.082 -3.043 
AHA -3.011 -3.180  0.169 
Galardin -11.046 -4.073 -6.973 
Actinonin -9.526 2.200 -11.726 
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Solid-state NMR (SS NMR) is a technique that has shown a rapid 
development in recent years.[1−4] The exciting progress in sample 
preparation methods,[5] tailored pulse sequences,[4,6−8] and 
instrumentations, make now possible to investigate relatively 
large proteins. In spite of this development, the number of 
proteins for which an almost complete solid-state assignment is 
available is still limited.[9] Interestingly, it is generally observed 
that 13C chemical shifts do not change much passing from the 
solution assignment to the one observed in microcrystalline 
samples (the differences are generally <1 ppm).[9] This opens the 
way to a fast liquid-based solid-state assignment, in which the 
available liquid assignment is transferred to the solid-state 
spectra, and only a minimal number of solid-state spectra are 
acquired, to unambiguously confirm the assignment obtained in 
solution. The possibility to have, in a short time, an attainable 
solid-state assignment is valuable, as it opens the possibility to 
investigate the same protein as part of larger aggregate 
(oligomerization, protein-protein complexes) without the line 
broadening associated to the increase in molecular weight in 
solution. 
In the present work we demonstrate that it is possible to 
rapidly provide a large fraction of the solid-state NMR assignment 
of a relatively large protein (17 kDa), using a pair of experiments 
(CP MAS PDSD, J-dec PDSD), which can be acquired in a 
limited amount of time (12-15 h each), and manually assigned in 
few days using the available liquid-state assignment as a 
guideline. 3D NCACX and NCOCX PDSD spectra fully validate 
the assignment and further increase the overall fraction of 
assigned peaks, although they require considerably more 
experimental time. 
Thus, we investigated through SS NMR a microcrystalline 
sample of the catalytically active domain of the zinc-containing 
matrix metallo-proteinase 12 (Zn-MMP-12, 159 AA, 17.6 kDa), for 
which the X-ray structure, and the solution NMR assignment are 
available.[10] 
The crystallographic structure indicates that the active site 
domain is composed by three α-helices (44 AA, 28% of the total 
residues), and by seven β-strands (27 AA, 17%). The remaining 
88 residues form unstructured turns. The C-terminal coordinated 
Zn plays a role in the enzymatic activity. 
The SS NMR sample was prepared by crystallizing the 
protein from PEG 8000 30%, following the already published 
procedure.[10] The microcrystalline precipitate is formed just after 
12 h, and the crystallization is complete after 1-2 days. 
Figure 1 reports the 13C−13C CP MAS PDSD spectrum 
acquired at 16.4 T (700 MHz of 1H Larmor frequency) and MAS 
frequency ωR/2pi = 11.5 kHz. Several spectra were acquired with 
variable mixing time of 5 and 15 ms, and MAS frequency 8.5 kHz. 
As it appears from Figure 1, the spectra are extremely well 
resolved. The assignment of the PDSD was directly obtained on 
the basis of the 13C chemical shifts determined in solution.[10] The 
good resolution of the spectrum in Figure 1 allowed us to assign 
up to 75% of the 13C aliphatic spins with minor adjustments (<1 
ppm) with respect to the solution shifts (Table 1), and checking 
the consistency with the spin pattern of each residue as far as the 
aliphatic part of the spectrum is concerned. The limitation to 
further extend the assignment transfer arises from some 
ambiguities, essentially for the more crowded region of the 
Cα−Cβ correlations and for the leucine Cγ−Cδ correlations. 
The carbonyls can be safely assigned for the 17 Gly (using 
the 8.5 kHz MAS frequency PDSD to avoid superposition with the 
C’ spinning sidebands), and for other 60 residues (48% of the 
overall carbonyls, Table 1), while the aromatic sidechains remain 
unassigned. 
A significant improvement in the solid-state assignment was 
achieved using the J-decoupled PDSD sequence (J-dec 
PDSD).[11] This sequence provides an enhanced resolution in the 
Cα−Cx correlations (with Cx = C’, Cβ, Cγ, etc.) refocusing the 
JCα−Cβ and JCα−C’ scalar coupling in the indirect dimension (F1). 
These couplings can also be refocused in the direct dimension if 
the acquired FID is properly transformed using the Maximun 
Entropy processing (MaxEnt). Even without MaxEnt processing 
(i.e. refocusing only the J-couplings in F1) the PDSD spectrum 
appears considerably more resolved (Figure 2) allowing one to 
nearly complete the assignment of the Cα−Cβ correlations (86% 
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13C aliphatic spins) and to assign up to 70% of the C’ nuclei 
(Table 1). This assignment was fully validated using 3D NCACX 
PDSD and 3D NCOCX PDSD experiments.[4,12] The third 
dimension, introduced with the 15N indirect evolution, provides an 
improved resolution that allowed us to resolve those 13C shifts 
which were partly overlapped in the previous spectra (see Figure 
S2 and S2). 
These 3D spectra, together with the previous PDSD and J-
dec PDSD spectra, also allowed us to further increase the 
fraction of assigned resonances (93%, with 92% aliphatic and 
93% C’ nuclei, Table 1). In such a way, we arrived to assign up to 
94% of the backbone and 90% of the sidechain resonances. The 
time required to obtain this increase is however rather long (6 
days for each 3D and roughly 1-2 weeks for the spectral 
assignments) with respect to the 2D PDSD-based assignment. 
On the other hand, although this was not the primary goal of this 
work, we also found that the present sets of 2D and 3D spectra 
can provide more than 70% assignment independently of the 
availability of the solution data, which is also a remarkable result. 
We do not exclude that the use of other tailored experiments 
allow one to assign even more, resolving some ambiguities of the 
present 3D or assigning some residues of the N- and C- terminal 
part which are lost in the solution assignment probably because 
of the mobility in solution. 
The success of the liquid-based assignment is essentially 
ascribable to the relatively small differences among liquid and 
microcrystalline solid-state chemical shifts. In Figure 3 we plot, for 
each residue, the differences between the solid-state and liquid–
state 13C chemical shifts. It is apparent how the differences are 
limited: the overall RMSD is 0.52 ppm, with about 93 % of the 
resonances that differ by less than 1 ppm. Only 6% are more than 
1 ppm shifted, and only 3 resonances shift more than 2 ppm (1%). 
Interestingly, the deviations larger than 2 ppm belong to the 
resonances of Ile 180, a residue demonstrated to be involved in 
conformational equilibria in solution, but to be frozen in slightly 
different conformations in X-ray structures of the protein bound to 
different inhibitors.[10] We would like to stress that comparing 
PDSD patterns rather than isolated cross peaks is a very 
powerful way of transferring side chain assignments, which 
tolerates well differences in shifts of 1-2 ppm, as observed here. 
In this respect, we also notice that the similarity of the 15N shifts 
between solid state and solution is lower than that observed for 
13C (see Figure S3), as previously observed.[13] Nevertheless, for 
the present system, 90% of the nitrogen resonances could be 
assigned by the combined approach described above. 
In summary, we report the almost complete solid-state 
assignment of the 13C (see also Figure 4), and 15N nuclei of 
microcrystalline Zn-MMP-12, which, up to now, is the largest 
protein for which a solid-state NMR assignment is available. The 
assignment was extended up to 93% for 13C and 90% for 15N, and 
we demonstrate that it is possible to safely translate a large 
fraction of the 13C liquid assignment to solid-state in less than a 
week. The possibility to have both solid-state and liquid state 
assignments for relatively large proteins may be an important 
asset to investigate biological processes at the molecular level. 
Indeed, many processes such as oligomerization or protein 
complex formation, which start from solution state, are potentially 
easily investigated in the solid-state NMR, which is much less 
affected by the line-broadening due to the increased molecular 
weight. Even protein-ligand interactions may be conveniently 
followed by SS NMR. 
 
 
Figure 1. Aliphatic region of the 13C−13C CP MAS PDSD of the Zn-MMP-12 
(16.4 T, 11.5 kHz MAS frequency, 15 ms mixing time). 
 
Figure 2. CACO regions in 13C−13C PDSD (left side) and 13C−13C J-decoupled 
PDSD (right side) of Zn-MMP-12 (16.4 T, 11.5 kHz MAS frequency, 15 ms 
mixing time for both spectra). The J-decoupled PDSD was processed with 
Fourier transformation, which retains scalar coupling in F2. Notice the resolution 
improvement with respect to the fully coupled PDSD. 
 
 3
Figure 3. Plot of the 13C chemical shift differences among solid-state (δS) and 
liquid state (δL) chemical shifts (∆δ = δS − δL) for each residue positions.
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Figure 4. Particular of the aliphatic region of the 13C−13C PDSD spectrum with reported assignment. The blue, 
red, and green colors indicate the correlation among sidechain resonances and Cα (blue), Cβ (red) and Cδ 
(green) resonances. 
Table 1. Percentage assignment of the microcrystalline Zn-MMP-
12.[a] 
 Cα Csidechain  Caliphatic C’ total 
PDSD 76 % 75 % 75 % 48 % 68 % 
+ J-dec[b] 88 % 83 % 86 % 70 % 81 % 
+ 3D[c] 96 % 90 % 92 % 93 % 93 % 
[a] As the assignments of the terminal N- and C- part of the protein 
are not available in solution, all the percentages are referred to 
the 151 AA for which the solution assignment is available. 
[b] 13C−13C PDSD J-decoupled. 
[c] 3D NCACX and 3D NCOCX. 
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Supporting Information 
Materials and Methods 
Solid-State NMR spectroscopy: All the NMR spectra were recorded on a Bruker Avance 700 wide 
bore instrument operating at 16.4 T (700 MHz of 1H Larmor frequency and 176.0 MHz of 13C 
Larmor frequency). A double-channel and triple-channel 4 mm CP-MAS probehead was used. The 
spinning frequency of the 4mm ZrO2 HR MAS rotors was stabilized to ±2 Hz. Solid-state chemical 
shifts are referred to DSS following the procedure reported in literature.[1] The probe temperature 
was kept to 280 K, which ensure a sample temperature around 290 K. 
In double resonance CP experiments the 1H 90° pulse was set to 3.5 µs, during cross-polarization 
the 1H B1 was 61 kHz with a mixing time of 0.75 ms. A 100%/50% ramp was applied on the carbon 
channel with a 100% power level of 46 kHz. 
Similar parameters were used for a standard proton-driven spin diffusion sequence (2D PDSD); the 
13C 90° pulse was 4.2 µs, and the mixing times were varied from 5 to 15 ms. The MAS frequency 
was varied from 8.5 to 11.5 kHz. The SPINAL-64[2] decoupling at 71 kHz of power was used on 
proton, switching off the decoupling during the mixing time. All the experiments were acquired 
with 16 scans per experiment, with 1536 direct points, and 1280 experiments in the State-TPPI 
scheme. 
The same parameters and MAS frequency were used for the J-decoupled PDSD, using a 350 µs 
gauss shaped pulse for the selective Cα inversion. This spectrum was acquired with 48 scans, 2048 
direct points and 384 experiments using the States-TPPI scheme. 
The triple resonance 3D NCACX PDSD and 3D NCOCX PDSD experiments were acquired using 
the standard sequences.[3] The 13C 90° pulse was 5.2 µs. The HN Hartmann-Hahn matching was 
optimized with 1H 90° of 3.5 µs, 37 kHz for the 15N B1 and a 100%/50% ramp on the 1H channel 
applied for 1.8 ms at 60 kHz of 100% power. The NC matching was optimized using the 15N B1 of 
35 kHz and a Tangent Amplitude Modulated ramp at 25 kHz on 13C. The NC matching was 6.25 ms 
long using a simultaneous 1H CW decoupling of 94 kHz. SPINAL64 1H decoupling at 71 kHz was 
used during the direct and indirect acquisition times. The A weak 1H CW radio frequency optimized 
at 10 kHz was used during the 35 ms of PDSD mixing time. Both NCACX and NCOCX 
experiments were recorded at 11 kHz MAS frequency, with 64 scans per experiment, 1536 direct 
points, and 96 increments in the indirect 13C dimension and 32 increments in the indirect 15N 
dimension using the TPPI scheme for both the indirect dimensions. 
Parameters similar to that used for the 3D experiments were used also for the 2D NCA spectrum.[3] 
2D data were processed using zero-filling up to 4096 points in the direct dimension and 2048 points 
in indirect dimension, and using gaussian and square cosine filters for direct and indirect dimension, 
respectively. 
 
Preparation of the microcrystalline Zn-MMP-12 sample: The catalytic domain of Zn-MMP-12 
protein with NNGH (N-isobutyl-N-[4-methoxyphenylsulphonyl]glycyl hydroxamic acid) inhibitor 
was expressed and crystallized following the already published procedure.[4] The microcrystals thus 
obtained were washed in 920 µl of a low-salt reservoir buffer (10 mM Tris·HCl/25% PEG 8000 pH 
8) for 1 day. Approximately 20 mg of these crystals were transferred in a 50 µl 4mm ZrO2 HR 
MAS rotor, and sealed with the upper spacer in order to maintain the amount of water constant.  
 
Figures 
 
 
 
 
 
 
 
Figure S1. A) Representation of the NCACX (red) and NCOCX (blue) correlation experiments 
(16.4 T, ωR/2π = 11 kHz). Le circles and arrows show detected nuclei and the correlation scheme, 
respectively. B) Sequential specific assignment using NCACX (red) and NCOCX (blue) spectrum 
for 8 residues (Ile110-Gly117) of the microcrystalline catalytic domain of MMP-12. 
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Figure S2. 2D Adiabatic-CP NCA correlation experiment of the Zn-MMP-12 (16,4 T, ωR/2π = 11 
kHz). Weak N-Cβ correlation peaks are also observable. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Plot of the 12Cα, 13C’ and 15N chemical shift differences among solid-state (δS) and 
liquid-state (δL) chemical shifts (∆δ = δS − δL), for each residue positions. The Root Mean Square 
Deviation (RMSD) is 0.47, 0.56, and 1.19 ppm for 13Cα, 13C’ and 15N respectively. 
Assignment Tables 
Table S1. 13C and 15N chemical shifts values (ppm) of the microcrystalline precipitate of the 
catalytically active domain of Zn-MMP-12 with NNGH. 
 
Residue AA 15N 13CO 13Cα 13Cβ 13Cγ 13Cδ 13Cε 
HIS 112  173.1 54.1 31.0    
TYR 113 119.9 173.6 56.5 38.9    
ILE 114 128.0 174.8 57.9 38,6 26.6/16.9 11.1  
THR 115 116.9 174.5 58.1 72.1 22.5   
TYR 116 118.0 171.3 54.6 43.0    
ARG 117 119.5 173.9 54.3 35.6 27.2 40.3  
ILE 118 127.3 175.0 61.4 37.0 27.9/17.0 13.7  
ASN 119 127.8 173.7 56.5 41.5 174.3   
ASN 120 110.8 169.0 51.7 38.7 177.6   
TYR 121 115.2 175.7 57.9 40.7    
THR 122 119.3 173.4 55.9 66.6 19.1   
PRO 123  176.7 62.8 31.5 26.7 50.3  
ASP 124 121.5 175.7 55.7 41.7 183.1   
MET 125 113.1 174.7 53.3 38.9 32.0   
ASN 126 118.4 177.4 53.2 38.3 176.0   
ARG 127 126.5 177.8 60.1 30.0 26.3 42.6  
GLU 128 116.2 178.6 59.2 28.5 36.1 176.4  
ASP 129 120.0 178.6 56.9 40.7    
VAL 130 123.7 177.2 66.3 31.2 23.9/21.5   
ASP 131 118.4 179.2 57.8 40.5    
TYR 132 119.8 176.3 61.2 38.6    
ALA 133 121.2 179.3 55.3 18.4    
ILE 134 113.8 177.3 61.7 35.3 27.4/18.7 8.4  
ARG 135 119.7 179.9 59.9 30.1 27.4 43.6  
LYS 136 119.0 178.3 58.1 31.2 24.5 27.9  
ALA 137 123.0 178.5 55.2 18.8    
PHE 138 113.9 178.6 63.6 38.5    
GLN 139 119.1 177.7 58.3 28.6 34.0   
VAL 140 117.2 178.2 65.9 31.0 23.0/21.9   
TRP 141 116.9 180.3 57.8 29.9    
SER 142 119.2 177.5 60.5 63.2    
ASN 143 115.4 176.2 54.7 38.5 172.5   
VAL 144 107.1 173.9 60.0 32.4 21.1/18.8   
THR 145 109.3 174.1 59.7 72.6 24.9   
PRO 146 129.8  61.9 31.8 27.4 51.5  
LEU 147 115.4 177.6 55.0 42.4 26.2 22.5/24.5  
LYS 148 122.4 172.6 54.0 36.6 25.3 30.2 41.5 
PHE 149 118.1 176.2 55.4 41.2    
SER 150 116.7 171.5 55.7 65.1    
LYS 151 126.4 175.4 55.6 33.6 25.0 30.0 42.2 
ILE 152 122.8 174.9 59.4 40.8 27.9/17.0 13.9  
ASN 153        
THR 154 114.5 171.3 61.1 71.2 21.8   
GLY 155 111.6 173.7 43.6     
MET 156 119.1 174.7 55.1 32.4 31.8   
ALA 157 121.5 176.5 49.4 23.5    
ASP 158 122.4 176.8 57.4 40.9 179.4   
ILE 159 125.0 173.1 61.4 39.9 26.6/14.7 14.6  
LEU 160 130.1 175.5 53.2 44.0 27.2 23.9/25.3  
VAL 161 125.5 175.1 61.8 32.9 20.6/20.1   
VAL 162 127.5 174.5 60.7 37.2 21.4/20.7   
PHE 163 125.5 175.7 56.4 41.2    
ALA 164 125.0 175.7 51.3 22.1    
ARG 165 118.8 175.4 53.5 34.4 26.3 43.4  
GLY 166 107.5 175.1 45.9     
ALA 167 135.3 176.3 52.8 18.5    
HIS 168        
GLY 169  170.1 44.4     
ASP 170        
ASP 171 120.8 175.5 54.6 39.2 179.9   
HIS 172  174.0 53.3 30.2    
ALA 173 123.6 179.6 53.5 18.4    
PHE 174 119.9 177.6 57.1 39.6    
ASP 175 116.4 176.6 53.6 42.0 179.8   
GLY 176 108.6 172.9 43.5     
LYS 177 123.6 177.2 58.2 32.0 24.6 29.3  
GLY 178 120.6 173.3 42.5     
GLY 179 109.6 173.6 46.0     
ILE 180 130.3 177.0 60.0 35.9 27.2/18.0 10.0  
LEU 181 128.4 175.6 55.4 43.9 26.2 21.4/24.4  
ALA 182 114.2 175.6 50.7 23.2    
HIS 183 116.7 171.6 54.1 31.1    
ALA 184        
PHE 185 131.4 175.4 56.5 41.1    
GLY 186 105.0 175.4 43.9     
PRO 187 131.1 174.0 63.7 32.1  48.6  
GLY 188 106.4 171.5 43.8     
SER 189 115.0 175.7 58.7 64.3    
GLY 190 112.1 175.4 46.8     
ILE 191 133.8 174.6 61.8 37.9 27.9/16.3 14.2  
GLY 192 106.0 174.1 46.4     
GLY 193 119.9 171.6 46.2     
ASP 194 122.6 173.7 56.2 39.4 179.9   
ALA 195 120.2 174.5 50.5 21.0    
HIS 196 122.0 172.5 50.8 33.6    
PHE 197 122.7 174.0 56.5 40.8    
ASP 198        
GLU 199        
ASP 200  179.2 54.1 40.1    
GLU 201 130.6 176.6 56.0 31.4 36.2 183.3  
PHE 202 119.6 177.3 56.7 39.3    
TRP 203 116.9 174.7 53.6 26.2    
THR 204 126.5 174.7 59.6 71.8 21.1   
THR 205 123.0 173.7 60.7 69.3 21.6   
HIS 206  175.5 62.1 32.0    
SER 207  176.4 58.9 63.1    
GLY 208 107.3 173.0 44.4     
GLY 209 107.8 173.7 45.2     
THR 210 124.6 172.7 62.1 68.3 24.3   
ASN 211 125.1 175.9 55.3 40.4 180.7   
LEU 212 131.3 176.3 58.3 41.2 27.7 27.4/22.4  
PHE 213 121.0 175.3 61.4 37.8    
LEU 214 118.2 178.7 57.8 42.7 26.8 23.6/26.6  
THR 215 112.4 177.0 66.3 68.2 22.3   
ALA 216 124.2 178.5 55.4 17.3    
VAL 217 118.5 178.7 67.9 31.1 23.8/23.2   
HIS 218 118.5 176.1 58.4 28.4    
GLU 219 115.6 176.8 58.6 28.6 33.3 176.2  
ILE 220 118.0 177.4 63.0 36.7 29.0/18.9 12.0  
GLY 221 107.9 176.9 47.9     
HIS 222 119.7 180.4 57.5 28.3    
SER 223 122.5 175.6 55.8 63.0    
LEU 224 114.6  54.8 42.2 25.8 21.8/25.1  
GLY 225  173.4 45.5     
LEU 226 120.9  54.6 42.7 22.3 22.3/26.9  
GLY 227 107.9 174.9 46.8     
HIS 228 115.5 174.9 55.1 29.6    
SER 229 114.2 174.8 55.2 65.1    
SER 230 118.9 173.0 58.2 64.0    
ASP 231 124.8 174.9 50.8 42.2 180.2   
PRO 232  177.7 63.1 31.9 27.4 50.5  
LYS 233 116.9 176.6 55.5 31.7 24.8 28.2  
ALA 234 124.1 179.7 51.7 19.8    
VAL 235 131.8 179.1 64.4 31.1 23.2/20.9   
MET 236 115.9 177.2 53.3 27.5 30.0   
PHE 237 128.6  56.6 39.1    
PRO 238  174.7 63.2 31.9 26.8 49.1  
THR 239 114.7 172.7 61.6 72.0 21.9   
TYR 240 126.6  58.1 39.1    
LYS 241 129.9 173.9 54.4 34.3 23.0 30.1 42.0 
TYR 242 124.0 174.8 61.1 37.8    
VAL 243 123.8 172.2 59.1 34.9 21.3/19.5   
ASP 244 119.2 178.6 54.7 41.9    
ILE 245 124.7 177.1 64.0 37.6 26.8/17.7 13.4  
ASN 246 118.2 176.2 55.1 38.3 173.5   
THR 247 108.7 175.3 61.7 69.4 22.6   
PHE 248 123.2 174.4 59.7 39.7    
ARG 249 125.9 174.8 53.9 33.6 26.0 43.3  
LEU 250 120.9 175.6 54.8 43.2 27.2 21.7/25.4  
SER 251 117.8 175.4 57.0 65.6    
ALA 252 124.2 180.5 55.0 17.2    
ASP 253 118.1 178.2 57.7 43.9 179.7   
ASP 254 118.2 177.9 58.3 44.2 180.6   
ILE 255 118.8 177.1 65.0 37.9 30.3/16.8 13.2  
ARG 256 119.5 180.2 58.3 30.2 27.1 43.2  
GLY 257 107.6 176.2 47.2     
ILE 258 124.0 177.6 60.8 38.6 30.6/20.5 15.2  
GLN 259 123.7 178.8 59.2 26.8 35.0 181.7  
SER 260 116.3 174.3 60.6 63.0    
LEU 261 119.4  56.1 43.8 26.4 21.9/25.6  
TYR 262        
GLY 263 111.2 171.2 44.0     
 
Table S2. 13C and 15N chemical shifts values (ppm) of Zn-MMP-12 catalytically active domain 
with NNGH in solution. 
 
Residue AA 15N 13CO 13Cα 13Cβ 13Cγ 13Cδ 13Cε 
HIS 112  173.4 54.3 31.5     
  
TYR 113 120.3 173.9 56.6 38.2   
 
ILE 114 128.6 175.3 58.8 40.2 27.8/17.0 12.9 
 
THR 115 117.4 174.6 58.5 72.6 22.0  
 
TYR 116 117.4 171.7 55.0 43.2   
 
ARG 117 119.2 174.2 54.4 34.9 28.9 42.1 
 
ILE 118 127.3 175.1 61.4 36.5 27.7/16.5 12.9 
 
ASN 119 128.7 173.8 56.3 41.7 175.3  
 
ASN 120 113.2 169.8 51.9 38.5 177.8  
 
TYR 121 115.1 174.6 58.7 40.7   
 
THR 122 115.8 173.5 56.0 67.0    
PRO 123  177.1 62.9 31.8  50.3  
ASP 124 121.9 175.9 56.3 41.8 183.2   
MET 125 113.4 174.8 53.4 39.1 32.0   
ASN 126 118.8 177.4 53.3 38.3 176.0   
ARG 127 126.2 178.0 60.4 29.6 26.3 43.3  
GLU 128 116.2 179.4 59.6 28.5 36.1   
ASP 129 119.9 179.2 56.9 40.7    
VAL 130 124.1 177.2 67.0 31.2 23.8/21.1   
ASP 131 118.4 179.6 58.0 40.4    
TYR 132 119.7 176.4 61.6 38.7    
ALA 133 121.4 179.4 55.5 18.5    
ILE 134 114.0 177.2 62.0 35.3 27.3/18.0 8.2  
ARG 135 119.8 179.8 60.2 30.0 27.2 44.0  
LYS 136 119.0 178.8 58.3 31.0 24.1 27.8 41.8 
ALA 137 123.6 178.7 55.6 19.0    
PHE 138 114.4 178.8 63.6 38.7    
GLN 139 119.1 177.9 58.5 28.4 34.2   
VAL 140 117.3 178.4 66.0 31.1 23.0/21.1   
TRP 141 116.9 180.9 58.4 29.8    
SER 142 118.6 175.7 61.4 63.5    
ASN 143 115.3 176.7 55.0 38.8    
VAL 144 106.5 174.5 60.3 32.7 21.5/19.3   
THR 145 110.4 173.2 59.9 72.2 24.5   
PRO 146  175.5 63.4 32.3    
LEU 147 110.7 176.4 54.9 42.9    
LYS 148 122.4 173.7 54.2 35.0 24.4 28.5 42.2 
PHE 149 119.5 176.6 55.5 41.7    
SER 150 116.7 171.0 56.6 65.7    
LYS 151 127.7 176.6 55.3 33.3 24.8 29.6 42.0 
ILE 152 123.9 175.4 58.8 40.5 26.0/17.3 12.8  
ASN 153  175.0 53.6 39.9    
THR 154 111.8 172.6 60.3 70.9 21.5   
GLY 155 110.0  44.1     
MET 156 119.1 175.0 55.1 31.8    
ALA 157 127.2 176.4 49.5 22.0    
ASP 158 121.5 177.0 57.8 41.5 179.4   
ILE 159 124.4 173.3 61.6 40.2 26.0/14.7 14.5  
LEU 160 130.1 175.7 53.2 43.5  24.4/26.2  
VAL 161 125.4 175.1 61.8 32.8 20.4/20.0   
VAL 162 127.1 174.8 60.8 37.2 21.1/20.8   
PHE 163 125.7 176.1 56.9 40.8    
ALA 164 126.0 174.9 51.1 22.6    
ARG 165 118.2 175.8 53.7 33.6 26.1 43.1  
GLY 166 108.1 175.8 46.5     
ALA 167 134.1  53.1 17.9    
HIS 168  174.1      
GLY 169        
ASP 170  174.1 56.9 40.7    
ASP 171 121.6       
HIS 172 120.6 172.8 53.6 30.0    
ALA 173 123.3 180.3 53.6 18.3    
PHE 174 120.0 176.3 57.3 38.7    
ASP 175 116.4 177.4 53.6 41.6 179.6   
GLY 176 110.1 173.2 43.7     
LYS 177 124.1 177.8 58.4 32.0 24.9 28.8 42.2 
GLY 178 121.2 174.1 42.9     
GLY 179 110.7 174.7 46.4     
ILE 180 129.8 177.0 62.1 38.0 28.1/18.0 11.9  
LEU 181 128.2 176.0 55.5 43.9 26.0 21.0/24.4  
ALA 182 114.5 175.9 51.7 22.1    
HIS 183 116.7 171.8 54.3 31.0    
ALA 184 119.9 179.6 53.6 18.1    
PHE 185 131.2 175.6 56.7 41.3    
GLY 186 105.4  44.4     
PRO 187  174.7 63.9 31.8 34.2   
GLY 188 106.9 173.3 44.2     
SER 189 114.5 176.1 58.5 64.2    
GLY 190 112.4 175.0 47.2     
ILE 191 134.0 174.4 61.9 38.0 27.7/16.0 13.9  
GLY 192 106.1 174.4 46.7     
GLY 193 119.6 172.1 46.9     
ASP 194 122.6 173.6 56.4 39.7 180.1   
ALA 195 119.8 174.6 50.8 21.1    
HIS 196 121.8 172.8 50.6 33.7    
PHE 197 122.8 174.1 56.7 40.9    
ASP 198  176.0 50.6 23.2    
GLU 199  176.4 59.3 35.5    
ASP 200  179.5 54.1 40.2    
GLU 201 130.7 176.6 56.0 31.0 36.4 183.2  
PHE 202 119.4 177.3 56.7 39.3    
TRP 203 116.8 174.8 53.7 26.1    
THR 204 126.0 175.4  72.5    
THR 205 122.8 174.9 60.9 69.3 22.4   
HIS 206 120.7       
SER 207 123.6 176.0 58.3 63.4    
GLY 208 115.3 173.5 45.0     
GLY 209 108.2 173.7 45.8     
THR 210 125.2 172.6 62.5 68.5 23.8   
ASN 211 125.5 176.4 55.4 41.7 180.2   
LEU 212 131.8 176.3 58.7 41.1 27.7 27.7/22.3  
PHE 213 120.3 175.5 61.8 37.7    
LEU 214 118.3 178.9 57.9 43.1 26.2 23.8/25.9  
THR 215 112.6 177.2 66.7 68.3 21.7   
ALA 216 124.2 178.6 55.7 17.3    
VAL 217 118.6 178.7 68.3 31.1 23.5/23.3   
HIS 218 118.2 176.1 58.8 28.6    
GLU 219 115.7 177.7 58.8 28.6 33.3   
ILE 220 118.0 177.3 63.5 37.2 29.1/18.8 11.9  
GLY 221 108.2 177.3 48.2     
HIS 222 119.7 180.8 57.7 28.3    
SER 223 122.5 175.8 56.6 63.0    
LEU 224 114.3 178.0 55.0 42.2 24.2 22.1/24.6  
GLY 225  174.2 44.4     
LEU 226 121.0 177.5 55.1 42.5 21.8 26.3/21.8  
GLY 227 109.8       
HIS 228 115.7 175.2 55.2 29.2    
SER 229 114.3 175.4 55.1 65.3    
SER 230 119.9 173.4 58.6 64.0    
ASP 231 126.8   42.0    
PRO 232  177.8 62.9 31.9  50.6  
LYS 233 116.7 176.8 56.2 31.9 24.9 28.2  
ALA 234 123.9 179.7 51.8 19.6    
VAL 235 131.4 179.0 64.8 31.1 23.0/20.7   
MET 236 115.5 177.2 53.4 27.0    
PHE 237 128.4  56.5 39.9    
PRO 238  174.2 63.7     
THR 239 116.5 173.3 61.9 71.8 21.9   
TYR 240 128.0 174.1 58.9 38.9    
LYS 241 129.9 173.4 55.4 34.5 24.0 28.8 42.1 
TYR 242 124.1 174.9 60.9 38.3    
VAL 243 124.4 172.1 59.2 35.1 21.1/19.6   
ASP 244 119.1 179.1 55.0 41.9    
ILE 245 124.4 177.2 64.4 37.6 27.0/17.8 13.5  
ASN 246 118.5 176.5 55.4 38.3    
THR 247 109.4 173.9 60.9 69.4 21.1   
PHE 248 123.3 174.4 59.8 39.9    
ARG 249 126.2 174.7 54.1 33.4 26.0 43.4  
LEU 250 121.1 177.0 54.7 42.9 26.7 22.4/26.5  
SER 251 118.3 175.0 57.6 65.9    
ALA 252 123.6 180.1 55.5 17.8    
ASP 253 117.7 178.7 58.1 43.9 180.2   
ASP 254 118.8 177.8 57.7 44.2 180.0   
ILE 255 118.9 177.6 65.5 38.2 30.5/16.6 12.5  
ARG 256 119.2 180.5 59.3 29.8 27.1 43.2  
GLY 257 106.8 177.1 47.4     
ILE 258 123.6 177.9 60.9 38.5 30.7/20.6 14.9  
GLN 259 123.5 179.3 58.6 27.2 34.9 180.7  
SER 260 115.5 174.9 61.3 62.9    
LEU 261 119.1 176.7 56.5 43.5 25.4 21.5/25.6  
TYR 262  176.0 59.8     
GLY 263 110.2 
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5 General discussion and perspectives 
 
5.1 General discussion 
  The catalytic domains of MMP-1, MMP-7, MMP-8, MMP-12, the full length 
MMP-12 (Glu219Ala), and the hemopexin domain of MMP-12 were prepared from 
Escherichia coli strains. The proteins have been chosen according to a general strategy 
aimed to select some of the most pathologically relevant matrix metalloproteinases. Thanks 
to the methods and strategies developed during this PhD project a large amount of 
concentrated protein samples have been produced. These samples allowed us to deeply 
investigate the structural features of the selected catalytic domains of matrix 
metalloproteinases and to carefully analyze the interaction of these proteins with inhibitors 
and substrate models. 
  Concerning the fibroblast collagenase, its expression is detected in a variety of 
physiological processes including embryonic development, wound healing, as well as in a 
number of pathological processes, including arthritis, cardiovascular disease and different 
types of malignant tumors. Therefore, several candidate drugs have been designed and 
successfully tested in vitro. Unfortunately, they failed the clinical trials due to a lack of 
selectivity. The structural analysis of several protein-ligand adducts would be of great help in 
order to increase the selectivity towards this important target. During this project two 
different protein constructs (Asn106-Gly261 and Pro21-Pro269) have been designed and 
expressed in order to deeply investigate interactions of the protein with ligands. Although all 
attempts to develop a reproducible crystallization protocol failed, nevertheless the 
methodological advancements allowed us to produce large amounts of stable and soluble 
MMP-1 samples which have been employed to design a new approach for protein-ligand 
structural analysis. In this approach a combination of in silico tools and experimental NMR 
data was proposed for a relatively fast determination of protein-ligand structural models 
(Chapter 4.1). The strategy that we proposed promises to be useful also for the structural 
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determination of different protein-ligand adducts, whenever the structure of the free protein 
is known and the structural changes upon complexation are not expected to be dramatic. 
  In a different research line, the catalytic domain of MMP-1 (activated from pro-cat 
MMP-1) has been also exploited to develop an high-throughput screening protocol based on 
SPR techniques. It is currently believed that MMPs can not be anchored on the sensor-chip 
surface without losing their activity. Therefore our efforts have been devoted to develop a 
strategy to monitor the activity of the anchored protein. Several samples of MMP-1 have 
been used to develop the experimental protocol that coupling the Fourier Transform-SPR 
(FT-SPR) technique with Electrospray Ionization-Mass Spectroscopy (ESI-MS) allows us to 
evaluate the enzymatic activity of MMP-1 catalytic domain anchored on gold surfaces 
(Chapter 4.2). The results we got demonstrate the possibility of monitoring enzyme activity 
and/or interactions with other molecules. The same approach has been extended to MMP-12 
and MMP-8. The strategy has been further implemented by using the in situ Atmospheric 
Pressure MALDI-MS (Chapter 4.3). We suppose that the new experimental procedure is 
particularly suitable for SPR/MALDI-MS coupled investigation of enzyme activity and/or to 
monitor the interactions with other molecules.  
  Also the macrophage metalloelastase (MMP-12) is a relevant target for drug design. 
Under pathological conditions MMP-12 is involved in emphysema and multiple sclerosis. 
The enzyme is also able to degrade ECM components such as elastin and collagen type IV 
and involved tissue remodeling. To accomplish rational drug design for the protein, high 
resolution structures of the protein with ligands are essential. For this purpose, during this 
PhD study we developed methods to obtain large amounts of the catalytic domain of MMP-
12 from Escherichia coli. These samples have been employed for NMR studies and for 
crystals preparation. In particular the availability of the stable samples made possible to 
collect structural data on adducts of the collagen fragment ProGlnGlyIleAlaGly peptide with 
the protein and on a large number of adducts of a homologous series of ligands with the 
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catalytic domain of MMP-12. The reaction mechanism of the catalytic domain of MMPs 
was well provided by crystal structures of the uninhibited form of the protein and of the 
adducts with the collagen fragment peptide (Chapter 4.4). 
  Thanks to the soaking protocols developed during the project the structural details 
of the adducts of MMP-12 with 14 structural-related inhibitor have been deeply analyzed. 
From combining the structural information with calorimetric and inhibition measurements 
we obtained hints for the planning of new finely tuned inhibitors for MMP-12 (Chapter 4.5). 
  The expertise acquired on MMPs has been of fundamental importance also to 
speed-up our advancements in solid-state NMR. The recent results in solid-state NMR 
demonstrate the potential of this technique for solving membrane protein structure, one of 
the major challenges in structural biology today, or for getting information on protein 
aggregates. Two of the main limitations in solid-state NMR are related to the large amount 
of 13C- and 15N-labeled sample needed for the measurement and to the physical state of the 
sample (only microcrystalline samples ensure high quality spectra). The high yield of the 
MMP-12 and the quality of the microcrystals allowed us to obtain well-resolved 2D and 3D 
spectra that have been used for assignment of the protein. In the attached article (Chapter 
4.6) we demonstrate that it is possible to translate in a short time a large fraction of the 13C 
liquid assignment to solid-state. This opens the possibility to investigate proteins involved in 
important biological processes such as oligomerization or protein-protein interactions, 
without the line broadening associated to the increase in molecular weight present in 
solution.  
  Although the studies performed on the catalytic domains can provide important 
information on the dynamical properties, on the enzymatic mechanism and on the structural 
features of this important class of proteins, only the investigation on the active full length 
proteins provides a full picture of the protein structure and function. At this regards our 
efforts have been devoted to obtain concentrated sample of MMP-12 full length with a well-
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folded state. The new protocol, developed during this PhD project, allowed us to overcome 
all the problems previously found by the researchers. The difficulty associated to the 
expression of full length MMPs is demonstrated by the absence in literature of NMR 
investigation, although two crystal structures have been published. A complete NMR 
investigation has been already carried out on the active full length MMP-12 (Glu219Ala) 
and its solution structure is in progress. 
  Neutrophil collagenase (MMP-8) is another important target belonging to the MMP 
family. With other collagenases (MMP-1, MMP-13, MT1-MMP (MMP-14), and MMP-2) 
MMP-8 (collagenase-2, neutrophil collagenase) it is able to degrade type I collagen and it is 
involved in arthritis and cancer. Therefore also MMP-8 is a potential pharmaceutical target 
and the investigation of its enzymatic activity can provide valuable data on the degradative 
mechanism of collagen. Also for the catalytic domain MMP-8 methods to obtain a large 
mount of the protein for NMR samples and crystals preparation have been developed. 
Although quality of the crystals can not be compared with that of MMP-12 nevertheless the 
structures of the free-form of MMP-8 and that obtained in presence of the collagen fragment 
ProGlnGlyIleAlaGly were of fundamental importance to clarify the reaction mechanism of 
MMPs (Chapter 4.4). The solution structure of the catalytic domain of MMP-8 in complex 
with the nanomolar inhibitor NNGH is in progress. 
  Also MMP-7, matrilysin-1 which lacks the hemopexin domain, has an important 
role in cancer development. The limited structural information available in literature seems 
to be related to the difficulties found in protein expression, stability and solubility. Therefore 
also this protein has been investigated in order to develop new protocols for sample 
preparation. Although a well-folded protein is currently obtained the solubility remains low 
so preventing any structural investigation.  
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5.2 Perspectives 
  The methods of expression and refolding of several members of human matrix 
metalloproteinases, developed during this project, will allow the scientific community to 
produce large amounts of concentrated samples of the catalytic domain of four different 
MMPs in order to further expand the structural investigation and the biophysical 
characterization of this family of proteins. In fact to achieve candidate drugs with high 
affinity and selectivity for each MMP the subtle structural differences among each member 
of the protein family have to be deeply investigated and elucidated.  
  Besides these important results and perspectives involving the studies on catalytic 
domains more exciting expectations are waited from the research line focused on the MMP-
12 full length protein. Actually, all domains of active MMP participate to the degradation 
mechanism of ECM components. Although some theoretical studies on the role of the 
different domains on the degradation process have been published, only few experimental 
studies exist in literatures and the mechanism is still unclear. This lack of information is 
mainly due to the difficulties in “handling” the full length form of these proteins and in 
preparing concentrated samples. In particular the dramatic self-hydrolysis that affects the 
full length MMPs is the main limiting factor for the biophysical of studies. The results 
obtained in the last year have provided the tools to fill this gap so opening new perspectives 
in MMP research. 
  In particular the advancements realized in protein engineering, expression and 
purification allowed us to produce concentrated samples for NMR, x-ray crystallography 
and biological studies. The structural analysis of the inhibited full length of MMP-12 is 
being in progress and the results will be available at the beginning of the next year. 
Moreover new studies with substrate models of elastin and collagen have been already 
planned and will be carried out during the next year. Obviously this will be the matter of a 
new PhD project aimed to describe all the steps associated to elastin and collagen 
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degradation by the full length of MMP-12. Besides the elucidation of the dynamical 
processes associated to substrate degradation these studies will be relevant for drug design. 
Actually most of the inhibitors of MMP, designed to target the active site of the catalytic 
domain, are affected by the lack of selectivity. Therefore the investigation of the whole 
active protein would provide a new point of view allowing to identify new and protein-
specific binding sites and to the design of more selective inhibitors. 
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